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I. Abstract: 
 
CREB3L2 (cAMP Response Element Binding protein 3 Like 2) is a bZIP 
domain containing transcription factor. It is one of several endoplasmic 
reticulum (ER)-stress transducers that lead to an unfolded protein response 
(UPR). CREB3L2 is activated by regulated proteolysis via Site-1/Site-2  
(S1P/S2P) proteases, due the accumulation of misfolded proteins in the ER. 
Such regulation is shared with other transcription factors (TFs) such as ATF6 
and SREBP. During B-cell differentiation, the UPR is important for plasma cell 
adaptation to high levels of antibody secretion. However, to date only one 
UPR regulator has been implicated in plasma cell differentiation, XBP1. The 
high expression of CREB3L2 in plasma cells suggests that it may also 
contribute to secretory adaptation and offers the opportunity for therapeutic 
targeting. Therefore, the aim of this project is to test the involvement of the 
transcription factor CREB3L2 in plasma cell differentiation through 
investigating its expression, regulation and function in human B-cell 
differentiation and B-cell tumours. 
 
Evaluation in myeloma and ABC-DLBL cell lines revealed a direct relationship 
between CREB3L2 activation and UPR induction. In primary cells, CREB3L2 
is expressed at the earliest stages of plasma cell differentiation and then 
becomes strongly induced and activated as the cells transition to the plasma 
cell state. To investigate the potential role of CREB3L2, S1P and S2P 
inhibitors were employed to block it’s processing. Inhibition of S1P/S2P during 
plasma cell differentiation led to a profound reduction in plasmablast number 
linked to a decrease in proliferation and an increase in autophagy. While few 
cells survive following treatment with the inhibitors, phenotypically the cells 
appear normal. In contrast, immunoglobulin secretion is severely reduced. 
Moreover, inhibition of S1P is associated with a unique gene expression 
profile involving gene signatures related to IRF4 and mTOR function as well 
as metabolic pathways. 
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To further investigate the contribution of CREB3L2 to the events observed 
with S1P/S2P inhibitors, siRNA-mediated knockdown and ChIP-seq 
experiments were performed in primary differentiating B-cells. Although the 
changes in gene expression after knockdown did not reach statistical 
significance, genes showing variation have known roles in ER stress 
responses, autophagy and plasma cell development. Moreover, ChIP-seq of 
CREB3L2 demonstrated direct binding to several of the differentially 
expressed genes. The ChIP-seq experiment also included an evaluation of 
ATF6 and XBP1 binding in the same cells. The results revealed a high degree 
of overlap for binding, including to loci previously identified in the gene 
expression analyses.  
 
In conclusion, the results show that S1P/S2P control CREB3L2 processing in 
differentiating B-cells and suggest that CREB3L2 is involved in the early 
commitment to plasma cell fate, prior to the requirement for XBP1.  CREB3L2 
is likely to function in combination with other RIP-activated TFs by regulating 
genes involved in metabolism, necessary for effective transition to high 
secretory activity. Thus, S1P/S2P-regulated pathways play a pivotal role in the 
B-cell to plasma cell transition and represent a previously unrecognised 
component of the regulatory network that turns these cells into efficient 
antibody “factories.” 
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1. Introduction 
 
In vertebrates, the immune system has developed a defensive network 
divided into two groups: innate immunity and adaptive immunity. Innate 
immunity is a nonspecific type that is present from birth and includes the 
membrane barriers of the organism, their associated secretions and 
keratinisation, as well as factors in the blood and tissues such as 
complement, granulocytes and macrophages. In contrast the adaptive 
immune system has the capacity to mount a response, which is specific to the 
invading organism, and can establish memory of a previous encounter. The 
major cells of the adaptive immune response are T- and B-lymphocytes. They 
share unique features; specifically they have unique antigen receptors that 
recognise a wide range of ligands (antigens). The diversity of these antigen 
receptors is generated via somatic gene rearrangement in the V (D) J 
segments of the heavy and light chains of the immunoglobulins or T-cell 
receptor genes that provide their unique specificity for antigen. Moreover, for 
T-cells their recognition of antigen is dependent on antigen presentation via 
the major-histocompatibility complex (MHC). This provides one of the major 
differences between B- and T-lymphocytes; B-lymphocytes recognize their 
antigens as whole intact three-dimensional structures whereas T-cells 
recognize their antigens as processed peptide fragments presented via MHC 
molecules. Other features also distinguish B-cell and T-cell receptors. Firstly, 
B-cells express immunoglobulins either as membrane bound receptors or as 
secreted forms sharing the same specificity following plasma cell 
differentiation. As secreted antibody the immunoglobulin of the B-cell receptor 
contributes to immunological memory and the cross-talk between innate and 
adaptive immunity. Secondly the nature of the functional effect of 
immunoglobulin can be altered during an immune response via the process of 
heavy-chain class-switching. Finally the affinity of the B-cell receptor can be 
improved during an immune response, such that its affinity for antigen is 
greater on secondary encounter. In contrast T-lymphocytes express T-cell 
receptors (TCR) only as a membrane bound form, do not undergo functional 
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class-switching and show no evidence of maturation for improved affinity 
within an individual T-cell clone. Thus B-lymphocytes have several unique 
developmental stages. The plasma cell stage, which represents the terminal 
effector stage of the B-cell lineage, accompanies the transition of the 
membrane bound B-cell receptor to the secreted immunoglobulin molecule 
(3). 
 
Conversion to a “professional secretory cell” status is a hallmark of plasma 
cell differentiation. The increase in protein production results in an increased 
burden on the endoplasmic reticulum (ER), the site of protein manufacture, 
modification by glycosylation, disulphide bond formation and structural folding. 
An evolutionarily conserved collection of signalling pathways termed the 
unfolded protein response (UPR) allows the ER to maintain function in the 
face of an imbalance. It is known that the UPR is critical in plasma cells for 
adaptation to functional secretory activity and may affect plasma cell longevity 
(4). However to date only one UPR regulator has been principally implicated 
in plasma cell differentiation, XBP-1. The key attributes that XBP-1 governs 
are the expansion of the secretory apparatus and the production of high levels 
of immunoglobulin (5, 6). Despite this, the initial stages of plasma cell 
differentiation are not affected by loss of XBP-1. These data suggest that 
other factors may be playing a role in preparing the cell for secretion in what 
can be termed an “anticipatory” UPR. In recent years, a novel family of ER 
stress transducers have been described that share significant homology with 
the classical UPR-activated transcription factor ATF6. This CREB3 family of 
transcription factors have been implicated in regulating development, 
metabolism, secretion, survival and transformation in other cell lineages, with 
evidence for cell-type specific effects (7). One family member, CREB3L2, is 
specifically up regulated during plasma cell differentiation (4, 8). The range of 
biological processes that have been attributed to CREB3-family regulation 
would fit well with the requirements needed during plasma cell differentiation. 
The role of non-classical UPR-related factors, in particular the CREB family, of 
which CREB3L2 is strongly expressed in plasma cells, has not been studied 
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in the B-cell lineage and may provide an important contribution and the 
opportunity for therapeutic targeting. Therefore, in this project I aim to test the 
involvement of CREB3L2 in the process of plasma cell differentiation. 
 
1.1 B-cell differentiation 
 
B-lymphocytes arise from haematopoietic stem cells in the bone marrow in 
response to many different stimuli such as cytokines. The B-cell receptor is 
the principle distinguishing feature of the lineage and is composed of a unique 
heavy and light chain combination in each B-cell, with each immunoglobulin 
molecule representing a combination of 2 heavy chain and two light chain 
proteins. Two loci, kappa and lambda can generate light chains, while one 
heavy chain locus is present. During B-cell differentiation the heavy chain 
locus rearranges first, and after productive rearrangement of one allele, the 
other allele is silenced ensuring that only one heavy chain rearrangement is 
expressed (3).  
 
The first distinguishable B-cell is the pro-B cell with only heavy chain DH, JH 
gene segments rearranged and without immunoglobulin production.  The 
second stage in the B-cell lineage is the pre-B cell that is characterized by 
heavy chain VDJ unit formation accompanied by surrogate light chain. After 
positive selection the, pre-B cells differentiate to immature B-cells, which are 
characterized by the productive rearrangement of one allele of either kappa or 
lambda loci, and expression of monomeric IgM at the B-cell surface as an 
antigen specific receptor (Figure 1.1). The monomeric IgM results from μ of 
the heavy chain paring with the light chains. The specificity of the 
immunoglobulin is provided by the combined rearranged heavy and light chain 
variable regions. Immature B-cells differentiate in to mature B-cells expressing 
IgM+ IgD+ at their surfaces in peripheral lymphoid organs. Several functional 
subsets such as follicular and marginal zone B-cells arise (3).  
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There are 2 major types of B-cell activation, T-cell dependent and T-cell 
independent (Figure 1.1). In T-cell dependent B-cell activation, both an 
antigen specific B-cell and T-cell have to interact. During the interaction the B-
cell has to endocytose antigen via its B-cell receptor (BCR) and present this 
antigen as processed peptide, via MHC class II to the T-cell. The T-cell must 
also have been previously activated by a professional antigen presenting cells 
(APC) such as a dendritic cell via their MHC class II (9, 10). On the other 
hand, some types of B-cells can be activated independently from T-cells by 
toll-like receptor activation or highly repetitive antigen receptor ligands to drive 
T-independent differentiation (11).  
 
 
 
 
 
 
 
 
 
 
Figure-1.1: B-cell development. B-cells undergo Ig gene rearrangement in the 
bone marrow leading to the expression of a functional surface BCR. Selected B-
cells migrate to the periphery and upon encounter with antigen can differentiate 
into short-lived plasma cells or form a germinal centre (GC). B-cells in the GC 
undergo class switching and somatic hypermutation, leading to improved antibody 
affinity and functional adaptation. B-cells exiting the GC may become memory B-
cells or differentiate into antibody secreting cells that migrate to bone marrow 
niches for long-term survival (adapted from Dr. Reuben Tooze). 
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Upon encountering an antigen, to which they are specific, naïve B-cells 
migrate to the margin of the B-cell follicle and T-zone in the secondary 
lymphoid organs (lymph node, spleen and Peyer’s patches of the intestine). 
Here, B-cells depend on encounter with an appropriately activated and 
antigen specific CD4+ T follicular helper (TFH) cells in order to engage in the 
“cognate interaction” necessary for further activation and differentiation. This 
cognate interaction occurs principally via MHC class II and CD40, as a co-
stimulatory molecule on B-cells and its ligand CD154 on TFH. In addition there 
is local cytokine secretion (Il-2, Il-4, Il-5 and IL-21) by the TFH. The activated 
B-cells either turn into plasmablast and migrate to the medulla of the lymph 
node (most of the plasma cells formed at that stage are short-lived) or return 
to the B-cell follicle where they proliferate extensively forming a secondary 
follicle. A few days of B-cell proliferation results in the formation of a germinal 
centre (GC) (Figure 1.1). The GC is composed of three zones; dark zone, light 
zone and surrounded by a mantle zone where the residual naïve B-cells of the 
primary follicle are located. The dark zone is composed mainly of centroblast; 
proliferating B-cells whereas, the light zone is composed of centrocytes; 
smaller cells with lower rate of division. In the dark zone, centroblasts undergo 
somatic hypermutation (SHM); a high rate of mutation selectively targeting the 
variable region of the rearranged immunoblobulin gene segments. The SHM 
process is essentially random and is coupled to affinity maturation in order to 
select B-cells with improved affinity for antigen. The process of affinity 
maturation occurs in the light zone and is derived from competition of B-cells 
for a limited supply of antigen presented on follicular dendritic cells. This 
results in the emergence of B-cells with higher affinity and loss by apoptosis 
of B-cells with lower affinity. Such B-cells may re-enter the dark zone to 
engage in another round of mutation and selection for even higher affinity or 
develop in to memory B-cells that may also have undergone immunoglobulin 
class switch recombination or into plasma cells that migrate to the bone 
marrow, and become long lived (3, 4, 7, 12-15) (Figure 1.1).  
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At present the factors controlling these decisions in the GC are still being 
defined. However, it is suggested that the affinity of BCR plays an important 
role (16). In addition, IRF4 plays role in controlling the decision in such that 
the strength of BCR signalling influences IRF4 expression. High BCR 
signalling avidity induces higher levels of IRF4 hence, inhibiting GC reaction 
and induces plasma cell differentiation (17).	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1.1.1 Transcription factors involved in B-cell differentiation  
 
B-cell differentiation is regulated by the sequential action of multiple TFs that 
are called master regulators (12, 13, 18).  They can be divided into several 
groups; the first group includes those factors necessary for maintaining the 
core B-cell program such as PAX5 (Paired box protein 5, also known as B-cell 
lineage-specific activator protein; BSAP). The second group regulates specific 
stages of mature B-cell differentiation in particular the germinal centre 
response, such as BCL6 (B-cell lymphoma 6). The third group controls the 
final step of B-cell to plasma cell differentiation and includes IRF4 (Interferon 
regulatory factor 4), BLIMP1 (B-lymphocytes induced maturation protein 1) 
and XBP1 (X-box binding protein 1) (12, 13) (Figure-1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.2: The figure depicts the various stages of differentiation from B-
cell to mature PC, including the associated transcriptional factor expression 
profile (PAX5, BCL6 in blue boxes and IRF4, BLIMP1, XBP-1 in red boxes, 
characteristic surface phenotype, cycle status, immunoglobulin secretory 
activity and half life (adapted from Dr. Gina Doody).  
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1.1.1.1 Factors that maintain the B-cell program 
 
The establishment of the B-cell fate as discussed in part 1.1 reflects the 
sequential action of TFs that together determine B-cell specification, and 
repress alternate cell fate decisions. In cooperation with other factors such as 
PU.1, EBF1 and E2A, PAX5 is required for maintaining the B-cell program in 
mature B-cells. Moreover, it is required for B-cell activation through regulation 
of its target genes such as CD79a (Igα), CD19 and BLNK (B-cell linker) that 
are important for BCR signalling (16, 19-21). An additional role is the 
repression of XBP1 that is crucial for plasma cell differentiation (13). Thus 
PAX5 maintains B-cell identity and inhibits plasma cell formation.  
 
Somatic hypermutation and affinity maturation is a critical feature of the B-cell 
lineage, and formation of GCs is tightly controlled. BCL6 is the central 
transcriptional regulator of the GC (12, 13). It is present at high level in GC B-
cells, and BCL6 deletion prevents GC formation (13, 22). BCL6 acts in several 
ways including suppression of BCL2 to promote a pro-apoptotic environment 
facilitating affinity maturation (16) and represses the exit of B-cells from the 
GC. This is achieved by repressing IRF4 and BLIMP1, the two transcription 
factors essential for PC differentiation, hence preventing the progression to 
plasma cell formation (23, 24). Strong BCR signalling is proposed as the 
mechanism that removes BCL6 repression of BLIMP1 and IRF4 leading to 
plasma cell progression (23). 
 
1.1.1.2 Factors that maintain the plasma cell program 
 
IRF4 is one of the TFs known to be essential for establishing the plasma cell 
program. It is a dose dependent TF: expressed at low level in B-cell lineage 
but higher level upon differentiation (12, 25). It is expressed in activated B-
cells before BLIMP1 suggesting it as the initiator of plasma cell formation. In 
GC B-cells it can supress BCL6 hence activating BLIMP1. It also directly up-
regulates BLIMP1, for example following IL-21 stimulation IRF4 binds in 
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conjunction with phospho-STAT3 to a regulatory region of BLIMP1 thus, 
promoting plasma cell formation (26-28). 
 
BLIMP1 (also known as PRDM1) is one of the crucial TFs for plasma cell 
formation and immunoglobulin (Ig) secretion (12, 13). It is encoded by the 
PRDM1 gene (12). It is expressed in all ASCs in mice and human but absent 
in the early stages of B-cell lineage. In BLIMP1 knockout mice mature plasma 
cells fail to form indicating its requirement in the terminal differentiation of 
plasma cells. However in conditional knockout mice, a population of cells 
expressing IRF4 forms which have weak secretory activity, indicating that 
BLIMP1 is required for the establishment rather than the initiation of the 
plasma cell program (12). It regulates plasma cell differentiation through 
repressing BCL6 and PAX5 genes, as well as other aspects of the B-cell 
program and triggering plasma-cell differentiation by activating XBP1 (12, 13, 
19, 24, 25).  BLIMP1 is also implicated in driving the exit from cell cycle that 
accompanies terminal plasma cell differentiation.  
 
The final central regulator of plasma cell differentiation is XBP1. This is a bZIP 
containing transcription factor, which is an evolutionarily conserved 
component of the unfolded protein response (UPR) of the endoplasmic 
reticulum. It is an essential transcription factor that couples B-cell 
differentiation to expansion of the secretory pathway (12, 29-31).  This will be 
discussed further below. 
 
1.2 The Unfolded Protein Response (UPR) 
 
Cells are exposed to many different sources of exogenous or endogenous 
stress that can impact on the secretory apparatus. The exogenous sources 
include viruses, hypoxia, radiation, free radicals, toxins, microbial pathogens 
and nutrient deprivation. On the other hand, the endogenous sources of 
endoplasmic reticulum stress (ER-stress) principally result from the 
accumulation of unfolded/misfolded proteins during protein synthesis or due to 
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a dramatic change in the secretory load placed on a cell (32). The proper 
folding of the newly synthesized proteins and post-translational modifications 
are essential for proteins to gain their three-dimensional structure and hence, 
proper protein function. Therefore, all organisms have developed mechanisms 
to ensure proper protein folding (33, 34).  
 
The endoplasmic reticulum (ER) is responsible for protein synthesis, folding 
and posttranslational modifications. There are several conditions known to 
interfere and affect protein synthesis and folding such as calcium depletion, 
oxidative stress, hypoglycaemia and hypoxia that lead to the formation of 
misfolded/unfolded protein. These accumulate in the ER and result in ER 
stress. ER stress if not resolved will cause cellular damage. However, the ER 
responds to such stress by activating a series of pathways together known as 
the UPR (34-36). This evolutionarily conserved response was firstly described 
in yeast cells, which has only one UPR signalling pathway (IRE1; inositol-
requiring enzyme-1 coupled to HAC1p the ortholog of XBP1). Higher 
eukaryotes have evolved two additional UPR-components PKR-like 
endoplasmic reticulum kinase (PERK), and activating transcription factor 6 
(ATF6) (35). Together these comprise the three principal ER-stress 
transducers (32, 37).  
 
The UPR is an adaptive response, and the accumulation of misfolded proteins 
in the ER activates the UPR to attenuate translation hence decreasing the ER 
load. Additionally, activation of the UPR leads to the induction of genes 
encoding ER-chaperones that are required for proper protein folding. 
Furthermore, the activation of the UPR is crucial for enhancing the 
degradation of accumulated misfolded proteins in the ER via ER-associated 
degradation (ERAD) (33, 35). 
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1.2.1 UPR signalling pathways 
  
In the absence of ER-stress, IRE1, PERK and ATF6 proteins remain inactive 
bound to the immunoglobulin heavy chain binding protein (BIP; also known as 
GRP78 and HSPAS). The accumulation of misfolded proteins causes ER-
stress leading to the binding of BIP to the misfolded proteins and its 
consequent dissociation from IRE1, PERK and ATF6 (32, 33, 37-39). 
However, release from BIP, at least from IRE1 and PERK, is not sufficient to 
trigger the UPR signalling cascade. Structural studies of yeast Ire1 identified a 
groove in the luminal domain, similar to that found in MHC molecules, that 
facilitates direct binding with unfolded proteins (40) Additional functional 
studies provided evidence that Ire1 is directly activated by increased level of 
unfolded proteins and the function of BiP is to stabilize inactive monomeric 
Ire1 in the steady state (41, 42). By inference, the structural similarity of the 
PERK ER luminal domain suggests it is also likely to be activated by directly 
binding to unfolded proteins (43).	  
 
1.2.1.1 IRE1 
 
IRE1 is a type-1 transmembrane protein of about 110 kDa. In mammals, two 
homologs of yeast Ire1 have been identified; IRE1α and IRE1β. The former is 
highly expressed in pancreas and placenta whereas the latter is mainly 
expressed in intestinal epithelial cells. Although they have comparable 
cleavage, specificity suggesting that they recognise the same substrate, they 
differ in their tissue expression (32, 33, 38).  
       
IRE1 has endoribonuclease and kinase activities. Misfolded proteins in the ER 
bind directly to IRE1 through a groove in its luminal domain and trigger BIP 
dissociation, stimulating IRE1 auto-phosphorylation and homo-dimerization 
which in turn activates its endoribonuclease activity to splice a 26 nucleotide 
sequence from XBP1 mRNA (the only known substrate for IRE1) (Figure-1.3) 
(32, 33, 38). This results in a translational frame-shift, which produces a larger 
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form of XBP1 (spliced XBP1; XBP1s) of 376 amino acids that translocates into 
the nucleus and activates its target genes. In contrast, unspliced XBP1 
(XBP1u) encodes a short-lived protein, which is composed of 261 amino 
acids. 
 
1.2.1.2  PERK 
 
PERK is a type-1 transmembrane protein that in resting cells is bound to BIP 
in a similar manner to IRE1. However, upon the accumulation of misfolded 
proteins, the PERK kinase is activated and undergoes auto-phosphorylation 
following BIP dissociation. Moreover, due to the structure similarities in the 
luminal domain between IRE1 and PERK, it has been found that the unfolded 
proteins can bind directly to it through a groove in its luminal domain and also 
influence it activation (43) (Figure-1.3). This leads to the phosphorylation of 
eIF2α (eukaryotic initiation factor 2 on α subunit), which results in translation 
attenuation, hence decreasing the load that is made on the ER. 
 On the other hand, activating transcription factor 4 (ATF4) escapes 
suppression by PERK resulting in its preferential translation and activation of 
some UPR target genes such as growth-arrest DNA damage gene 34 
(GADD34). 
 
1.2.1.3 ATF6 
 
This type 2 transmembrane protein has two mammalian homologs: ATF6α 
(90kDa) and ATF6β (110kDa). ATF6 has both a nuclear and Golgi localisation 
signal but is retained in the ER by interaction with BIP. Upon accumulation of 
unfolded proteins in the ER, BiP dissociates from ATF6α allowing its Golgi 
localisation. In the Golgi ATF6 is then cleaved via S1P (site 1 protease) and 
S2P (site 2 protease). S1P cleaves the luminal domain of ATF6 while S2P 
cleaves the N-terminus of ATF6. The final cleavage releases the 50-kDa 
cytosolic fragment of ATF6α, which then translocates into the nucleus and 
activates its target genes such as BiP and XBP1 (Figure-1.3) (32, 33, 38).  
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Figure-1.3: The three axes of the mammalian UPR. Misfolded proteins in the 
ER directly bind to IRE1 and PERK as well as causing BiP to dissociate from the 
attached proteins (ATF6, IRE1 and PERK) that stimulate A, B and C pathways; A. 
ATF6 migrates to the Golgi and is cleaved via S1P/S2P. The cleaved p50 ATF6 
translocates in to the nucleus and activates its target genes. CREB3L2 has a 
similar regulatory pathway as ATF6, producing p60 that migrates to the nucleus to 
activate its target genes B. IRE1 phosphorylates and causes splicing of XBP1 
mRNA. The spliced form of XBP1 translocates in to the nucleus and activates its 
target genes. C. PERK phosphorylates and causes the phosphorylation of EIF2α 
leading to attenuate translation and arrest cell growth hence decreasing the load 
on ER. However, ATF4 escapes that repression and translocates to the nucleus 
and activates its target genes (5).  
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1.3 Role of the UPR in B-cell differentiation 
Plasma cells are terminally differentiated antibody secretory cells arising from 
B-cells. The unique feature of plasma cells is the ability to secrete 
immunoglobulins, which increase throughout the differentiation. To 
accommodate the huge amount of the secreted immunoglobulins, plasma 
cells have increased the ratio of the cytoplasm to nucleus to accommodate 
the enlarged ER (16, 44). Such large amounts of the secreted 
immunoglobulins may increase the load on ER and cause ER-stress. 
However, plasma cells have adapted a physiological response to ER-stress 
called the UPR. The UPR is required for the proper function and survival of 
secretory cells such as plasma cells, pancreatic β cells, chondrocytes and 
skeletal muscle cells, acting by increasing the expression of ER chaperones 
and folding enzymes while at the same time decreasing protein synthesis or 
even commencing cell cycle arrest to reduce the load on ER (30, 45). In the 
case of plasma cells, the stimulation of an UPR induces the expression of 
heat shock protein BiP/GRP78, which is required for proper folding of the 
immunoglobulins (16, 46, 47). In addition, UPR activation in plasma cells 
triggers IRE1 release from BiP hence, XBP1 splicing to form XBP1s that is 
known to be one of the most crucial modulators in plasma cell 
differentiation(16, 48). 
 
Early reports indicated that the UPR is required for B-cell differentiation in 
response to LPS (lipopolysaccharide) (44, 49) however, the precise link was 
not known until 2001 when Reimold et al. (31),found that XBP1 is expressed 
in myeloma cell lines, splenic B-cells and in plasma cells in vitro in response 
to LPS stimulation. The important role of XBP1 in terminal B-cell differentiation 
was subsequently confirmed by the demonstration that ectopically expressed 
XBP1s can restore antibody secretion in Xbp1-/- B-cells (29). Additionally, 
using a CH12 B-cell line model, p50ATF-6α and XBP1s were induced as B-
cells differentiated to antibody secretory cells in response to LPS (50). 
However, in the same model CHOP was not induced. These results 
suggested that certain components of the UPR such as IRE1 and ATF6 are 
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important in B-cell differentiation, but that PERK might be dispensable (30, 
50). The lack of PERK involvement was corroborated in a study 
demonstrating that PERK was not activated during B-cell differentiation in 
response to LPS and that B-cells deficient in PERK develop normally and 
secrete immunoglobulins (51). Furthermore, the role of ATF6 in plasma cell 
differentiation is also questionable. Splenic B-cells from Atf6α-/- mice produced 
normal levels of immunoglobulin when stimulated with LPS in vitro and the 
mice mounted normal antibody responses in vivo when challenged with either 
T-D or T-I antigens (52). 
 
The activation of IRE1 and PERK during the UPR shows similar kinetics in 
most cell types studied (53) ,prompting the question of how the pathways are 
differentially controlled during B-cell differentiation. Possible explanations are 
the presence of a negative regulator of PERK, such as p58 IPK or that a 
higher threshold is required for PERK activation compared to IRE1 (51). 
Interestingly, the UPR also intersects with TLR signalling pathways in cells of 
the immune system, providing scope for modifying the UPR in the context of 
different types of infections (54). 
 
1.4 UPR in B-cells: The overload model 
 
XBP1 is an important transcription factor for B-cell development (31, 39, 55, 
56). The Glimcher lab was the first to describe the role of XBP1 in plasma cell 
differentiation starting from the observations that the level of XBP1 was high in 
the absence of PAX5 in pre-pro-B cells thus PAX5 was identified as having a 
negative regulatory effect on XBP1 in the early stages on B-cell development 
(55). This was followed in the work of Reimold et al 2001 on the role of XBP1 
on plasma cell formation using chimeric mice reconstituted with XBP1 
deficient bone marrow (31). These experiments showed that XBP1 deficiency 
resulted in profound reduction in plasma cell number and immunoglobulin 
secretion, suggesting that XBP1 plays a crucial role in the differentiation of B-
cells to plasma cells (31). This was followed by a further study confirming the 
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role of XBP1 in plasma cell differentiation and linking it with UPR by Iwakoshi 
et al 2003. This work found that XBP1s was required to restore Ig production 
in Xbp1-/- B-cells. Moreover, XBP1 was required to handle the huge amount of 
Ig secreted through activation of the UPR and IRE1 dependent splicing of 
XBP1 (57).  
 
These combined findings led to a secretory overload model of UPR activation 
during plasma cell differentiation. Two cytokines IL-4 and IL-6 that promote 
plasma cell differentiation were linked to XBP1 expression (57). An auto-
regulatory loop was proposed between XBP1 and IL-6 that links UPR with 
plasma cell differentiation (29, 57). This model starts with B-cell activation by 
anti-CD40, BCR and IL-4 driving the B-cell to proliferate, differentiate and 
secrete immunoglobulins. The increase in expression and switch to secretory 
form of immunoglobulins leads to accumulation of unfolded protein in the ER, 
inducing a UPR through IRE1 splicing of XBP1. This produces an adaptive 
response to reduce the load on ER in the activated B-cells through expansion 
of the ER to accommodate the secreted immunoglobulins. Once XBP1s is 
formed, it induces the production of IL-6, which in turn induces plasma cell 
proliferation and Ig secretion (Figure-1.4) establishing a loop (29). 
 
Additional work from the Staudt lab established a relationship between 
BLIMP1 and XBP1 by gene expression profiling in BLIMP-1 deficient and 
XBP1 deficient mice (58). The profiles revealed that BLIMP1 acts upstream of 
XBP1 in a de-repression model. PAX5 represses XBP1 in activated B-cells, 
but BLIMP1 represses PAX5 hence removing the repressive action of PAX5 
on XBP1. Thus BLIMP1 dependent repression of PAX5 allows expression of 
XBP1 and a productive UPR required for Ig secretion. This suggests a 
dependence of XBP1 on BLIMP1 expression. This relationship was confirmed 
in by the finding that BLIMP1 was induced in the Xbp1-/- cells whereas; XBP1 
was not induced in the Blimp1-/- cells indicating that XBP1 is downstream of 
BLIMP1 (58). 
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1.5 The UPR in B-cells: Conflicting results, the high-secretory model 
 
More recently the central role of the UPR in plasma cell differentiation has 
been challenged. There were several conflicting results related to XBP1. The 
first results emerged from the Ploegh lab, which found that XBP1 was 
essential for IgM translation but was not required for other glycoprotein 
production or degradation in B-cells induced to differentiate upon LPS 
stimulation (56). In subsequent work from the same lab, it was found that 
activation of XBP1 occurred normally in B-cells lacking any secreted IgM 
indicating that XBP1 activation was a differentiation-dependent event not due 
to the accumulation of secreted Igs, and thus in conflict with the predictions of 
the overload model (39).  
 
Furthermore using a B-cell conditional knockout mouse, the Glimcher lab 
found that XBP1 was not required for the early stages of plasma cell 
differentiation including phenotypic maturation but was required for high-level 
XBP-1s Positive 
feedback 
Plasma cell  
proliferation and survival 
IL-6 XBP-1u IL-4R 
CD40 
B-cell Plasma cell 
IRE1 
splicing 
Unfolded 
proteins 
Figure-1.4: Auto-regulatory loop between XBP1 and IL-6. This model provides a 
link between plasma cell differentiation and the UPR, starting with the initial stages 
of differentiation leading to an increase in the secretory capacity and load on ER. 
The accumulation of large amounts of immunoglobulin in the ER induces a UPR 
and activates IRE1 splicing of XBP1. Once XBP1s is formed, it induces the 
production of IL-6, which in turn induces plasma cell proliferation and Ig secretion 
establishing a loop (8). 
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immunoglobulin secretion (5).  These data have been additionally 
corroborated in the work of Taubenheim et al., 2012 who showed that XBP1 
deficiency did not affect plasma cell number using Xbpfl/flCd19cre/+(fl/fl) mice 
(6). They also found that XBP1 does not function as a key regulator in 
establishing plasma cell differentiation.  
 
However in both studies, absence of XBP1 affected plasma cell capacity to 
establish a normal secretory apparatus and secrete high immunoglobulins 
levels confirming that XBP1 does have a principal role in controlling the 
primary function of plasma cells (6).  
 
Currently, it is not known whether XBP1 acts alone during plasma cell 
differentiation or whether there are other factors that may cooperate and 
compensate when it is deficient. The evidence so far is that PERK and ATF6α 
are not important in the physiological B-cell UPR (51) (52). However, it 
remains unclear whether ATF6β can substitute for the loss of ATF6α. In 
yeast, Ire1 is the only UPR sensor, while plants additionally have two ATF6-
like proteins that are processed by S1P/S2P cleavage (59). In plants the 
activation of S1P/S2P can be triggered by a number of additional stress 
stimuli, including heat shock and changes in salt concentration. Interestingly, 
in higher eukaryotes the S1P/S2P pathway of regulation is shared with a 
number of other transcriptional regulators such as SREBP and the CREB3 
family.  
 
1.6 S1P/S2P 
 
The ATF6 pathway of the UPR is controlled by the induced translocation of 
ATF6 to the Golgi and its regulated intramembrane proteolysis (RIP) via 
S1P/S2P cleavage at this site. This pathway is shared by ATF6 with SREBP 
and the CREB3 family (60-65). SREBP (Sterol regulatory element binding 
protein) (64, 65) is a master regulator of lipid homeostasis (65).  In an inactive 
state, it remains bound to SCAP (SREBP cleavage activating protein) on the 
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ER membrane (65). However, low sterol levels or high carbohydrates levels 
trigger the SREBP-SCAP complex to leave the ER and enter the Golgi 
apparatus to be cleaved by S1P and S2P (64-66). The cleaved SREBP 
translocates into the nucleus and activates its target genes via Sterol 
Response Elements (SRE) (64). Thus SREBP shares a very similar pattern of 
regulation to ATF6.  While the role of SREBP in plasma cell differentiation 
remains to be determined, the target of this project is CREB3L2, which 
belongs to the CREB3 family of ER-resident transcription factors also 
activated by RIP (2).  
 
1.7 CREB3 subfamily 
 
The CREB3 (cAMP Responsive Element Binding protein 3) subfamily is 
composed of several transcription factors that contain a bZIP (basic leucine 
zipper) domain. More than 55 bZIP containing transcription factors have been 
reported in human. However, due to their sequence similarities in the coiled-
coil region, they have been further divided into 16 families and among these is 
the family composed of OASIS/CREB3L1, BBF2H7/CREB3L2, CREB-
H/CREB3L3 and AIbZIP/CREB3L4  (Figure-1.5) (2, 67).   
 
 
 
 
 
 
 
 
 
 
 
 
 
CREB3 
CREB3L1 
CREB3L2 
CREB3L3 
CREB3L4 
N 
C 
C 
C 
C 
N 
N 
N 
N C 
TA bZIP TM 
371 229 220 155 245 
519 374 353 292 394 
520 378 357 296 398 
461 322 306 245 343 
395 281 276 217 313 
Figure-1.5: Diagrammatic structure of CREB3 subfamily members. TA, 
Transcriptional Activation. bZIP, basic Leucine Zipper domain. TM, Trans 
membrane domain. N, N-terminus. C, C-terminus (2). 
Chapter-1 20	  
 
The family of proteins to which CREB3L2 belongs, includes 4 additional 
members. All of these proteins are controlled by RIP in that they get cleaved 
at their N-terminus in the Golgi, and their N-termini translocate into the 
nucleus to activate their target genes and resolve ER stress (2, 67, 68). They 
differ in their tissue distribution; CREB3L1 is highly expressed in osteoblasts, 
CREB3L3 in the liver and CREB3L4 in prostate cancer cells (2, 67). 
 
CREB3L1 and CREB3L2 are bZIP transcription factors, forming a chimeric 
oncoprotein with FUS in low-grade fibromyxoid sarcoma (LGFMS). 95% of 
LGFMS cases are due to FUS-CREB3L2 7; 16 (q32-34; p11) whereas, only 
5% of the cases are due to FUS-CREB3L1 11; 16(p11; p11). CREB3L3 is 
highly expressed in normal hepatocytes. In addition, it acts as growth 
suppressor where it is under expressed in hepatocellular tumours suggesting 
its role in tumorgensis (2). Moreover, it is activated by the UPR through 
cleavage via S1P/S2P (69).  CREB3L4 is induced by androgen and is highly 
expressed in prostate cancer cells (2). In addition, it is required for the 
development of germ cells and UPR during spermiogensis (69). 
 
1.8 CREB3L2/BBF2H7 
 
The principal focus of this study is CREB3L2, also known as BBF2H7 (Box B 
Factor 2 Human homology in chromosome 7). It was first identified in the 
chimeric gene (Fus/CREB3L2) in two cases of LGFMS (70-72). Subsequent 
studies demonstrated that the FUS/CREB3L2 chimeric gene is specific for the 
diagnosis of LGFMS (71, 73, 74).  
 
The CREB3L2 locus spans more than 120 kbp of genomic DNA (12 exons) at 
chromosome 7q33 (71, 75). It is homologous to CREB3L1, CREB3L3, 
CREB3L4 and drosophila Bbf-2 in its bZIP domain with the highest similarity 
to CREB3L1, indicating they may have comparable functions. However 
CREB3L2 and CREB3L1 have different expression patterns. CREB3L2 is 
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highly expressed in chondrocytes and placenta but weakly in prostate and 
colon whereas, CREB3L1 is highly expressed in prostate and pancreas with 
moderate expression in colon (71).  
 
In work leading up to this project the Tooze and Doody lab have developed an 
in vitro model of human plasma cell differentiation (4). In a detailed 
characterisation of gene expression spanning multiple stages of the 
differentiation, this work identified CREB3L2 as amongst the genes mostly 
strongly induced in plasma cells, and distinct from other CREB3 family 
members (76). The observation that CREB3L2 is highly expressed in normal 
plasma cells compared to B-cells has also been confirmed in other studies (8, 
77). Furthermore, in the gene expression profiling experiments CREB3L2 has 
a similar dynamics to other TFs critical in PC differentiation including PRDM1 
and IRF4 (figure-1.6 A-B).   
 
Thus CREB3L2 displays a pattern of regulation concordant with plasma cell 
differentiation and expansion of the secretory apparatus suggesting a 
potential role for this CREB3 family member in the differentiation process (4). 
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Figure-1.6: CREB3L2 expression in plasma cell differentiation. A. The kinetic 
expression pattern of 50 genes forming a PB/PC cluster obtained from timed 
sampling of in vitro differentiated human B-cells or ex vivo purified plasma cells. B. 
Average CREB3L2 expression from 3 donors during PC differentiation as 
determined by microarray (adapted from Mario Cocco and Matt Care).   
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Both the regulatory inputs driving CREB3L2 expression and the direct targets 
of this TF are not fully defined. In developing cartilage, Creb3l2 is upregulated 
by the master transcription factor Sox9, which controls chondrocyte 
differentiation and also regulates expression of cartilage matrix proteins (78). 
During chondrogenesis, the increased production of cartilage matrix proteins 
triggers a UPR, resulting in the enhanced processing and stability of 
CREB3L2. In this setting, CREB3L2 can transcriptionally activate Sec23a, 
which encodes for the Sec23A protein (coat protein complex 2; COPII) 
required for protein transportation from ER to Golgi (2, 79, 80). The loss of 
Sec23A in Creb3l2 deficient animals led to an accumulation of ECM proteins 
in the ER and enhanced ER-stress. Creb3l2 knockout mice develop severe 
chondrodysplasia, consistent with a vital role in chondrogensis, and fail to fully 
develop the chest cavity leading to early death (2, 79). 
 
ATF5 was identified as another target of CREB3L2 in mouse in a genome-
wide RNAi screen (81). This study revealed CREB3L2 downstream of RAS-
mitogen-activated protein kinase can activate ATF5, which in turn induced 
MCL1 (anti-apoptotic factor) expression, hence increasing the survival of 
glioma cells (81). This was followed up in the work of Izumi et al. who 
confirmed a role for CREB3L2 in controlling ATF5-MCL1 in chondrocytes (82). 
The findings in this report led to the conclusion that CREB3L2-ATF5-MCL1 
may represent a general pathway, which suppresses apoptosis induced by 
ER-stress (82).  Importantly MCL1 is known to be one of the critical 
determinants of long-lived plasma cells in the bone marrow (83). 
 
1.9 cyclic AMP and UPR response elements 
 
A striking feature of the transcription factors involved in the UPR is the usage 
of related DNA-elements to control partially overlapping sets of target genes. 
The transcriptional response depends on binding of the individual TF to a 
specific sequence in promoter or distal gene regulatory element and the 
subsequent interaction with transcriptional machinery. Understanding how 
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DNA-occupancy by these factors relates to each other is essential to explain 
their distinct roles in the UPR and in differentiation (35).  
 
A bZIP domain is shared between the CREB3 subfamily, ATF4, ATF6 and 
XBP1. These factors nonetheless differ in their DNA-binding specificity. The 
consensus sequences for the distinct regulatory element recognised by these 
factors are known as: Cyclic AMP response element (CRE- TGACGTCA), 
UPR response element (UPRE- TGACGTG (G/A) or the variant 
CGACGTGG), ER stress response element (ERSE- CCAAT (N9) CCACG), 
and ER stress response element-II (ERSE-II- ATTGG (N1) CCACG). The 
CRE represents the canonical element for the CREB/ATF family of bZIP 
proteins, and the UPRE a motif controlled preferentially by XBP1 as a 
homodimer, and these are most closely related (84). However both ERSEs 
and UPREs are enriched amongst sites bound by XBP1 in vivo (85). 
 ERSEs are bound by either XBP1 or ATF6 at the CCACG component while 
the general transcription factor NF-Y binds at the CCAAT element. Explaining 
some functional redundancy between the ATF6 and XBP1 arms of the UPR. 
While a specific consensus selected by CREB3L2 is not established the 
known motif data suggest that CREB3L2 is likely to act via canonical CRE 
sites and thus control a distinct set of regulatory elements, which may partially 
overlap, with those of XBP1 (35, 85). 
 
In conclusion, the UPR is a critical element for plasma cells to adapt to high 
secretory activity during terminal B-cell differentiation. However, to date XBP1 
is the only known regulator of the UPR that is implicated in plasma cell 
differentiation.  On the other hand, high expression of CREB3L2 in plasma 
cells suggests possible involvement of this factor and its regulated cleavage 
may provide a potential therapeutic target.  
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1.10 Aims 
The aim of this project will be to investigate the expression, regulation and 
function of CREB3L2 in human B-cell differentiation and B-cell tumours. 
Specifically: 
1. To establish the patterns of CREB3L2 expression during B-cell 
differentiation and in human B-cell lines. 
2. To determine the regulation of CREB3L2 in response to B-cell 
activation and the unfolded protein response in normal human B-cells 
and B-cell malignancies. 
3. To determine impact of site-1/2 protease inhibition on CREB3L2 and 
related responses during plasma cell differentiation and in B-cell 
malignancies. 
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2. Material and Methods 
 
2.1 Recombinant DNA techniques 
2.1.1 Cloning 
Bacterial strains 
The following bacterial strains of E. coli were used: 
DH5α: F-ΔlacZ ΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rK-mK+) 
supE44 thi-1 gyrA96 relA1 
BL21 Gold:  F- ompT hsdS (rB-mB-) dcm+ Tet gal endA Hte  
Bacteria were grown in Luria Broth (LB) (1% (w/v) bactopeptone, 0.5% (w/v) 
NaCl, 0.5% (w/v) yeast extract, pH 7.5) in the presence of the appropriate 
antibiotic at 37oC, or in some instances at 30oC, with continual agitation. 
Transformed stocks of bacteria were additionally maintained on LB agar plates 
(LB containing 1.5% (w/v) bactoagar).  
2.1.1.A pIRES2-EGFP vectors 
Human CREB3L2 (encoding amino acids 1-378 with amino terminal HA-tag) 
in pUC57 (Genescript), human ZBTB32 (encoding amino acids 1-502 with 
amino terminal HA-tag) in pUC57 (Genescript) and pIRES2-EGFP vector 
(Clontech) were digested using EcoRI (New England Biolabs) and BglII (New 
England Biolabs) with EcoRI buffer (New England Biolabs). The vector was 
treated with calf intestinal phosphatase (CIP) (New England Biolabs) to 
remove the 5’ phosphate group required by ligases in order to prevent vector 
re-ligation. The digested constructs were visualised using 0.8% agarose gel 
electrophoresis and ethidium bromide (EtBr) staining. Fragments of the 
correct size were excised from agarose gels, purified using a QIAquick® Gel 
Extraction Kit (QIAGEN), ligated at room temperature using T4 DNA ligase 
(Invitrogen) and transformed into DH5α competent cells by incubating at 42oC 
for 2 minutes. DNA from the transformed cells was extracted using a 
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QIAprep®Spin Miniprep kit (QIAGEN) and checked for the presence of 
appropriate insert by digestion with EcoRI and BglII. After that, larger amounts 
of the constructs were prepared using PureLinkTM HiPure Plasmid Filter 
Midiprep kit (Invitrogen). The constructs’ concentration was obtained using a 
NanoDrop spectrophotometer to determine the OD260 (Labtech). 
2.1.1.B pGEX6P-1 vectors 
Human CREB3L2 (encoding amino acids 1-378) in pUC57 (Genescript), 
human ZBTB32 (amino acids 1-117) in pUC57 (Genescript) and pGEX6P-1 
vector were digested by BamHI (New England Biolabs) and SalI (New 
England Biolabs) with BamHI buffer (New England Biolabs). The vector was 
CIP treated and resulting fragments were visualised using 0.8% agarose gel 
electrophoresis and EtBr staining.  
Then the required fragments were purified using a QIAquick® Gel Extraction 
Kit (QIAGEN), ligated at room temperature using T4 DNA ligase (Invitrogen) 
and transformed into competent DH5α or BL-21 Gold cells. DNA from the 
transformed cells was prepared using a QIAprep®Spin Miniprep kit (QIAGEN) 
and checked by digestion with BamHI and SalI. After that, larger amounts of 
the constructs were obtained using a PureLinkTM HiPure Plasmid Filter 
Midiprep kit (Invitrogen). The constructs’ concentration was obtained using a 
NanoDrop spectrophotometer (Labtech). 
2.1.2 Agarose gel electrophoresis 
0.8 % (w/v) of agarose was dissolved in 1X TBE buffer (89mM Tris-base, 
80mM boric acid, 2mM EDTA) with the addition of 2 drops of ethidum bromide 
(0.625mg/ml, Fisher Scientific). DNA mixed with buffer containing 40% 
sucrose, 30% (v/v) glycerol, 0.25% (w/v) xylene cyanol FF and 0.25% 
Bromophenol blue was loaded into the gel and run at 90 volts. A molecular 
weight ladder (1Kb+; Invitrogen) was used to assess the DNA product size 
and visualised using the Geldoc XR system (Bio-Rad). 
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2.2 Cell culture 
2.2.1 Cell lines 
The human cervical epithelial cell line Hela was used for transfections and 
evaluation of vectors generated in the course of this study. Human multiple 
myeloma cell lines (U266 and H929) were obtained from the American Type 
Culture Collection (ATCC). Human B-cell lines OCI-LY3 and OCI-LY10 
representative of activated B-cell type diffuse large B-cell lympoma were a gift 
of Dr Eric Davis.  Cells were routinely cultured in RPMI-1640 medium (Sigma) 
containing 10% heat-inactivated fetal calf serum (HIFCS, Invitrogen) and L-
glutamine.  
Population and ethics 
 
Whole blood obtained from healthy volunteer donors was collected in EDTA 
tubes after informed consent. Approval for this study was provided by U.K. 
National Research Ethics Service via the Leeds East Research Ethics 
Committee (approval reference: 07/Q1206/47). 
 
2.2.2 In vitro generation of human plasma cells 
 
Buffers: 
 
• MACS buffer no preservative, 10 % BSA 
• 20 units/ml hIL-2: STOCK, 10,000 units/ml 
• 50 ng/ml hIL-21: STOCK, 100 µg/ml 
• 10 µg/ml F(ab)2: STOCK, 1.2 mg/ml 
• 20 µl/ml Amino acids: STOCK, 50X 
• 5µl/ml Lipid mix: STOCK, 200X 
• 11 µl/ml Tx Hybridoma 
• 10 ng/ml hIL-6: STOCK, 100,000 ng/ml 
• 100 units/ml INF-γ: STOCK, 1X107 units/ml 
Chapter-2 30	  
 
Irradiated CD40L-expressing murine L cells 
 
Murine L cells stably transfected with human CD40L were seeded in Iscove's 
Modified Dulbecco's Medium (IMDM) with 10% HIFCS in to one T175 flask 
and placed in a humidified incubator maintained at 37oC and 5% CO2. Two 
days later, the cells were trypsinised and split into four T175 (1:6). After two 
days, the cells were trypsinised and passed through a cell strainer into 2X 50 
ml falcon tubes to avoid clumps. Then the cells were counted using trypan 
blue and re-suspended with IMDM/10%HIFCS so that each falcon tube should 
not contain more than 108 cells. After that, the cells were irradiated in ice 2 
times, 25 Gray for 45 minutes with gentle mixing in between. Next, 100 µl of 
the cells were used to check CD40L expression by flow cytometry using 
CD154 antibody. Then, 1X106 of irradiated murine L cells expressing human 
CD40L were prepared in 1.5 ml freezing vials and stored at -80oC.  
 
Seeding of irradiated CD40L-expressing murine L cells: 24 h prior to 
processing the blood samples, 1 vial of irradiated CD40L cells (according to 
the number of the donors) was thawed and washed with 10 ml of IMDM 
complete media. Then, the cells were re-suspended with 12 ml of fresh 
complete IMDM media and plated into a 24-well plate (0.5 ml/well; 6.25 X 
104/well). The plate was placed in the 37oC humidified incubator with 5% CO2. 
 
Day-0 
 
50 ml of human peripheral blood was collected in EDTA (EK3) tubes and 
diluted 1:2 with room temperature phosphate buffered saline (PBS).  Then, 17 
ml of lymphoprep reagent was added to a 50 ml falcon tube and 34 ml of the 
diluted blood was slowly added on top of the lymphoprep. The tubes were 
centrifuged 2400rpm/ 1114 x g for 20 minutes at 18oC using an acceleration 
value of 5 and no brake in an Eppendorf 5810R centrifuge. After 
centrifugation, the buffy coat was isolated and transferred to a 50 ml tube and 
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washed three times; twice with cold PBS and once with MACS buffer (1x PBS, 
0.5% FCS, 2mM EDTA) and centrifuged at 1500 rpm for 10 minutes. Next, the 
total peripheral blood mononuclear cells (PBMCs) were counted using trypan 
blue. B-cells were isolated by magnetic labelling using a memory B-cell 
isolation kit (composed of biotin antibody cocktail against CD2, CD14, CD16, 
CD36, CD43, CD235a (GlycoprotienA) and microbeads; Miltenyi Biotech). 
Then, the cells were separated using an LD Column in a magnetic field in 
MACS buffer. The cells were counted and re-suspended in IMDM media to 
give 2.5 X 105/ml/well. 0.5 ml of IMDM media with 2X cytokines and anti-B cell 
receptor (IL-2 (n2 X 20/10000, Roche), IL-21 (n2 X 50/100000, PeproTech) 
and F(ab)2 (n2 X 10/1200, Jackson ImmunoResearch) and 0.5 ml of cells in 
IMDM were added to each well with CD40L cells and placed in the 37oC 
humidified incubator with 5% CO2. 
Day-3 
 
The cells were collected from the wells and counted using trypan blue. The 
cells were re-suspended with IMDM media/10%FCS with 1X supplements (IL-
2 (n X 20/10000), IL-21 (n X 50/100000, PeproTech), amino acids (n X 1/50, 
Sigma), TX-HYB (n X 11μl/ml, Gentaur) and lipids (n X 1/200, Sigma) and re-
seeded at density of 1X105/well in to a 24-well plate. 
 
Day-6 
 
The cells were collected from the wells and counted using trypan blue. The 
cells were re-seeded into a 12-transwell plate using conditioned media 
obtained from cultured M210B4 cells and specific supplements (IL-6 (n2 X 
10/100000, Sigma), IL-21 (n2 X 50/100000, PrproTech), amino acids (n2 X 
1/50, Sigma), TX-HYB (n2 X 11μl/ml, Gentaur), INF-α (n2 X 100/10000000, 
Sigma) and lipids (n2 X 1/200, Sigma) at cell density of 5 X 105/well. 
 
After day-6: The cells can be re-seeded at day-10 or 13 or 20 using the same 
conditions as day-6. 
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Induction of the unfolded protein response 
The endogenous expression (full-length and cleaved forms) of CREB3L2 was 
studied in the U266 myeloma cell line using reagents know to generate ER-
stress: thapsigargin and DTT. Live cells were counted using a Hemacytometer 
and trypan blue dye. 1X106 cells were spun at 1500 rpm for 5 min and re-
suspended with 11 ml of fresh RPMI-1640 media and distributed in to seven 
25cm2 flasks (1.5 ml each). After that, 1 μM thapsigargin and 1mM DTT were 
prepared in RPMI-1640 media. 1.5ml of each ER-stressor or media alone was 
added to the corresponding flask and incubated at 37oC for the indicated time 
(t=0 or unstressed, 2h, 4h or 6h). At each time point, the cells were washed 
once with PBS and re-suspended with 50 μl 2X sample loading buffer 
containing the reducing agent 2-mercaptoethanol, boiled for 15 minutes and 
loaded on to a 10% SDS-PAGE gel and subsequently evaluated by Western 
blotting. 
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2.2.3 Plasmid transfection 
The CREB3L2-pIRES2EGFP construct was checked by transfecting it into 
Hela cells. Prior to transfection, the cells were split into 6-well plates and 
grown until they reached 80% confluence. The construct was then introduced 
into the cells using the Gene Juice transfection reagent (Novagen) according 
to the manufacturer’s instructions. Briefly, for each well a ratio of 1 μg of 
purified plasmid DNA was mixed with 3 μl of Gene Juice reagent prior 
incubation with the cells. GFP expression was checked by fluorescence 
microscopy 24-48 hours post transfection. 
2.2.4 siRNA-mediated knockdown 
 
CREB3L2 was knocked-down using Amaxa nucleofection technology. 2 X 106 
myeloma cells were used per nucleofection and resuspended in solution V 
containing either 400 or 600 pmoles of siRNA. Transfection was accomplished 
using the D.023 program on the Amaxa nucleofector. Cells were then added 
to 4 ml complete RPMI-1640 media and incubated for 24 hours and 48 hours 
(table-6). The siRNAs used were CREB3L2 siRNA 1 (s34890), CREB3L2 
siRNA 2 (s34891), and scramble/negative control (catalogue number 
4390843) purchased from ThermoFisher. 
 
Human B-cells were isolated from normal donors and cultured using the in 
vitro generation of mature plasma cells protocol up to day-3. CREB3L2 was 
knocked down in the day-3 B-cells using a human memory B cell kit from 
Lonza . 2 X 106  human B-cells were used per nucleofection with 400 pmoles 
of siRNA. Cells were transfected using the U.015 program on the Amaxa 
machine and then added to 4 ml IMDM media with supplements (Il-2, Il-21, 
amino acids, lipid mix and TX-HYB) into a 6-well plate and incubated for 24 
hours and 48 hours (table-6). A second attempt was performed using 
600pmoles of CREB3L2 siRNA 1 and or 2. 
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2.3 Techniques for protein analysis 
Glutathione S transferase (GST)-fusion proteins expression and 
purification 
2.3.1 Small scale GST-fusion protein production 
Small scale GST-CREB3L2 fusion protein production was attempted first to 
check CREB3L2 expression from several bacterial strains (DH5α and BL21-
Gold). Transformed bacteria was used to inoculate 3 ml of Luria Broth 
containing 100 μg/ml ampicillin (LB-Amp) (Starter culture) and grown at 37oC 
for 24 hours. Then, 750 μl of bacterial culture was diluted in to 10 ml LB-Amp 
and grown until it reached an OD600 of 0.6-0.8. Then the culture was induced 
with 10 μl 0f 100 mM Isopropyl β-D-1- thiogalactopyranoside (IPTG) for 2 
hours and spun at 15000g, 4oC to sediment the bacteria. After that, the pellet 
was re-suspended with cold PBS and sonicated (10 seconds, 4 bursts at 5 
microns) to release the protein from the cells. Then the sample was 
centrifuged at 15,000g, 4oC to separate the soluble from the non-soluble 
proteins. After that, 50 μl of pre-washed 50% Glutathione SepharoseTM 4B 
(GE Healthcare) was added to the soluble protein and incubated overnight on 
a rotating wheel at 4oC. Then, 15 μl of the sample was mixed with 15 μl of 2X 
sample loading buffer (10mg bromophenol blue, 15ml 20% SDS, 10ml 
glycerol, 12.5ml upper tris and 12.5ml dH2O) containing the reducing agent 2-
mercaptoethanol, boiled for 5 min and loaded on to a 10% SDS-
polyacrylamide gel (Table-1). The gel was stained with Coomassie Blue 
protein stain for 30 minutes and de-stained with 45% methanol/45% acetic 
acid. Finally, the gel picture was captured using Geldoc XR (Biorad). 
2.3.2 Large scale GST-fusion protein production 
To generate large-scale protein production, 10 ml of LB-Amp was inoculated 
with transformed bacteria (Starter culture) and grown at 37oC for 24 hours. 
Then, 10 ml of bacterial culture was diluted into 1000 ml LB-Amp and grown 
at 37oC until it reached an OD600 of 0.6-0.8. Then the bacteria were induced 
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with 1ml of 100mM IPTG for 2 hours and spun at 4oC to harvest the bacteria. 
After that, the pellet was re-suspended with cold PBS and sonicated (20 
seconds, 7 bursts at 5-10 microns). To enhance protein solubility, 200 μl of 
Triton® X-100 (Sigma) was added to the protein and incubated for 1 hour at 
4oC on a rotating wheel. Then the sample was centrifuged and the 
supernatant was transferred into a tube containing 1 ml of pre-washed 50% 
Glutathione SepharoseTM 4B (GE Healthcare) and incubated for 1 hour on a 
rotating wheel at 4oC. Then, the protein was purified by column 
chromatography and eluted with GST elution buffer (10 mM reduced 
glutathione, 50 mM Tris pH 8.0). Then, 15 μl of the sample and 15 μl of 2X 
reducing sample buffer was boiled and loaded on to a 10% SDS- 
polyacrylamide gel (Table-2.1). The gel was stained with Coomassie Blue 
protein stain for 30 minutes and then de-stained. Finally, the gel picture was 
captured using Geldoc XR. The GST-CREB3L2 fusion protein was 
concentrated using a centricon filter (Milipore Amicon Bioseparations). 
 
Table-2.1: The composition of 10% Polyacrylamide gel 
 
 
 
 
  
Tris Buffer  
 
dH20 
Poly-
acrylamide 
30% (w/v) 
Acrylamide 
Bis: 0.8% (w/v)  
10% APS 
(1g/10ml) 
Temed  
(FW 116.2) 
Resolvi
ng gel 
Lower (1.25ml) 
1.5M Tris pH8.8 
0.4% SDS 
2.05ml 1.7ml 30μl 5μl 
Stackin
g gel 
Upper (1.25ml) 
0.5M Tris pH6.8 
0.4% SDS 
3.25ml 0.5ml 30μl 5μl 
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2.3.3 Western blot evaluation 
Cells were lysed by RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS with the addition of 
protease inhibitors), loaded on to 10% or 12% SDS-polyacrylamide gel 
(Table-2.1) and transferred to nitrocellulose membrane (0.45 micron; Thermo 
Scientific) using transfer buffer (25 mM Tris, 192 mM Glycine and 20% 
Methanol) with 100 volts for 1 hour. The quality of transfer was assessed by 
Ponceau stain (0.2% ponceau/3% trichloroacetic acid). Then, the membrane 
was blocked using blocking buffer (1% non-fat milk/PBS/0.01%Tween® 20) 
for 1 hour at room temperature. Primary antibodies were diluted in buffer 
containing 2%BSA/PBS/0.01% Tween® 20 using the recommended dilutions 
(Table-2.2) and incubated with the membrane on a rocking platform for 1 hour 
at room temperature. After that, the membrane was washed 3 times (20 
minutes each) with the wash buffer (1% PBS/0.01% Tween® 20). The 
secondary antibody was diluted in the blocking buffer and applied to the 
membrane for 30 minutes at room temperature on a rocking platform. Then, 
the membrane was washed 3 times with the wash buffer and treated with 
Supersignal® West Pico Chemiluminescent substrate (Thermo Scientific) for 5 
minutes. The membrane was exposed to film (Amersham HyperfilmTMECL; 
GE Healthcare) and developed using X-ray developer (SRX-101A). 
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Table-2.2: Antibodies used in Western blotting 
Antigen Company Target Recommen
ded 
dilution 
Secondary 
antibody  
CREB3L2 Abcam HA-tag 1:10,000  
Goat anti-rabbit  
1:20,000 
CREB3L2 Aviva  N-terminus 1:1000 
CREB3L2 Novus 
Biological 
N-terminus 1:500 
CREB3L2 ProteinTech N-terminus 1:500 
CREB3L2 abcam C-terminus 1:1000 
XBP1s Biolegend N-terminus 1:500 
ATF6 
NBP1-
40256-
0.1mg 
Novus 
Biological 
N-terminus 1:500 Goat anti-
mouse 
1:20,000 
SREBP1 
(2A4) 
ab3259 
abcam N-terminus 1:1000 
SREBP1 
ab135133 
abcam N-terminus 1:1000 Goat anti-rabbit 
1:20,000 
Actin 
A1978 
Sigma life 
science 
N-terminus 1:100,000 Goat anti-
mouse 
1:20,000 
Atg3 Signalling Atg3 1:1000 Goat anti-rabbit 
1:2000 Atg5 Atg5 
Atg7 Atg7 
Atg12 Atg12 
LC3 LC3 
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2.3.4 Immuno-precipitation technique (IP) 
5 X 106 cells were lysed by RIPA buffer and 2 μg of each antibody was added 
to 200 μl of the lysate and incubated for 1 hour on a rotating wheel at 4oC. 
This was followed by the addition of 30 μl of Protein A Agarose (Thermo 
Scientific) and incubated for 1 hour on a rocking platform at 4oC to allow the 
binding of Protein A Agarose with protein-antibody complex. Then the 
samples were centrifuged for 1 minute, 3000rpm/855 x g at 4oC followed by 
washing steps (4 times with RIPA buffer). Then, 25 μl of 2X gel loading buffer 
with 2-merceptoethanol was added, mixture boiled for 5 minutes and loaded 
on to a 10% SDS-PAGE gel. The gel was transferred to nitrocellulose 
membrane, blocked in 1% milk/PBS-T and probed with appropriate antibody 
(Table-2.2). 
2.4 Enzyme Linked ImmunoSpot (ELISpot) Assay for detection of 
secreted IgM and IgG 
 
Preparation of ELISpot plates  
 
The coating mAb MT91/145 (IgG) and coating anti-IgM antibody were diluted 
to 15 µg/ml and 10 µg/ml, respectively, in sterile PBS, pH 7.4. Then, the 
PVDF membranes in the plates were pre-wet using 50 µl of 70% sterile 
ethanol for maximum of 2 minutes and washed 5 times using 200 µl/well with 
sterile water. After that, 100 µl/well of the diluted antibodies were added and 
incubated 6-8 hours at room temperature or overnight at 4oC. 
 
Incubation of cells in the plates 
 
The plates were washed 5 times with 200 µl/well of sterile PBS and then 
blocked with 200 µl/well of IMDM/10%FCS for 30 minutes at room 
temperature. After that, the isolated human B cells (Day-6) were re-
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suspended in IMDM/cytokines without TX-HYB mix and added to the wells. 
The plates were placed in a 37oC humidified incubator with 5% CO2 for 16-24 
hours. 
 
Detection of spots 
 
The detection mAbs MT78/145 biotin and anti-IgM biotin antibody were diluted 
to 1 µg/ml in sterile PBS/0.5%BSA. Then, the samples were removed from the 
plates and washed 5 times with 200 µl/well of sterile PBS. Next, 100 µl/well of 
the diluted antibodies were added to the corresponding plate and incubated 
for 2 hours in dark at room temperature. After incubation, the plates were 
washed 5 times with 200 µl/well of sterile PBS. Afterward, 100 µl/well of 
1:1000 streptavidin-HRP antibody in sterile PBS/0.5%BSA was added to each 
plate and incubated for 1 hour in dark at room temperature. After incubation, 
the plates were washed 5 times with 200 µl/well of sterile PBS.  
In order to detect the spots, 100 µl/well of filtered 3,3’,5,5’-
Tetramethylbenzidine (TMB) substrate solution was added to each plate and 
incubated until the spots developed and then washed thoroughly with 
deionized water and left to dry. Once dried, the plates were stored at dark until 
analysed.  
  
2.5 Human IgG and IgM ELISA quantification  
 
Buffers: 
 
• ELISA Coating buffer: 0.05 M Carbonate-Biocarbonate, pH 9.6 
• ELISA Wash solution: 50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0 
• ELISA Blocking buffer: 50 mM Tris, 0.14 M NaCl, 1% BSA, pH 8.0 
• Sample/Conjugate Diluent: 50 mM Tris, 0.14 M NaCl, 1% BSA, 0.05% 
Tween 20, pH 8.0 
• Enzyme substrate TMP  
• ELISA Stop solution: 0.18 M H2SO4 
Chapter-2 40	  
 
Human IgM  
 
ELISAs were performed as per the manufacturer’s instructions for the human 
IgM quatification kit (E80-100, Bethyl Laboratories, Inc). 96-well plates were 
coated with 100 µl of 1:100 affinity purified antibody in coating buffer for 1 hr 
at room temperature. After incubation, the plates were washed five times with 
ELISA washing buffer. Then, 200 µl of the ELISA blocking buffer was added to 
prevent the non-specific binding and incubated for 1 hr at room temperature or 
overnight at 4oC. After that, the plates were washed five times using ELISA 
washing buffer. The standards (1-8) were diluted using the sample/conjugate 
Diluent according to the following Table-2.3. 
 
Table-2.3: Dilution/concentration of IgM ELISA standards. 
 
Standard ng/ml RS10-110-4 
(0.44 mg/ml IgM) 
Sample Diluent 
1 1000 10 µl 4.4 ml 
2 500 500 µl from std 1 500 µl 
3 250 500 µl from std 2 500 µl 
4 125 500 µl from std 3 500 µl 
5 62.5 500 µl from std 4 500 µl 
6 31.25 500 µl from std 5 500 µl 
7 15.6 500 µl from std 6 500 µl 
8 0 Blank 500 µl 
 
In addition, the samples were diluted according to the predicted concentration 
in order to fit within the standards’ range.  
Next, 100 µl of the standards/samples were added to the appropriate wells 
and incubated for 1 hour at room temperature. After that, the plate was 
washed the same as described before. Then, 100 µl of 1:75,000 HRP 
detection antibody (A80-100P) in the sample conjugate diluent was prepared 
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and added to each well and incubated for I hour at room temperature. After 
incubation, the plate was washed as described above and 100 µl of TMB 
substrate was added to each well and incubated in the dark for 15 minutes at 
room temperature until the enzymatic reaction develops to the blue colour 
according to the IgM concentration. After that, the reaction was stopped using 
100 µl of stop solution (0.18 M H2SO4) and the concentrations were quantified 
using a plate reader and a standard curve.  
 
Human IgG  
ELISA quantification for human IgG was performed using a kit from Bethyl 
Laboratories, Inc. (Cat. No. E80-104), in an analogous manner to the IgM 
assay. The IgG assay utilised the appropriate standards (intial-8) diluted using 
the sample/conjugate Diluent according to the following table-2.4 and were 
detected with the paired anti-IgG secondary. 
 
Table-2.4: Dilution/concentration of IgG ELISA standards. 
 
Standard ng/ml RS10-110-4 
(4.4 mg/ml IgG) 
Sample Diluent 
Initial 1000 5 µl 22 ml 
1 500 500 µl from initial 500 µl 
2 250 500 µl from std 1 500 µl 
3 125 500 µl from std 2 500 µl 
4 62.5 500 µl from std 3 500 µl 
5 31.25 500 µl from std 4 500 µl 
6 15.6 500 µl from std 5 500 µl 
7 7.8 500 µl from std 6 500 µl 
8 0 Blank 500 µl 
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2.6 Cell phenotype evaluation by flow cytometry 
 
Approximately 2x105 cells per sample were stained with the indicated 
antibodies. Cells were centrifuged at 1500 rpm for 5 minutes before being 
washed with FACs buffer (PBS, 0.5%BSA, 0.05% azide). Non-specific 
staining was blocked using 25 µl of the blocking buffer (932 μl FACS 
buffer/10% BSA, 16.6 μl human IgG (Sigma), 50 μl NMS) and incubated for 
15 minutes at 4oC. Then, the cells were stained using ISO/4-colour antibodies 
(Table-2.5) or anti-CD154 for 20 minutes at 4oC. After that, the cells were 
suspended in cold FACs buffer and the phenotype was evaluated on an 
LSRIII flow cytometer (BD Biosciences) using DIVA software (BD 
Biosciences). 
 
Table-2.5: List of the BD antibodies used for cell phenotype studies by flow 
cytometry. 
ISO Antibody Cocktail 
 PE CD19 PE 
 V450 CD20 V450 
 PEcy7 CD38 PECy7 
 APC CD138 APC 
 CD154 PE 
 CD27 FITC 
 
 
2.7 Carboxyfluorescein Succinimidyl Ester (CFSE) cell proliferation 
assay 
 
1.5 X 106 human B cells were isolated from the total PBMC as described 
above. The cells were spun down at 1500rpm/435 x g (Eppendorf centrifuge 
5810R, 17.3cm radius) for 5 minutes and the resulting pellet was re-
suspended with 1 ml PBS/5%FCS. After that, 110 µl of PBS/5%FCS and 1.1 
µl of 5 mM CFSE dye were added gently and quickly to the cells in the dark 
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and incubated for 5 minutes at room temperature. After incubation, the cells 
were washed twice with PBS/5%FCS and re-suspended with IMDM media 
and incubated on top of CD40L-expressing L cells (Day-0). The cells were 
treated with the inhibitors and their corresponding vehicle on Day-3 and 
analysed on Day-6 using flow cytometry. 
 
2.8 Techniques for analysis of gene expression and regulation 
RNA extraction 
Cells were lysed by 800 μl of Trizol®. Then, 160 μl of chloroform was added 
to the mixture, mixed by inversion and centrifuged at 12,000g for 15 minutes 
at 4oC to allow the separation between the aqueous and organic phases. RNA 
(top aqueous layer) was transferred into a new tube. Then, 10 μg of RNase 
free glycogen was added. RNA was precipitated using 0.4 ml of isopropyl 
alcohol, incubated for 10 minutes at room temperature and spun at 12,000g 
for 10 minutes at 4oC. The precipitate was washed with 1 ml of 75% ethanol 
and air-dried. RNA was dissolved in 45 μl of dH2O and incubated for 10 
minutes at 55oC followed by treatment with DNase1 (DNA-free Kit, Ambion) 
for 1 hour at 37oC. Then, 5 μl of inactivating agent was added to the sample 
and incubated for 2 minutes at room temperature. 
cDNA synthesis 
5 μl of RNA (DNaseI treated) was mixed with Mix 1 (Table-2.6) and incubated 
at 65oC for 5 minutes to denature the double-stranded RNA and to prevent re-
annealing. Then, 10 μl of Mix 2 was added and incubated at 42oC for 50 
minutes to synthesise cDNA. Then, the sample was incubated at 70oC for 15 
minutes to terminate the synthesis followed by chilling on ice for 5 minutes. 
After that, 0.5 μl of RNase H (2U/µl) was added to remove RNA template 
leaving behind only cDNA. A control without reverse transcriptase was 
generated at the same time. 
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Table-2.6: Reaction mixtures required for cDNA synthesis 
 
 
 
 
 
Real-time PCR (q-PCR) 
Real-time PCR was used to amplify the two transcripts of CREB3L2 using 
specific primers that were designed by Primer3 software version 4.0 (Table-
2.7). A 10 μl reaction was used in such that 5 μl of Fast Start Universal Sybr 
Green (Roche), 2.6 μl dH2O, and 0.4 μl primer (100 nM) mixture was added 
to 2 μl of the cDNA sample and the reaction was performed using a 
Stratagene Mx3005P machine. In a separate reaction, the gene PPP6C was 
used as a control due to its known stable expression as determined in 
previous gene expression analysis (4). Table-2.8 shows the thermal set up 
used for the q-PCR. 
Table-2.7: The sequence of primers used in real-time PCR. 
Mix 1 Mix 2 
1μl Oligo dT 4μl 5X Buffer 
1μl dNTPs 2μl DTT 
3μl dH2O 2μl MgCl2 
 1μl RNase Out 
 0.25μl RT 
 0.75μl dH2O 
Primer Sequence 
PPP6C For 5’-AGGCTAAATGGCCTGATCGTA-3’ 
Rev 5’-TCTCCAGGCATTAGCATTTCC-3’ 
Transcript 1 (both) For 5’-CCTCATGTACCACACGCACT-3’ 
Rev5’-GGTTCCACCTCCATTGACAC-3’ 
Transcript 1 (Isoform 1) For 5’-CCCCTGTCAAAATCAGAGGA-3’ 
Rev 5’-TTTTTCTCCAGGCTGTCCAT-3’ 
Transcript 2 (Isoform 2) For 5’-TGACGATGAGGTGGAAAGTG-3’ 
Rev5’-CAGAGTGACAGACGGAACGA-3’ 
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Table-2.8: Thermal set up for q-PCR used. 
 
 
 
 
 
 
 
 
 
 
2.9 ChIP (Chromatin Immunoprecipitation) Assay 
 
Buffers: 
 
• 1 M HEPES, pH 8.0 
• 0.5 M EDTA, pH 8.0 
• 0.5 M EGTA, pH 8.0 
• 10X Cross linking buffer: 500 mM HEPES, 1M NaCl, 10 mM EDTA, 5 mM 
EGTA  
• 1X Cross-linking buffer: 0.5 ml 10X Cross linking buffer, 3.3 ml 16 % 
Formaldehyde, 1.2 ml dH2O 
• 2M Glycine: 1.5 g Glycine in 10 ml PBS 
• ChIP Buffer A: 10 mM HEPES, 10 mM EDTA, 0.5 mM EGTA, 0.25 % 
Triton X-100 
• ChIP Buffer B: 10 mM HEPES, 200 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.01 % Triton X-100 
 10:00 
95oC 
00:15 
95oC 
 1:00 
95oC 
 00:30 
95oC 
  1:00 
60oC 
  
 00:30 
55oC 
2:00 
50oC 
 
1 cycle 1 cycle 40 cycles 1 cycle 
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o 25 ml of dH2O was added first to stop precipitation and (DMSO, H2O 
soluble) protease inhibitors (Leupeptin, Antipain, Aprotinin, AEBSF, 
Pepstatin A and Chymostatin) were added immediately before use 
• 20 % SDS (BioRad) 
• ChIP IP buffer: 25 mM Tris HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1 % 
Triton X-100, 0.25 % SDS 
o Protease inhibitors were added immediately before use 
• ChIP IP without SDS: 25 mM Tris HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 
1 % Triton X-100 
• Glycerol Storage buffer: ChIP IP buffer without SDS, 20 % Glycerol 
• RIPA buffer: 10 mM Tris HCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 140 mM 
NaCl, 1 % Triton X-100, 0.1 % NaDOC, 0.1 % SDS 
• LiCl buffer: 10 mM Tris HCl pH 8.0, 1 mM EDTA, 0.17 M LiCl, 0.5 % NP40, 
0.5 % NaDOC 
• Sodium Biocarbonate 0.5 M: 0.21g NaHCO3 in 5 ml dH2O (Made up fresh 
just before use) 
• Elution buffer: 0.1 M NaHCO3, 1 % SDS 
• 1M TE buffer pH 8.0 
• 1M Tris-HCl pH 6.5 
• 3 M Sodium acetate pH 5.2 
 
Chromatin preparation from suspension cells 
 
 2 X 107 myeloma cells were harvested and suspended in 20 ml of RPMI-1640 
media. The cells were cross-linked using 2 ml of freshly prepared 1X cross-
linking buffer containing formaldehyde and incubated on a rotor at room 
temperature for 30 minutes. After the cross-linking, the formaldehyde was 
quenched using 7.34 ml of 2 M glycine in PBS for 5 minutes on a rotor at 
room temperature. The cells were pelleted (1500rpm/435g, 5 minutes) then, 
washed twice with 25 ml ice cold PBS (1500rpm/435g, 5 minutes at 4oC). 
After that, the cells were lysed using 2 ml ChIP buffer A followed by 2 ml ChIP 
buffer B with an incubation period of 10 minutes and centrifugation (16,100 x 
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g, 5 minutes at 4oC) after the addition of each buffer. After that, 600 µl of ChIP 
IP buffer was added to the pellet and split in to 2 X 1.5 ml eppendorfs and 
sonicated using Bioruptor (Diagenode IP) water bath sonicator for 15 minutes. 
After sonication, the tubes were centrifuged to remove the debris. 200 µl of 
the glycerol storage buffer was added to the supernatant (chromatin) and 
stored at -80oC. 
 
Immunoprecipitation of protein-chromatin complexes 
 
300 µl of beads (Immobilised Protein A-Thermo Scientific) were blocked using 
60 µl of BSA (10 mg/ml) for 2 hours at 4oC. At that time, the chromatin sample 
was thawed on ice and 200 µl of ChIP IP buffer without SDS was added to 
increase the volume size to 1 ml. After that, 60 µl of blocked beads was added 
to the chromatin sample to pre-clear the chromatin and incubated for 2 hours 
at 4oC on a rotor. Then, the beads were discarded and the supernatant was 
divided in to 5 tubes; 2 tubes for specific antibody (200 µl each), 2 tubes for 
the IgG control (200 µl each), and 1 tube for the INPUT (100 µl).  
 
For CREB3L2: 5 µl (2µg) of CREB3L2 antibody (NBP1-88697, Novus 
Biologicals) was added to each tube and incubated on a rotor overnight at 
4oC.  
 
For IgG: 1 µl (2µg) of IgG antibody was added to each tube and incubated on 
a rotor overnight at 4oC.  
 
For the INPUT: 10 µl of RNase A (1mg/ml) was added and incubated for 30 
minutes at 37oC. Then, 5 µl of 20% SDS and 5 µl of proteinase K (10 mg/ml) 
were added to the INPUT to digest the protein and inactivate the nucleases 
that might degrade the DNA during the purification step and incubated for 2.5 
hours at 37oC. After the incubation, the cross-linking of the chromatin INPUT 
sample was reversed by the incubation at 65oC overnight. 
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ChIP samples: After incubating chromatin samples (CREB3L2/IgG) with the 
appropriate antibodies, 50 µl of pre-prepared beads were added to each 
sample and incubated 5 hours on rotor at 4oC. After that, the ChIP samples 
were centrifuged and the supernatant was discarded. The chromatin/beads 
were washed 4X with RIPA buffer, 2X with LiCl buffer and 2X TE buffer.  
Then, 500 µl Elution buffer, 33 µl NaCl and 4 µl Proteinase K were added and 
incubated at 65oC overnight.  
 
DNA purification  
 
ChIP sample:  
 
ChIP samples were cooled down and spun. Then, 10 µl of 0.5 M EDTA and 
20 µl of 1M Tris-HCl pH.6.5 were added to the ChIP samples and incubated at 
45oC for 1 hour to neutralize the reversion of the cross-linking. After the 
incubation, ChIP samples were cooled down. Then, 500 µl of 3:1 
phenol:chloroform was added to each tube and centrifuged at 16,100 x g  for 
15 minutes at room temperature. After that, 500 µl of chloroform was added to 
the supernatant and centrifuged at 16,100 x g for 15 minutes at room 
temperature. Next, 4 µl of glycogen (Roche, 5 mg/ml), 50 µl of 3 M sodium 
acetate (pH 5.2) and 900 µl of ice-cold absolute ethanol were added to each 
tube and incubated at -20oC for 30 minutes. Then, the tubes were centrifuged 
at 16,100 x g for 15 minutes at 4oC. After that, the pellets were washed with 1 
ml 75% ice-cold ethanol. The pellets were air dried for 5 minutes and then, re-
suspended with 80 µl of 0.1 TE (pH 8.0) at 55oC for 10 minutes and stored at 
4oC for short-term storage and at -20oC for long-term storage.  
 
INPUT: 
 
The INPUT sample was cooled down and spun. Then, 150 µl of 3:1 
phenol:chloroform was added to each tube and centrifuged at 16,100 x g  for 
5 minutes at room temperature. After that, 150 µl of chloroform was added to 
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the supernatant and centrifuged at 16,100g x g for 5 minutes at room 
temperature. Next, 4 µl of glycogen (5 mg/ml) and 250 µl of ice-cold absolute 
ethanol were added to each tube and incubated at -20oC for 30 minutes. 
Then, the tubes were centrifuged at 16,100 x g for 15 minutes at 4oC. After 
that, the pellets were washed with 250 µl of 75% ice-cold ethanol. The pellets 
were air dried for 5 minutes and then, re-suspended with 80 µl of 0.1X TE 
buffer (pH 8.0) at 55oC for 10 minutes and stored at 4oC for short-term storage 
and at -20oC for long-term storage.  
 
2.10 Gene expression profiling 
 
RNA samples were collected from human B-cells that were isolated using a 
memory B-cell isolation kit (Miltenyi Biotec) and treated with PF-429242/dH2O 
and or Nelfinavir/ethanol.  
The RNA samples were extracted as described above re-suspended in 45 µl 
dH2O, 40 µl was stored at -80oC and the rest at -20oC for RNA testing.  RNA 
samples were quantified using Qubit® 2.0 Fluorometer (cat No Q32866) and 
the quality of RNA samples were checked using the Agilent RNA 6000 Nano 
kit (2100 analyser). After that, RNA samples were amplified using Illumina® 
TotalprepTM-96 RNA Amplification Kit (Figure-2.1). 
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Figure-2.1: RNA amplification steps using Illumina® TotalprepTM-96 RNA 
Amplification Kit. 
 
RNA amplification using Illumina® TotalprepTM-96 RNA Amplification Kit: 
As shown in Figure-2.1, RNA was first reverse transcribed to synthesize the 
first cDNA strand using a thermal cycler (Table-2.9) and reverse transcription 
master mix (Table-2.10). 
 
 
 
 
 
 
Reverse transcription to 
synthesize first strand cDNA 
Second strand cDNA 
synthesis 
cDNA purification 
 
In vitro transcription to 
synthesize cRNA 
cRNA purification 
Check the quality of cRNA 
using Qubit 
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Tabl-2.9:  Reverse transcription thermal cycler program 
 
Temperature Time Cycles 
42oC 2 hours 1 
4oC Hold - 
 
Table-2.10: Reverse transcription master mix 
 
Amount Component 
2 µl 10X First Strand Buffer 
4 µl dNTP Mix 
1 µl T7 Oligo(dT) Primer 
1 µl RNase Inhibitor 
1 µl ArrayScriptTM Reverse Transcription 
 
Then, the second strand of the cDNA was synthesised using the appropriate 
thermal cycler program (Table-2.11) and second strand master mix (Table-
2.12). 
 
Table-2.11: The synthesis of cDNA second strand thermal cycler 
 
Temperature Time Cycles 
16oC 2 hours 1 
4oC Hold - 
 
Table-2.12: Second strand master mix 
 
Amount Component 
63 µl Nuclease-free water 
10 µl 10X Second Strand Buffer 
4 µl dNTP Mix 
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2 µl DNA Polymerase 
1 µl RNase H 
 
After that, the synthesised cDNA was purified using cDNAPure beads. Next, 
the purified cDNA was in vitro transcriped (IVT) to synthesise the cRNA using 
the appropriate thermal cycler program (Table-2.13) and IVT master mix 
(Table-2.14). 
 
Table-2.13: IVT thermal cycler program 
 
Temperature Time Cycles 
37oC 4-14 hours 1 
4oC Hold - 
 
Table-2.14: IVT master mix 
 
Amount Component 
2.5 µl Biotin-NTP mix 
2.5 µl T7 10X Reaction Buffer 
2.5 µl T7 Enzyme Mix 
 
After the incubation, cRNA samples were purified using the cRNA binding 
beads and eluted with 40 µl cRNA elution buffer at 55oC.  Then, the cRNA 
samples were quantified using the Qubit kit and stored at -20oC (short time 
storage) or -80oC for long time storage until hybridised.  
cRNA samples were hybridized using whole-Genome expression direct 
hybridisation assay. 
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Whole-Genome Gene Expression Direct Hybridisation Assay 
 
750ng/15µl of cRNA samples were dispensed on to the BeadChip and 
inserted into the Hyb Chamber, which then incubated in the Illumina 
Hybridization Oven for 14-20 hours at 58oC. Meanwhile, the High-Temp wash 
buffer (lot No 10005610) was prepared and placed in to a Hybex Waterbath 
insert with base temperature of 55oC and left overnight. After the incubation, 
the BeadChip was removed from the oven and the wash buffers (100% EtOH, 
High-Temp wash buffer (prepared 24 hours before) and E1BC wash buffer) 
were prepared. The BeadChip was washed using High-Temp buffer, then 
E1BC, followed by 100% EtOH and High-Temp wash buffer. After that, the 
BeadChip was blocked using E1 blocking buffer and then stained using Cy3-
Streptavidin. After that, the BeadChip was dried and stored in a dark 
environment until ready to be scanned. The BeadChip was scanned with 
Illumina BeadScanner and the initial data were processed using Illumina 
GenomeStudio Gene Expression Module (Gene Expression Omnibus: 
GSE41208). HUGO Gene Nomenclature was used to annotate the final 
report. The threshold was 3. Any probe was less than 3 were removed from 
the analysis. R Limma was used to generate the linear model and the 
differentially expressed genes were assessed using Limma empirical Bayes 
module (bioinformatic analysis performed by Dr Matthew Care). 
 
2.11 Chromatin Immunoprecipitation Sequencing (ChIP-Seq) 
 
ChIP assay was performed as described in Section 2.9. The additional 
antibodies used included anti-ATF6 (NBP140256, Novus Biologicals) and anti-
XBP1s (619502, Biolegend). The libraries were prepared for input chromatin 
according to the manufacturer’s instructions using Illumina ChIP-seq Sample 
Prep kit (Illumina®). However, the libraries for ChIP samples were prepared 
using MicroPlex Library Preparation TM kit (Diagenode). In addition, AMPure 
XP beads (Beckman Coulter) were used for size selection and the samples 
were run on an Illumina Hiseq 2500. Dr Mario Cocco performed library 
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preparation and purification. Peak calling was performed by Dr Matthew Care 
as previously described (86). 
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3. Generating reagents required for the evaluation of CREB3L2 
 
The aim of this project is to study the role of CREB3L2 in B-cell differentiation 
and the UPR. Therefore, the first step was to generate CREB3L2 constructs in 
mammalian and bacterial expression vectors to be used for the study. In 
parallel, similar constructs were also made for the transcription factor 
ZBTB32. ZBTB32 was identified as one of the most characteristic genes 
associated with ABC-DLBCL (87) and may potentially contribute to the 
regulation of the transition from plasmablast to plasma cell in the same 
operational window as CREB3L2; however, no further work was completed on 
this factor beyond the generation of the vectors described below. The 
mammalian expression constructs have the potential to be used as positive 
controls for validation of antibodies and to allow overexpression of the 
proteins for functional assessment. The GST-fusion proteins may be used as 
immunogens for the development of new antibodies or alternatively could be 
employed for biochemical assays to determine DNA or protein interaction 
partners. 
 
3.1 Generation of CREB3L2-pGEX6P-1 and CREB3L2-pIRES2EGFP 
constructs 
 
3.1.1 Cloning 
 
CREB3L2 and ZBTB32 were cloned into two vectors: pIRES2-EGFP for 
mammalian expression and pGEX6P-1 for bacterial expression. The pIRES2-
EGFP vector contains a CMV promoter to drive expression of CREB3L2 or 
ZBTB32 at high levels in mammalian cell lines. As the name implies, there is 
also an IRES-EGFP expression cassette located downstream of CREB3L2 
which allows a convenient means of monitoring transfection. The pGEX6P-1 
vector is used to generate N-terminal GST-fusion proteins that can be 
expressed in large quantities in bacterial hosts and purified using the GST-
tag. 
Chapter-3 55	  
 
3.1.1A CREB3L2-pIRES2EGFP and ZBTB32-pIRES2EGFP constructs 
 
The amino terminal portions (containing the DNA-binding domain) of human 
CREB3L2 (amino acids 1-378) and ZBTB32 (amino acids 1-502) were cloned 
into the pIRES2-EGFP vector (as described in the Materials and Methods, 
Figure-6A). Two positive clones from each construct (CREB3L2-pIRES2EGFP 
and ZBTB32 pIRES2EGFP) were selected and verified by re-streaking them 
on to kanamycin-LB plates and processing a further four clones for evaluation 
by restriction digest (Figure 3.1 B and C). 
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Figure 3.1: Cloning of CREB3L2 and ZBTB32 into pIRES2-EGFP vector (A-
C). A. Diagrammatic representation of CREB3L2 and ZBTB32 constructs with the 
restriction enzymes used for cloning and verification indicated. B. CREB3L2-
pIRES2EGFP and ZBTB32-pIRES2EGFP miniprep digestion. The expected insert 
sizes were 1197 bp and 1524 bp, respectively. Red boxes indicate inserts of 
correct molecular weight. These clones were subsequently validated in part C. C. 
Validation of CREB3L2-pIRES2EGFP and ZBTB32-pIRES2EGFP clones by 
additional round of colony selection and miniprep digestion. Numbering at the top 
indicates the designated clone number. L, molecular weight ladder. 
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3.1.1B CREB3L2-pGEX6P-1 and ZBTB32-pGEX6P-1 constructs 
 
Three unsuccessful attempts were made to clone the amino termini of 
CREB3L2 and ZBTB32 into pGEX6P-1 vector using BamHI and SalI with 
NEB2 (10 mM Tris-HCl pH7.9, 10 mM MgCl2, 50 mM NaCl, 1 mM DTT) and 
NEB3 (50 mM Tris-HCl pH7.9, 10 mM MgCl2, 100 mM NaCl, 1 mM DTT) 
buffers. In each instance, the diagnostic restriction digests failed to generate 
fragments of the expected molecular weights for vectors with inserts (Figure 
3.2). 
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Figure 3.2: A. Diagrammatic representation of CREB3L2 and ZBTB32 
insertion in to pGEX6P-1. B. Digests of CREB3L2- and ZBTB32-pGEX6P-
1 with BamHI and SalI. Numbering at the top indicates the designated 
clone number. L, molecular weight ladder. 
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To solve the problem, the parental vector pGEX6P-1 was re-digested with two 
different combinations of enzymes; one digested with BamHI and SalI and the 
second with BamHI and XhoI (since Xhol and Sal1 have compatible cohesive 
ends). In addition, CREB3L2 and ZBTB32 inserts were re-digested using the 
same restriction enzymes but with changing the buffer to the unique BamHI 
buffer (150mM NaCl, 10mM Tris, pH 7.9, 10mM MgCl2, 1mM DTT).  
CREB3L2 and ZBTB32 were successfully liberated from the pUC57 vector 
(Figure 3.3), extracted, ligated in to pGEX6P-1, transformed into DH5α 
competent cells and grown on ampicillin-LB plates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine the outcome of CREB3L2-pGEX6P-1 transformation, eight 
clones were selected, DNA purified and digested by BamHI and SalI with 
BamHI buffer. Among the eight, only one clone (CREB3L2-pGEX6P-1 13) had 
the right molecular weight (Figure 3.4 A). This was therefore re-streaked on to 
ampicillin-LB plates and four clones were selected for validation (Figure 3.4 
B).  
 
Figure 3.3: CREB3L2 and ZBTB32 digestion. 0.8% agarose gel electrophoresis 
of pUC57-CREB3L2 and pUC57-ZBTB32 digestion with BamHI and SalI giving 
the expected insert sizes of 1149bp and 366bp, respectively. 
Lad
der
 
CR
EB
3L2
 
ZB
TB
32 
12kb- 
 
4kb- 
 
2kb- 
1.6kb- 
 
1.0kb- 
850bp- 
 
650bp- 
500bp- 
 
400bp- 
300bp- 
 
200bp- 
 
100bp- 
Chapter-3 58	  
 
On the other hand, none of the eight clones that were chosen from ZBTB32-
pGEX6P-1 transformation worked (Figure 3.5A). Therefore, different sets of 
restriction enzymes were chosen to digest the purified ZBTB32-pGEX6P-1 
and CREB3L2-pGEX6P-1 (Figure 3.5B). By changing the restriction enzymes 
used to evaluate the presence of ZBTB32, all the eight clones that were 
purified were shown to have the expected size of insert. Two positive clones 
(ZBTB32-pGEX6P-1 21 and ZBTB32-pGEX6P-1 23) were selected and 
validated by re-streaking them on to ampicillin-LB plates (Figure 3.5C). 
Additionally, six clones of CREB3L2 had the right molecular weight, which 
then were validated by re-streaking one positive clone (CREB3L2-pGEX6P-1 
23) on to ampicillin-LB plates, purified and digested using the same enzymes 
(Figure 3.5D). 
 
 
 
Figure 3.4: CREB3L2 cloning into pGEX6P-1 
(A-B). A. Restriction digest of eight clones of 
CREB3L2-pGEX6P-1 with BamHI and SalI. The 
expected insert size is 1149 bp. B. Validation of 
clone CREB3L2-pGEX6P-1 13 by secondary 
screening. Numbering at the top indicates the 
designated clone number. L, molecular weight 
ladder. 
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Figure 3.5: Optimising the generation of ZBTB32-pGEX6P-1 and CREB3L2-
pGEX6P-1 constructs (A-D). A. Restriction digest of eight clones of ZBTB32-
pGEX6P-1 with BamHI and SalI. B. Diagrammatic representation of CREB3L2-
and ZBTB32-pGEX6P-1 digestion using BamHΙ and PstΙ for CREB3L2 and PstΙ 
only for ZBTB32. C. Restriction digest of eight clones of CREB3L2-pGEX6P-1 with 
BamHΙ, PstΙ and ZBTB32-pGEX6P-1 with PstΙ. The expected insert sizes were 
1kb, 779bp, and 279bp for CREB3L2-pGEX6P-1 and 1kb for ZBTB32-pGEX6P-1. 
Three positive clones (CREB3L2-pGEX6P-1 23, ZBTB32-pGEX6P-1 21 and 
ZBTB32-pGEX6P-1 23) were validated by re-streaking them on to Ampicillin-LB 
plates. D. Validation of the selected clones by secondary screening. Numbering at 
the top indicates the designated clone number. L, molecular weight ladder. 
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Based on successful evaluation by restriction digest, the following constructs 
were prepared for future tests: 
CREB3L2-pIRES2EGFP (clone 14) 
CREB3L2-pIRES2EGFP (clone 21) 
CREB3L2-pGEX6P-1 (clone 132) 
CREB3L2-pGEX6P-1 (clone 233) 
 
ZBTB32-pIRES2EGFP (clone12) 
ZBTB32-pIRES2EGFP (clone13) 
ZBTB32-pGEX6P-1 (clone 211) 
ZBTB32-pGEX6P-1 (clone 213) 
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3.2 Generation of GST-CREB3L2 fusion proteins 
 
CREB3L2 was cloned into the pGEX6P-1 vector harbouring an N-terminal 
GST-tag. GST-CREB3L2 proteins (CREB3L2-pGEX6P-1 (132) and 
CREB3L2-pGEX6P-1 (233)) were induced in transformed DH5α and 
subsequently purified using affinity column chromatography. The generation 
and purification of small scale GST-CREB3L2 fusion protein revealed a 
protein with molecular weight of around the predicted size of 81 KDa (Figure 
3.6A). A large scale GST-fusion protein production was performed to purify 
larger amount of GST-CREB3L2, however, a protein of the expected 
molecular weight was not obtained (Figure 3.6B).  
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Figure 3.6: Generation of GST-CREB3L2. A. Small scale production from two 
separate clones with the following samples: whole cell lysate from un-induced 
bacteria, whole cell lysate from induced bacteria, affinity purified fusion protein. B. 
Large scale protein production from clone CREB3L2 233. Samples are 3 
consecutive eluates from the affinity column. Proteins were detected by 
Coomassie staining of 10% SDS-PAGE gels.  
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In order to check whether the lack of protein detection could be due to 
solubility and elution issues, the bacterial pellets and the Sepharose-bound 
material were run on a 10% SDS-PAGE gel.  However, GST-CREB3L2 was 
not found in the pellets or the beads (Figure-12A). The next step was to test 
the induction as the experiment in Figure 3.7A was carried out using a newly 
prepared batch of IPTG.  
Three different preparations of IPTG were examined using a small-scale 
ZBTB32-pGEX6P-1 purification (because this protein worked well with both 
the small and large scales): the batch used in Figure 11B and 12A, the 
previous batch used in the small-scale trial, and a freshly prepared solution. 
The test revealed that all three sets of IPTG worked (Figure 3.7B 1, 2) with the 
least induction efficiency using the old IPTG (Figure 3.7B 3). Therefore, large 
scale GST-CREB3L2 expression was repeated using the new IPTG but it still 
did not work, with only degradation products detected (Figure 3.7C). 
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Figure 3.7: Optimisation of GST-CREB3L2 large-scale expression. A. 
Checking the bacterial pellets and Sepharose-bound material from CREB3L2 and 
ZBTB32. B. Examination of three different preparations of IPTG (1, 2, and 3) using 
a small-scale ZBTB32-pGEX6P-1 purification. C. Large scale protein production 
from clone CREB3L2 233 using IPTG number 2 in Figure-7B. Samples are 3 
consecutive eluates from the affinity column. Proteins were detected by 
Coomassie staining of 10% SDS-PAGE gels.  
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To minimise the degradation products, CREB3L2-pGEX6P-1 was transformed 
into the BL21-Gold strain of bacteria, because it is protease deficient, and the 
large-scale purification was repeated. However, full-length purified protein was 
still not obtained (Figure 3.8A).   Then, the solubility and elution functions 
were examined as described previously. This analysis revealed bands with 
the correct molecular weight for GST-CREB3L2 in the bacterial pellets 
suggesting a sonication problem (Figure 3.8B). To solve the sonication issue, 
ten individual small-scale GST-fusion proteins were generated and purified 
using column chromatography. Nevertheless, purified protein was not 
recovered (Figure 3.8C).  
 
Surprisingly, when the beads and pellet were examined, a band was noticed 
in the beads that was loaded in 10% SDS-PAGE raising another problem 
which is elution (Figure 3.8D). Therefore, another 10 small-scale preps were 
generated and purified using a new reduced Glutathione elution buffer, (Figure 
3.8E) but without success.  
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Figure 3.8: Optimisation of the large-scale GST-
CREB3L2 expression (A-E). A. A large-scale 
preparation of GST-CREB3L2 transformed into 
BL21-Gold strain of bacteria. Samples are 3 
consecutive elutes from the affinity column. B. 
Assessment of protein in cell pellets and affinity 
beads. C. The generation of 10 individual small-
scale GST-fusion proteins and the purification 
using column chromatography. D. Examination of 
protein retention in cell pellet or on beads for the 
GST-fusion proteins purified in Figure-8C. E. 
Another 10 small scale GST-fusion proteins 
preparations using a new reduced Glutathione 
elution buffer. Samples are 3 consecutive eluates 
from the affinity column. All proteins were detected 
by Coomassie staining of 10% SDS-PAGE gels. 
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A previous publication suggested using a higher concentration of reduced 
Glutathione with the addition of sodium chloride (NaCl) for eluting GST-fusion 
proteins (88). Thus, a small scale experiment was conducted to check the 
suitability of the new elution buffer in eluting GST-CREB3L2; three small scale 
preps of GST-fusion proteins were examined such that one was boiled, the 
second eluted using the previously used elution buffer and the third was 
eluted using the new higher stringency buffer (20mM reduced glutathione, 
100mM Tris, 120mM NaCl). The experiment revealed better elution in the third 
condition with the new buffer (Figure 3.9A, B). Thus, the subsequent GST-
CREB3L2 fusion protein generations were 10 small-scale preps using the new 
elution buffer to avoid elution and sonication challenges. 
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Since the generation of large scale GST-CREB3L2 fusion protein was not 
successful, multiple small scales (40 in total) were performed with the use of 
new elution buffer (Figure 3.10) in an attempt to generate sufficient protein for 
use as an immunogen for antibody generation. 
 
 
 
 
 
 
 
 
 
 
 
A	  
B 
Figure 3.9: Optimisation of large scale GST-CREB3L2 fusion protein 
expression using a new elution buffer. A.  Examination of three small scale 
preps of GST-fusion proteins such that one prep was boiled (1), the second (2) 
was eluted using the previously used elution buffer and the third (3) was eluted 
using the new higher stringency buffer (20mM reduced glutathione, 100mM Tris, 
120mM NaCl). B. Validation of the new elution buffer with a repeat experiment.  
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3.2.1 Preparation of GST-CREB3L2 for immunisation 
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Figure 3.10: Multiple small-scale preps of GST-CREB3L2 fusion protein. A.  
The generation of 10 individual small-scale GST-fusion proteins and purification 
using column chromatography. B. Another 10 individual small-scale GST-fusion 
proteins generated and purified using column chromatography. C. The generation 
of 20 individual small-scale GST-fusion proteins and purification using column 
chromatography. Samples are 3 consecutive eluate  from the affinity column. 
Proteins were detected by Coomassie staining of 10% SDS-PAGE gels. 
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3.2.1 Preparation of GST-CREB3L2 fusion protein for immunization 
The goal of the fusion protein production was to generate in the order of 
250-1000 μg for a rabbit immunisation protocol. In order to evaluate the 
GST-CREB3L2 protein concentration, elutes were combined and run on 
10% SDS-PAGE (neat, 1:5, and 1:10) to estimate its concentration as 
compared with a BSA standard series (2mg/ml, 1mg/ml, 0.5mg/ml and 
0.25mg/ml) (Figure 3.11). By comparing it with the BSA concentrations, 
the concentration was less than 0.25 mg/ml for the total protein content. 
However, ideally 0.5mg/ml is required for immunisation, therefore, the 
protein preparation required concentration.    
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Figure 3.11: Estimation of GST-CREB3L2 fusion protein concentration. GST-
CREB3L2 fusion protein eluates were combined and run on 10% SDS-PAGE 
(neat, 1:5, and 1:10). BSA standard series (2mg/ml, 1mg/ml, 0.5mg/ml and 
0.25mg/ml) were run as well to estimate the GST-CREB3L2 fusion protein 
concentration. Proteins were detected by Coomassie staining of 10% SDS-PAGE 
gels. 
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3.2.2 Concentration of GST-CREB3L2 fusion protein 
 
GST-CREB3L2 fusion protein was concentrated using a Centricon filter 
(Millipore, Amicon). The procedure was carried out according to the 
manufacturer’s recommendation. The collected protein was run on 10% SDS-
PAGE along with the BSA standard series (1mg/ml, 0.5mg/ml, 0.25mg/ml and 
0.125mg/ml) to estimate its concentration after the procedure (Figure 3.12). 
The analysis revealed an approximate concentration of 0.25 mg/ml, which is 
half the required concentration. Therefore, it was anticipated that 20-40 more 
small-scale preps would be required to achieve the desired concentration for 
the five injections given during the rabbit immunisation protocol.   
 
 
 
 
3.3 Validation of CREB3L2 antibodies by Western blot analysis and 
immuno-precipitation technique 
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Figure 3.12: Concentrating GST-CREB3L2 fusion protein by Centricon 
filtration. GST-CREB3L2 fusion protein was concentrated using Centricon filter 
revealing the fusion protein in the retentate with no protein detected in the filtrate. 
The fusion protein concentration was estimated by comparing it with the BSA 
standard series (1mg/ml, 0.5mg/ml, 0.25mg/ml and 0.125mg/ml). Proteins were 
detected by Coomassie staining of 10% SDS-PAGE gels. 
 
Chapter-3 71	  
 
3.3 Validation of CREB3L2 antibodies by Western Blotting and 
Immunoprecipitation techniques 
3.3.1 Western blot analysis 
 
Previous publications investigating the role of CREB3L2 had employed an 
antisera generated by the authors against a fusion protein encoding amino 
acids 1-292 of the murine protein (89), but commercially available antibodies 
had not be used in the literature. The available CREB3L2 antibodies (Aviva 
αCREB3L2, Proteintech αCREB3L2 and Novus αCREB3L2) were validated 
by Western blot analysis through their recognition of CREB3L2-containing 
lysate prepared from HeLa cell transfections. Antibody to the HA tag acted as 
a positive control. The analysis revealed a specific binding of CREB3L2 
antibodies (Proteintech αCREB3L2 and Novus αCREB3L2) with the 
CREB3L2 protein (approximately 68 kDa) (Figure 3.13). However, CREB3L2 
antibody from Aviva showed only non-specific binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Validation of CREB3L2 antibodies by Western blot analysis (A-
B). Three available CREB3L2 antibodies from Aviva, Proteintech and Novus were 
validated by Western blot analysis. The positive control used was antibody to the 
HA tag. The numbers shown at the bottom of the figure were the antibodies’ 
recommended dilution from the corresponding company. NS, non-specific band. 
Arrow indicates CREB3L2. 
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3.3.2 Immuno-precipitation technique (IP) 
 
The CREB3L2 antibodies that were analysed by Western blot were further 
evaluated for their ability to IP. Using HA-CREB3L2 transfected Hela cells 
revealed that all three available CREB3L2 antibodies could precipitate 
CREB3L2 protein, with the least efficiency from the Aviva CREB3L2 antibody 
(Figure 3.14). Therefore, the two antibodies that effectively recognised 
CREB3L2 (from Novus and Proteintech) were used in subsequent studies. 
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Figure 3.14: Validation of CREB3L2 antibodies by immuno-precipitation 
technique. The CREB3L2 antibodies that were examined by Western blot 
analysis were validated by IP. The test was controlled by GFP (vector only) as a 
negative control and antibody to HA as a positive control. WCL (whole cell lysate) 
was used to check the HA-CREB3L2 protein from a Hela cell transfection.  
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3.4 Discussion 
 
The aims of this project are to investigate the expression, regulation and 
function of CREB3L2 in human B-cell differentiation and B-cell tumours. This 
chapter describes the reagents required for CREB3L2 studies in the project 
were successfully generated. The initial goal was to produce appropriate 
mammalian and bacterial expression constructs for CREB3L2 (CREB3L2-
pIRES2EGFP and CREB3L2-pGEX6P-1). In both instances, two rounds of 
selection and restriction digest tests verified the correct cloning. 
Subsequently, the production of protein from the mammalian expression 
construct was confirmed by transient transfection into HeLa cells. The ability 
to express the active cleaved portion of CREB3L2 with an HA tag was a 
useful tool in evaluating the commercially available CREB3L2 antibodies by 
Western blot analysis and immuno-precipitation techniques. Moreover, the 
constructs will be useful in studying CREB3L2 target genes using binding 
assays such as EMSA and ChIP and functional studies such as promoter 
reporter assays.  
 
The next step was the generation of GST-CREB3L2 fusion proteins (small 
and large scales) that could be used to make CREB3L2 antibody. The small-
scale GST-CREB3L2 fusion protein generation was successful however, the 
large-scale presented difficulties. The lack of detectable protein in the large-
scale prep necessitated a number of trouble-shooting steps. First solubility 
and elution efficiency were checked in the bacterial pellets and the 
Sepharose-bound material. Then, IPTG induction capability was examined 
using another protein, ZBTB32, due to its successful GST-fusion protein 
generation in both small and large scales. However, neither the solubility nor 
the elution tests provided a positive result; therefore the large-scale was 
repeated using newly prepared IPTG since there appeared to be a failure to 
induce protein (Figure-7B; 2).  The induction problem was resolved, yet only 
degradation products were detected and no full length CREB3L2 fusion 
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protein was purified. To overcome this issue, the CREB3L2-pGEX6P-1 
construct was transformed into protease-deficient competent bacteria (BL21-
Gold) and the large scale was repeated using the same IPTG used previously. 
Even with these new adaptations, the procedure did not result in the required 
fusion protein. However, this time the fusion protein was found in the bacterial 
pellet suggesting a sonication problem. Thus, to solve that issue, ten small-
scale GST-fusion protein preps were prepared and purified using column 
chromatography. Again, there was no detectable full-length protein, 
suggesting that the failure was not due to sonication challenges only.  
 
Surprisingly, the examination of the Sepharose bound material revealed the 
presence of a large amount of protein (Figure-8D), raising another issue, 
which is elution. Interestingly, it has been published that the use of reduced 
Glutathione in high concentration (20mM) with NaCl (120mM) improves the 
elusion efficiency (88).Thus, a small experiment was conducted to compare 
the elution efficiency (Figure-9 A-B) revealing a better elution using higher 
concentration of reduced Glutathione and salt in the elution buffer, confirming 
the published data. Thus, from the optimisation steps described above, GST-
CREB3L2 fusion proteins can be generated in multiple small-scales (10-20) 
using a higher stringency elution buffer (10mM Reduced Glutathione, 120mM 
NaCl, 100mM Tris pH 8.0) to avoid sonication and elution challenges, 
respectively.  
 
Forty small-scale preps of GST-CREB3L2 were generated (Figure-10) and 
eluates were combined to estimate GST-CREB3L2 concentration. In this 
case, other protein quantification assays, such as the Lowry assay, cannot be 
used because glutathione can interfere with the results. Furthermore, the 
protein preps contain a range of breakdown products and it is useful to 
determine the proportion of full-length fusion protein. Therefore, eluates were 
combined and the concentration was estimated by comparing it with a 
standard series of BSA dilutions on 10 % SDS-PAGE. The estimated amount 
was less than 0.25mg/ml (Figure-11) so the fusion protein was concentrated 
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using a Centricon filter that separates the fusion proteins in the retantate and 
other proteins, which are less than 10kDa in the filtrate. However, the 
obtained fusion protein was only 0.25mg/ml (Figure-12), which is less than the 
optimal required concentration (0.5mg/ml). Thus, another 20-40 small-scales 
generation will be needed to generate sufficient amounts of protein. Although, 
the commercially available antibodies appear to work in the assays tested, it 
would be useful to proceed with the plan to generate an in-house antibody 
that would provide a plentiful source of a single batch of reagent. The fact that 
many degradation products are present in the fusion protein prep is not a 
problem for subsequent use as an immunogen, since many epitopes are short 
amino acid sequences derived from larger proteins. In contrast, if the fusion 
protein were to be used for binding assays such as EMSA, an intact protein 
would be required. 
 
In summary, the reagents required for additional CREB3L2 studies have been 
generated; the CREB3L2 construct for expression in mammalian cells has 
been cloned and tested, the commercially available CREB3L2 antibodies 
validated and the GST-CREB3L2 fusion proteins were generated. 
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4. Tracking CREB3L2 expression and cleavage 
 
 
4.1 Tracking CREB3L2 expression in different cell lines by real-time 
PCR 
 
Full-length CREB3L2 is encoded by 12 exons and generates a protein that is 
retained in the ER until cleavage by UPR-activated proteases. The amino 
terminal portion that constitutes the active transcription factor is made up of a 
transactivation region, a basic DNA-binding domain and a leucine zipper (67). 
In addition to the main isoform, Panagopoulos et al. identified an alternative 
CREB3L2 transcript arising from an intronic polyadenylation site. The shorter 
form of CREB3L2 produces a protein that is limited to the transactivation 
domain with the potential for regulatory activity when tested with a GAL4 
DNA-binding domain fusion assay (75). Quantitative real-time PCR was used 
to check expression of the two CREB3L2 isoforms (Figure 4.1) in six different 
cell lines derived from B-lineage tumours and representative of different 
stages of B cell differentiation (Myeloma lines U266 and H929; ABC-DLBCL 
lines OCI-LY3 and OCI-LY10; Hodgkin’s lymphoma lines L428 and L1236). 
PPP6C was used as a control due to its stable expression during in vitro B-
cell differentiation to the plasma cell stage (4). The CT values for each primer 
pair were first normalised to the values for the control (PPP6C) and then 
normalised using the H929 cell line.  The analysis revealed that both 
CREB3L2 transcripts are expressed in the six cell lines used; with the lowest 
CREB3L2 expression detected in the OCI-LY3 cell line (Figure 4.2).  The two 
isoforms were expressed to a similar extent in the majority of cell lines, with a 
single exception for OCI-LY10, which had reduced amounts of isoform 2.  
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Figure 4.1: Assessment of CREB3L2 isoforms. A. Diagrammatic 
representation of CREB3L2 isoform-1 structure. B. Diagrammatic representation 
of CREB3L2 isoform-2 structure. C. The sets of primer pairs used to amplify the 
two isoforms of CREB3L2 are indicated on the diagram depicting the intron/exon 
structure of CREB3L2 isoforms modified from the NCBI entry. Arrows are not 
drawn to scale, but indicate the exon in which the primer is located. 
Figure 4.2: CREB3L2 expression in 
different cell lines. The expression of 
the two transcripts of CREB3L2 was 
checked in six different cell lines: U266, 
H929, OCI-LY3, OCI-LY10, L428 and 
L1236 using three primer pairs. CT 
values for each primer pair were first 
normalised to the values for the control 
(PPP6C) and then normalised using 
H929 cell line.   
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4.2 Tracking CREB3L2 expression and cleavage in myeloma cell lines 
and ABC-DLBCL cell lines 
The ER is dedicated to the synthesis and export of proteins and lipids. One of 
the main functions that occur during this process is the proper folding of 
proteins with the assistance of multiple chaperones. Any disruption of its 
function leads to the accumulation of mis-folded proteins in the ER, hence ER-
stress, which can lead to apoptotic cell death. However, eukaryotes have 
developed a mechanism to deal with the accumulation of misfolded or over-
abundant proteins termed the UPR, which composed of three arms: PERK, 
IRE1 and ATF6. In 2014, Saito et al. described an additional novel ER-stress 
transducer in chondrocytes called CREB3L2 (90). 
 
The mRNA expression pattern of CREB3L2 in differentiating B-cells suggests 
that it is likely to form part of the UPR in this lineage. To determine the extent 
of CREB3L2 processing that occurs in B-cells, first the endogenous 
expression of CREB3L2 protein was examined in myeloma cell lines (U266 
and H929) and in ABC-DLBCL cell lines (OCI-Ly3 and OCI-Ly10) using two 
ER-stressors that are known to trigger the UPR: 1μM Thapsigargin (TG) and 
1mM DTT at the indicated times (2hr and 4hr) (Figure 4.3 and Figure 4.4 
respectively). In addition, β-ACTIN was used as a loading control to confirm 
that an equal amount of protein was used in each lane. It has been shown by 
Kondo S et al, (2007) that CREB3L2 full length (FL) and cleaved form (CF) 
are predicted to be approximately 80 kDa and 60 kDa, respectively, using 
Western blotting (67). Lysate from Hela cells transfected with the CREB3L2 
amino-terminus encoding construct served as a positive control to indicate the 
mobility of the cleaved form. 
 
The results show that upon ER-stress by TG or DTT, the two forms of 
CREB3L2 (FL and CF), are expressed and increase over time with a relative 
ratio of approximately 2:1 of FL: CF in U266, OCI-Ly3 and OCI-Ly10 cells 
(Figure-4.3 and Figure-4.4).  A slightly different pattern was observed in H929 
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cells such that the increase in the relative ratio was approximately 1:1 in FL: 
CF (Figure-4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Endogenous expression of CREB3L2 in myeloma cell lines. A. 
U266, B. H929. Protein samples from whole cell lysates were loaded on a 10% 
SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was 
probed by CREB3L2 antibody. The control used for the cleaved form was the N-
terminus of CREB3L2 overexpressed in Hela cells.  Beta-ACTIN was used as a 
loading control. FL, Full Length. CF, Cleaved Form.  
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Figure 4.4: Endogenous expression of CREB3L2 in ABC-DLBCL cell lines. 
A. OCI-Ly3 and B. OCI-Ly10. Protein samples were loaded on a 10% SDS-PAGE 
gel and transferred to a nitrocellulose membrane. The membrane was probed by 
CREB3L2 antibody. The control for the cleaved form was the N-terminus of 
CREB3L2 overexpressed in Hela cells.  β-ACTIN was used as a loading control. 
FL, Full Length. CF, Cleaved Form.  
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4.3 Tracking CREB3L2 expression and cleavage in human differentiated 
B-cells 
 
Based on the gene expression data obtained by Cocco et al., CREB3L2 is 
predicted to increase as B-cells transition to antibody secreting cells, however, 
the active transcription factor may only be present after activation of the UPR. 
To determine whether the protein expression of CREB3L2 correlated with 
mRNA levels and differentiation stage, human B-cells were isolated from 
normal donors and differentiated in vitro. Protein samples were prepared at 
timed intervals and examined by Western blotting (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 shows the expression pattern of CREB3L2 in human activated B-
cells and during the transition to antibody secreting cells. The results revealed 
the presence of two bands of CREB3L2, FL (80 kDa) and CF (60 kDa), at 
each time point, however in Day-3 cells there is very little CF. In this particular 
Figure 4.5: CREB3L2 expression in human B-cells and antibody secreting 
cells (Day-3, -7, -9, -11 and Day-13) by Western blot. Protein samples were 
loaded on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. 
The membrane was probed by CREB3L2 antibody. The control for the cleaved 
form was the N-terminus of CREB3L2 overexpressed in Hela cells.  β-ACTIN was 
used as a loading control. FL, Full Length. CF, Cleaved Form.  
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experiment, the Day-7 sample was taken prior to the change-over to 
maturation media, which includes Il-6, IFN-α and IL-21. Following transition to 
the new media, both CREB3L2 FL and CF were expressed increasingly to 
Day-13, when cells have adopted a plasma cell phenotype and are secreting 
large amounts of antibody.  
Overall, the expression pattern agreed with the results obtained by Cocco et 
al (4). 
Densitometry was used to quantify the bands obtained in chapter-4 to 
summarize the expression pattern of CREB3L2 (FL and CF) from different cell 
types (Figure-4.6). 
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Figure-4.6: The endogenous expression 
pattern of CREB3L2 (FL and CF) in 
different cell types using densitometry. 
A. Myeloma cell lines A.  H929. B. U266. 
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4.4 CREB3L2 C-terminus 
 
The vast majority of the published work on S1P/S2P regulated proteins has 
focussed on the transcription factors that are released from the cytoplasmic 
portion of the proteins. Less is known about the fate of the remaining portion 
that resides in the ER lumen. In 2014, Saito et al. found that upon ER-stress 
in chondrocytes, the C-terminus portion of CREB3L2 is secreted into the 
extracellular space to function as a signalling molecule through the interaction 
with Indian hedgehog (Ihh) and its receptor Ptch1. Hedgehog signalling is an 
important pathway for cell proliferation and differentiation. In addition, it is 
involved in the commencement and survival of many tumours such as 
LGFMS. In mammals, the hedgehog-signalling pathway is composed of three 
types, Shh (Sonic hedgehog), Dhh (Desert hedgehog) and Ihh (Indian 
hedgehog). The Ihh hedgehog induces the expression of PTHrP (parathyroid 
hormone related protein) in prehypertropic chondrocytes to stimulate the 
proliferation of chondrocytes (90). 
 
Thus, CREB3L2 has dual roles: the N-terminus functions as a transcription 
factor and the C-terminus functions as a signalling molecule through 
hedgehog pathway upon ER stress (90). Interestingly, hedgehog signalling 
has also been implicated in the survival of myeloma cells (91). Therefore, the 
role of CREB3L2 C-terminus in the myeloma cell line (U266) was investigated  
 
To determine whether the C-terminal portion of CREB3L2 could be generated 
under conditions of ER-stress U266 cells were treated with media alone or 
containing 1 μM Tg for 12 hours. At this time point tissue culture supernatants 
were collected for evidence of secreted protein and the cells were lysed.  An 
isotype control or antibody against the C-terminus of CREB3L2 were then 
used to generate immunoprecipitates from both sources. The resulting 
complexes were run on SDS-PAGE, transferred to nitrocellulose and blotted 
with the C-terminus antibody followed by a heavy-chain specific secondary 
antibody (Figure 4.7). 
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The predicted CREB3L2 C-terminus molecular weight is 15 kDa (90). While 
there are a number of bands that appear to be unique to the CREB3L2 IPs, 
there are no bands consistent with the size of the C-terminus and relatively 
little difference between unstressed and stressed samples.  Additionally, the 
blot showed a high degree of non-specific binding making interpretation 
difficult. Therefore, CREB3L2 full length (HA-CREB3L2-FLAG) and CREB3L2 
C-terminus (CREB3L2-CTERM-FLAG) constructs were designed (Figure 4.8) 
and tested (Figure 4.9-4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supernatant 
Figure-4.7: The endogenous expression of CREB3L2 C-terminus in 
myeloma cell line U266. U266 cells were incubated in media alone 
(unstressed) or containing 1 μM Tg (stressed) for 12 hours. Then, the lysate 
and supernatants were immunoprecipitated using CREB3L2 C-terminus 
antibody (ab102989) or IgG control antibody and analysed by Western blotting. 
The arrow indicates a unique protein in the CREB3L2 IPs. 
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The full length CREB3L2 construct was designed such that an HA-tag would 
distinguish the N-terminus from the C-terminus marked by a FLAG-tag. Intact 
full-length protein would be recognised by antibodies to either, while the 
processed forms would only be detected by the appropriate tag. The 
constructs (HA-CREB3L2-FLAG and CREB3L2-CTERM-FLAG) were cloned 
into pIRES2-EGFP (Clonetech). Vectors containing either full length of 
CREB3L2 (encoding amino acids 1-521 with amino terminal HA-tag and with 
C terminal FLAG-tag) or the C-terminal CREB3L2 (encoding amino acids 431-
521 with C-terminus FLAF-tag) and pIRES2-EGFP destination vector 
(Clontech) were digested using EcoRI and BglII (Figure 4.9A). Fragments of 
the correct size were purified, ligated and transformed into DH5α. DNA from 
the transformed cells was extracted and checked for the presence of 
appropriate insert by digestion with EcoRI and BglI (Figure 4.9B).  
 
 
 
 
 
 
 
	   	  
CREB3L2-CTERM-FLAG vector (C-terminus) 
FLAG tag 
Figure-4.8: Diagrammatic representation of CREB3L2 full length and C-terminus 
vectors:  HA-CREB3L2-FLAG (1-521 amino acids) and CREB3L2-CTERM-FLAG 
(431-521) amino acids respectively. 
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The constructs were validated using transient transfection and Western 
blotting. Protein samples were prepared and run on 10% SDS-PAGE gel 
using HA antibody, CREB3L2 C-terminus antibody or FLAG antibody  (Figure 
4.10). The results show that the HA-antibody detected a protein consistent 
with the molecular weight of full length HA-CREB3L2-FLAG for each of the 
clones tested.  Neither CREB3L2 C-terminus antibody nor FLAG antibody 
could detect CREB3L2-CTERM-FLAG as shown in Figure 4.9B. Therefore, 
the blot was repeated, additionally including lysates from cells transfected with 
the HA-CREB3L2-FLAG, which had been shown to be well expressed. 
Neither the positive control full-length protein nor the C-terminal fragments 
were detected (Figure 4.11). Given that the full-length protein was 
successfully expressed, it seemed likely that the problem was with the 
antibodies used for detection. However, this component of the project was not 
pursued further due to time limitations. 
Figure-4.9: Cloning of HA-CREB3L2-FLAG and CREB3L2-CTERM-FLAG into 
pIRES2-EGFP vector. A. Preparative restriction digest of pIRES2-EGFP, HA-
CREB3L2-FLAG and CREB3L2-CTERM-FLAG for cloning. B. HA-CREB3L2-
FLAG-pIRES2EGFP and CREB3L2-CTERM-FLAG-pIRES2EGFP miniprep 
digestion. The expected insert sizes were 1647 bp and 318 bp, respectively. Red 
boxes indicate inserts of correct molecular weight. Numbering at the top indicates 
the designated clone number. L, molecular weight ladder. 
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Figure-4.10: Western blotting analysis 
of HA-CREB3L2-FLAG and CREB3L2-
CTERM-FLAG. A. Two clones from HA-
CREB3L2-FLAG constructs were 
validated using HA antibody. B. Two 
clones from CREB3L2-CTERM-FLAG 
constructs were tested using CREB3L2 
C-terminus  antibody,  C. or using FLAG 
antibody. 
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Figure-4.11: Western blotting analysis of CREB3L2-CTERM-FLAG. Two clones 
from CREB3L2-CTERM-FLAG constructs were evaluated using FLAG-antibody 
including HA-CREB3L2-FLAG clone 5 as a blotting control. 
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4.5 Discussion 
 
Although it is accepted that the transition from activated B-cell to antibody 
secreting cell (ASC) is accompanied by a UPR, evidence suggests that this 
cell lineage has developed a specialised version of the response that 
predominantly uses the IRE1-XBP1 pathway (52). Additionally, the 
requirement for XBP1 occurs at later stages of the differentiation process and 
is not the transcription factor responsible for driving changes during the early 
phases of becoming an ASC (5). Work leading up to this project identified a 
cluster of genes displaying a co-ordinated pattern of up-regulation during 
plasma cell differentiation, which included not only the key PC transcription 
factors PRDM1 and IRF4, but also CREB3L2. This finding was recently 
corroborated in study examining the transcriptional signature of murine ASCs 
(8). 
 
CREB3L2 is expressed in many human tissues such as: placenta, heart, 
brain, and skeletal muscle. CREB3L2 has been postulated to act as a 
component of the UPR during chondrocyte differentiation, when the 
differentiating cells start to secrete extracellular matrix proteins that generate 
a mild ER-stress (79). In this setting CREB3L2 is cleaved in response to 
physiological stress and subsequently activates genes required for protein 
transport. In addition, Panagopoulos et al., have reported that there is an 
alternative CREB3L2 transcript resulting from polyadenylation in intron-4. It is 
widely expressed in many human tissues and displays even stronger 
expression than the full length of CREB3L2 in some tissues (75). To 
determine the role of the novel form encoded by BC063666, firstly, they 
examined whether it functions as an activator or not by co-transfection with a 
luciferase reporter containing a GAL4 binding domain in to Hela cells. The 
results revealed that BC063666 has the potential to behave as an activator, 
despite not having the bZIP domain. In addition, they examined whether 
BC063666 can regulate CRE-containing binding sites but found no evidence 
to support this. Moreover, the subcellular localization of the three forms of 
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CREB3L2 was studied using EGFP fluorescence (CREB3L2, CREB3L2ΔTM 
and BC063666). As anticipated the results showed that full length CREB3L2 
was localised in the ER, while CREB3L2ΔTM was found in the nucleus. 
However, BC063666 was found in both the ER and in the nucleus suggesting 
that it may not be linked to ER-stress or it may have another cellular function. 
Thus, BC063666 is an alternative transcript of CREB3L2 that can act as a 
transactivator in a reporter assay; however, its cellular function remains 
unknown (75). 
  
In this project, the expression of CREB3L2 transcripts (isform-1 and isoform-
2) were examined in six different cell lines derived from B-lineage tumours 
representative of different stages of B cell differentiation (Myeloma lines U266 
and H929; ABC-DLBCL lines OCI-LY3 and OCI-LY10; Hodgkin’s lymphoma 
lines L428 and L1236) using quantitative real-time PCR. The results revealed 
that both CREB3L2 transcripts are expressed in all the six studied cell lines 
(U266, H929, OCI-LY3, OCI-LY10, L428 and L1236) with a single exception 
for OCI-LY10, which had reduced amounts of isoform 2.  These results are in 
line with the published results, where the majority of samples tested 
expressed roughly equivalent levels of the two transcripts (75). It is possible 
that the additional form of CREB3L2 may function as a dominant-negative or 
plays a role in regulating the levels of total CREB3L2 protein. 
 
To provide additional evidence that CREB3L2 is expressed from the activated 
B-cell stage onwards, the endogenous expression of CREB3L2 protein was 
examined in H929, U266, OCI-Ly3 and OCI-Ly10. Moreover, the relationship 
between a UPR and CREB3L2 levels was investigated using two ER-
stressors. The results showed that upon ER-stress by TG or DTT, CREB3L2 
FL and CF are induced and increase by time with relative ratio of 
approximately 2:1 for FL: CF in U266, OCI-Ly3 and OCI-Ly10 cells whereas, 
H929 cells expressed a relatively higher amount of CF. In addition, some 
additional bands were observed in the Western blots, lower than the predicted 
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molecular weight of FL and CF, suggesting that they could be the non-
glycosylated form of FL and CF as shown by Kondo S, 2007(67).  
 
From the gene expression profile data, the expression of CREB3L2 is 
predicted to increase as B-cells transition to ASCs, however, the active form 
of CREB3L2 may only be present after the activation of a UPR. To determine 
whether the protein expression of CREB3L2 correlated with mRNA levels and 
differentiation stage, human B-cells were isolated from normal donors and 
differentiated in vitro. The results revealed that the two forms of CREB3L2 (FL 
and CF) were expressed increasingly from Day-3 B-cells to Day-13 ASCs, 
suggesting that CREB3L2 is likely to play a role in the UPR signalling pathway 
that operates during B-cell differentiation (30). Taken together, the results 
from the cell lines and primary cells suggest that CREB3L2 is expressed as 
the cells initiate the process of differentiation and accumulate more protein as 
the cells mature. The presence of the processed form indicates that it is likely 
to be generated in response to ER-stress and its regulation and function may 
be similar to that observed in differentiating chondrocytes (79). It is also 
tempting to speculate that CREB3L2 might drive the necessary transcriptional 
changes to commence the expansion of the secretory machinery, prior to 
XBP1.    
 
Initial attempts were also made to determine whether the hedgehog signalling-
competent C-terminal portion of CREB3L2 was produced in stressed U266 
cells. While the preliminary data did not provide conclusive evidence, it 
remains an interesting avenue to pursue.  In normal B-cells, hedgehog 
signalling prevents apoptosis in the germinal centre and it has been linked to 
the survival of a number of B-cell malignancies including diffuse large B-cell 
lymphoma and myeloma (92-94). Establishing an additional role for CREB3L2 
via hedgehog signalling would provide additional rationale for targeting this 
protein as a therapeutic strategy.  
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5. Site-1 protease (S1P) and site-2 protease (S2P) inhibition in myeloma 
cell lines and ABC-DLBCL cell lines 
 
CREB3L2 is predicted to be a single-pass type 2 membrane-spanning protein 
that resides in the ER membrane until an ER stress event leads to its 
transport to the Golgi and subsequent proteolysis. The proteloytic cleavage 
involves the sequential activities of firstly S1P in an exposed luminal site and 
secondly S2P which catalyses an intramembrane cleavage (95). This is a 
conserved feature of a number of transcription factors that are released in this 
fashion to mediate changes in gene expression required for lipid metabolism 
or ER stress responses such as SREBP and ATF6. SREBPs (SREBP-1a, 
SREBP-1c and SREBP-2) are activated in response to sterol depletion 
whereas ATF6 (α and β) is activated in response to ER stress (96). 
 
Several studies have been carried out to investigate the impact of S1P/S2P 
inhibition on different cell types. For example, using S1P inhibitor in HepG2 
and Chines Hamster Ovary cells (CHO) blocks SREBP processing, which in 
turn leads to cholesterol and fatty acid depletion.  Hence, SREBP has been 
suggested as therapeutic target for dyslipidaemia and cardio-metabolic 
diseases (97). In addition, Guan et al., have shown that liposarcoma cells can 
be targeted through inhibiting S2P, which in turn activates ER-stress, resulting 
in cell death (98). Thus, these studies highlight the importance of S1P/S2P 
inhibition. 
 
In myeloma cell lines full-length CREB3L2 is expressed at a high level with 
some evidence of constitutive processing; however, there is a clear 
relationship between application of ER stress and the induction of both full 
length and processed CREB3L2 (Figure 4.3). Moreover, in differentiated 
human B-cells an increase in both full length and cleaved CREB3L2 is 
consistent with ER stress triggered by antibody production. Given that 
CREB3L2, and indeed other important ER stress transcription factors, is 
regulated by a defined mechanism involving S1P/S2P there is the potential to 
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modify expression using specific inhibitors. Since successful adaptation to ER 
stress is critical for cell survival, it is predicted that limiting the necessary 
transcription factors could have a profound effect. Therefore, it is important to 
test the impact of S1P and S2P inhibition on CREB3L2 and other UPR 
elements to examine its potential therapeutic intervention. Three commercially 
available S1P, S2P inhibitors;  (4-(2-aminoethyl) benzenesulfonyl fluoride  
(AEBSF) and PF-429242, as S1P inhibitors and Nelfinavir as S2P inhibitor 
were initially tested in neoplastic B-lineage cell lines.  
 
5.1 The impact of serine protease inhibitor AEBSF  
AEBSF is a generic serine protease inhibitor that can target S1P. It is an 
irreversible serine protease inhibitor similar to phenylmethylsulfonyl fluoride 
(PMSF) yet it is more stable and non-toxic. It works by reacting with the 
hydroxyl group of the serine residue resulting in cleavage (96). In the study by 
Okada et al., Hela cells were pre-treated with different concentrations of 
AEBSF, PMSF, aprotinin or chymostatin. Then, the cells were stressed using 
thapsigargin and lysates analysed by Western blotting. Their results revealed 
that AEBSF had the greatest inhibitory impact on ATF6α and ATF6β 
processing among the other three studied serine protease inhibitors. 
Therefore, based on these results, ABC-DLBCL (OCI-Ly3 and OCI-Ly10) cell 
lines were treated with 300 µM of AEBSF for 1h, 6hr and 24hrs in standard 
culture conditions.   At each time point, cells were collected for protein lysates 
and subsequently analysed by Western blotting (Figure-5.1). According to the 
proposed function of AEBSF as a S1P inhibitor, it should affect the CF of 
CREB3L2 only by inhibiting the cleavage, but the obtained results showed an 
effect on both forms of CREB3L2 that increased with time. In fact, the full-
length protein appeared to diminish more rapidly. By 24hr no protein 
(CREB3L2) was detected despite maintenance of β-ACTIN levels. It was 
concluded that AEBSF might have a non-specific effect on CREB3L2 and was 
not used in the human differentiated B-cells-plasma cell studies.  
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Figure 5.1: The impact of AEBSF on CREB3L2 in ABC-DLBCL (OCI-Ly3 and 
OCI-Ly10) cell lines. The cells were treated with 300 µM AEBSF for 1hr, 6hr and 
24hr, protein samples generated at each time point and analysed by Western 
blotting. The amino terminal portion of CREB3L2 (1-375 aa) was overexpressed in 
Hela cells and used as a positive control for detection of the cleaved form. β-
ACTIN was used as loading control. Full Length, FL. Cleaved Form, CF.  
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5.2 The impact of S1P inhibitor (PF-429242)  
5.2.1 Dose response analysis 
PF-429242 is a reversible, competitive and selective inhibitor for S1P (97). It 
was discovered by a Pfizer research group from a high throughput screen 
using purified human S1P. They generated 3 libraries to study the efficiency of 
different S1P inhibitors revealing PF-429242 (from the third library) to be the 
most selective for S1P, with an IC50 for S1P inhibition at 170 nM and no 
significant inhibition of proteinase, trypsin, thrombin and elastase at a 
concentration of 100 μM (99). In addition, PF-429242 has been shown to 
block SREBP processing and decrease cholesterol and fatty acids synthesis 
(97). 
To establish the effect of selective S1P inhibition on CREB3L2, the myeloma 
cell line U266 was treated with different concentrations of PF-429242; 5µM, 
10µM, 20µM and 50µM for 24hr (based on the published data Hawkins et al., 
2008)(97) with some slight modifications. Then, the cells were collected, 
protein samples were prepared and analysed by Western blotting for 
CREB3L2 (Figure-4.2). The results revealed a reduction in the intensity of 
CREB3L2 cleaved form in all the studied concentrations, with slight 
enhancement using 10µM and 20µM PF-429242 in agreement with the 
published data (97). Unlike treatment with AEBSF, the loss of cleaved 
CREB3L2 was accompanied by an increase in the detectable full-length 
protein, suggesting that PF-429242 was a more effective inhibitor of S1P-
mediated events. 
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Figure-5.2 The impact of PF-429242 on 
CREB3L2 in the U266 myeloma cell line. 
The cells were treated with the indicated 
concentrations of PF-429242 for 24hrs and 
the protein samples analysed by Western 
blotting using antibody to CREB3L2. The 
amino terminal portion of CREB3L2 (1-375 
aa) was overexpressed in Hela cells and 
used as a control for the cleaved form. β-
ACTIN was used as loading control.  
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5.2.2 Kinetic analysis 
The previous experiment suggests that treatment with 10µM PF-429242 
reduced the amount of cleaved CREB3L2 by greater than 50% at a 24 hour 
time point. To determine whether the inhibition could be sustained or even 
augmented, a later time point was also assessed. The U266 cell line was 
treated with 10µM PF-429242 for 24 or 40hr. Then, the cells were collected 
and the protein samples were prepared and analysed by Western blotting for 
CREB3L2 (Figure-5.3). The treatment for 24hr resulted in an even more 
profound loss of cleaved protein (estimated 70-80%), which was accompanied 
by a reciprocal gain of full-length protein. Conversely, longer treatment also 
generated higher amounts of full-length protein but did not prevent cleavage.   
The failure to inhibit at 40hr could be due to decreasing efficiency of the 
inhibitor over time and the rate of cell growth in culture. Thus, CREB3L2 
cleavage in U266 was best studied using 10µM PF-429242 for 24hrs. This 
agreed with other studies, such as that of Hawkins et al., where CHO cells 
treated with 10µM PF-429242 for 24hrs showed inhibition of endogenous 
SREBP 
processing (97).  
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Figure 5.3: The impact of 10µM PF-429242 on CREB3L2 in U266 for 24 and 
40hr. The cells were treated with 10µM PF-429242 for 24hr and 40hr under 
standard culture conditions. Protein samples were collected at each time point and 
analysed by Western blotting. The amino terminal portion of CREB3L2 (1-375 aa) 
was overexpressed in Hela cells and used as a control for the cleaved form. β-
ACTIN was used as loading control.  
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5.2.3 UPR signalling pathways 
 
Proper protein folding in the ER is an essential mechanism for secreted 
proteins prior to transportation to the Golgi and distribution to target organs. 
There are many environmental (e.g. calcium depletion), developmental (e.g. 
B-cell development) or pathological factors (e.g. viral infection) that can trigger 
the accumulation of mis-folded proteins in the ER and cause ER-stress (100). 
However, eukaryotic cells have evolved a physiological mechanism to 
overcome ER-stress called the UPR, which coordinates a transient 
suppression of protein translation, up-regulation of protein folding chaperones 
and disposal of the mis-folded proteins (101, 102). In instances where the ER-
stress is not resolved, the cells will undergo apoptosis.  
 
The UPR is composed of three signalling pathways: ATF6, IRE1 and PERK, 
which are normally bound to the protein folding chaperone BiP at the ER 
membrane. The three UPR-pathways are expressed in all cells where they 
become activated as BiP is titrated away in response to the accumulation of 
mis-folded proteins in the ER. IRE1 and PERK have similar modes of 
activation, where they undergo homodimerization and auto-phosphorylation in 
response to ER-stress. ATF6 is also released from BiP in response to the 
accumulation of mis-folded proteins. It then migrates to the Golgi and is 
cleaved via S1P and S2P, releasing the active form of ATF6, which is 
translocated to the nucleus to activate its target genes (30).  
 
A number of lines of evidence suggest that there is a link between UPR and 
the development of plasma cells (103). During B-cell terminal differentiation, 
large amounts of immunoglobulins are secreted, which increase the load on 
ER. Hence unfolded or misfolded immunoglobulins potentially accumulate in 
the ER and cause ER-stress with subsequent activation of the UPR signalling 
pathways (104).  
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The initial data describing a role for XBP1 in plasma cell generation was 
consistent with the secretion of immunoglobulin triggering an unfolded protein 
response (31). Later reports suggested that XBP1 could be expressed in cells 
that did not secrete immunoglobulin, challenging the idea that a UPR is 
required (39). Unlike the proposed requirement for XBP1, available data 
suggest that both the PERK and ATF6 axes may be dispensable for the 
formation of plasma cells (51, 52). Collectively, the available evidence 
suggests that B-cells utilise the UPR an unconventional fashion (30). To gain 
a better understanding of the interplay between components of the UPR 
during terminal B-cell differentiation, XBP1s, ATF6 and CREB3L2 were 
studied in myeloma cell lines and in differentiating human B-cells.  
 
To determine whether inhibition of S1P could be overcome by ER-stress, 
U266 cells were either stressed using ER-stressor thapsigargin (TG) or pre-
treated with 10µM PF-429242 for 24hrs, stressed using 1µM TG for 4hrs and 
then evaluated for the expression of XBP1s, ATF6 and CREB3L2 (Figure-
5.4). The results showed that PF-429242 treatment alone reduced the low 
basal expression of XBP1s. TG treatment substantially increased XBP1s, but 
S1P inhibitor only slightly reduced the amount in stressed cells. PF-429242 
treatment leads to a marked accumulation of full length CREB3L2 
accompanied by a reduction of the cleaved form in the basal state. In 
response to ER-stress, there is an up-regulation of both forms of CREB3L2 
and S1P inhibition reduces each. However, ATF6 did not respond to either TG 
or 10µM PF-429242 in the cell type studied.  
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Figure-5.4 The impact of 1µM TG and 10µM PF-429242 on CREB3L2, XBP1s 
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treated with TG for 4hr. Protein samples were collected and analysed by Western 
blotting using the indicated antibodies. 1-375 aa of CREB3L2 was overexpressed 
in Hela cells and used as a control for the cleaved form. β-ACTIN was used as 
loading control. FL, Full Length. CF, Cleaved Form. 
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5.3 The impact of S2P inhibitor (Nelfinavir)  
 
Nelfinavir is used in the treatment of human immunodeficiency virus (HIV) due 
to its potency as an HIV-1 protease inhibitor (105). Moreover, it has been 
used as antiviral therapy and anticancer drug based on its ability to inhibit Akt 
phosphorylation, signal transducer and activating transcription factor 3 
(STAT3) signalling, heat shock protein 90 (HSP90) function, cyclin-dependent 
kinase 2 (CDK2) function and general kinase activity, however, the exact 
mechanism by which it impacts on these diverse pathways has not been fully 
characterized (105).  
In a study conducted by Guan et al., the impact of Nelfinavir and its 
structurally similar analogs were evaluated on Castration-Resistance Prostate 
Cancer cells (CRPC). Treatment of CRPC with 10 μM Nelfinavir and its 
analogs resulted in decreased cell proliferation and the induction of apoptosis. 
In addition, they showed that the structurally related compounds inhibited S2P 
mediated intra-membrane proteolysis that resulted in the accumulation of 
SREBP-1 precursor and ATF6 full-length proteins in CRPC and DU145 cells. 
The lack of functional SREBP1 and ATF6 generates ER-stress and an 
inability to resolve the UPR, thus causing the cells to undergo apoptosis (105).  
Although Nelfinavir has been used to study inhibition of ATF6 cleavage (105), 
there appears to be a reproducible effect of Nelfinavir on the accumulation of 
precursor proteins only, whereas the data showing any effect of processed 
ATF6 or SREBP1 is less compelling. This is in contrast to the data for S1P 
inhibition, where gain of full-length protein is matched by loss of the cleaved 
form. In addition, it has been found that Nelfinavir’s half-life in the context of 
patient treatment is 3.5-5 hours (106). Whereas, it’s main metabolite, M8 is 
very unstable with a half-life of 0.44 h (107). 
Therefore, U266 cells were exposed to Nelfinavir to check its impact on 
CREB3L2. U266 cells were treated with different concentrations of Nelfinavir 
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(5 µM, 10 µM and 20 µM) for 24hr and subsequently stressed for 4 hours 
using 1 μM TG. Then, the cells were collected, protein samples were 
prepared and analysed by Western blotting for CREB3L2 (Figure 5.5). 
Unexpectedly, the results showed that Nelfinavir reduced both full length and 
cleaved form of CREB3L2 in all studied concentrations. This could be due to 
secondary effects of Nelfinavir on the cells as it has been shown to have off-
target, pleiotropic results in different cell types (105, 108). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-5.5 The impact of Nelfinavir on CREB3L2 in U266. The cells were pre-
treated with different concentrations of Nelfinavir (5µM, 10µM and 20µM) for 24hr 
followed by stimulation with 1µM TG for 4hr. Protein samples were collected and 
analysed by Western blotting for CREB3L2. 1-375 aa of CREB3L2 was 
overexpressed in Hela cells and used as a control for the cleaved form. β-ACTIN 
was used as loading control.  
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5.4  A The impact of S1P and S2P inhibitors in U266 
To confirm the differential impact of the S1P and S2P inhibitors, the effect of 
300µM AEBSF, 10µM PF-429242 and 10µM Nelfinavir on CREB3L2 in the 
U266 cell line was validated (Figure-5.6). The results showed that AEBSF led 
to a loss of all forms of CREB3L2 suggestive of having non-specific effect, 
strengthening the decision to omit AEBSF as a S1P inhibitor in the human 
differentiated B-cells-plasma cell studies. However, the treatment with 10µM 
PF-429242 led to the reduction in the formation of CREB3L2 cleaved form 
compared to the un-treated U266 cells. On the other hand, treatment with 
10µM Nelfinavir caused the accumulation of CREB3L2 cleaved form. Thus, 
PF-429242 and Nelfinavir treatment had an inhibitory impact on CREB3L2 
processing/cleavage in the U266 cell line, which in turn may affect the cell’s 
capability to respond to ER-stress.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Validating the impact of AEBSF, PF-429242 and Nelfinavir on 
CREB3L2 in the U266 cell line. The cells were pre-treated with 300µM AEBSF, 
10µM PF-429242 or 10µM Nelfinavir for 24hr and then stressed using 1 µM TG 
for 4hr. Protein samples were collected and analysed by Western blotting. 1-375 
amino acids of CREB3L2 was overexpressed in Hela cells and used as a control 
for the cleaved form. Beta-ACTIN was used as loading control. FL, Full Length. 
CF, Cleaved Form. 
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5.4 B The impact of S1P and S2P inhibitors in H929 
Previous results suggested that both the U266 and H929 myeloma cell lines 
expressed some level of CREB3L2 that could be augmented by treatment 
with an ER stressor, but with potentially different kinetics. Upon ER-stress 
(1μM TG or 1mM DTT treatment), the two forms of CREB3L2 (FL and CF) are 
expressed and increase by time with an approximate relative ratio of 2:1 FL: 
CF in the U266 cell line, whereas in H929 cells, the increase in the relative 
ratio was 1:1 FL: CF (Figure-4.3). Subsequently, S1P and S2P inhibitors (10 
µM PF-429242 and 10 µM Nelfinavir) were shown to block CREB3L2 
processing in the U266 cell line (Figure-5.6). To ascertain whether the 
inhibitors also functioned in H929, the cells were either stressed by 1 µM TG 
or pre-treated with either 10 µM PF-429242, or 10 µM Nelfinavir for 24hr and 
then stressed by 1 µM TG for 4hr. Then, the cells were collected and the 
protein samples were prepared and analysed by Western blotting for 
CREB3L2, XBP1s and ATF6 (Figure-5.7).  
 
As predicted, the expression patterns of CREB3L2 and XBP1s in H929 cell 
line were similar in response to the ER stress stimulus (1 µM TG) as indicated 
by the increase in the intensity of the bands. In addition, the results have 
shown that 10 µM PF-429242 had a greater inhibitory impact on CREB3L2 
cleavage in H929 cells, resulting in the reduction of the CF, which agreed with 
the results obtained in the U266 cells (Figure-5.3). Moreover, the formation of 
XBP1s was inhibited by 10 µM PF-429242 in H929 cells (Figure-5.7) whereas 
it did not alter the expression of XBP1s in U266 (Figure-5.4). ATF6 did not 
respond to either the ER-stressor TG or the S1P inhibitor 10 µM PF-429242, 
but was inhibited by the S2P inhibitor 10 µM Nelfinavir (Figure-5.7).  
 
Chapter-5 106	  
 
 
 
La
dd
er
 
Un
-tr
ea
te
d 
Tg
 
PF
-4
29
24
2/
 
Tg
 
Ne
lfin
av
ir/
 
Tg
 
XBP1s 
25
15
10
75- 
50- 
Β-ACTIN 
B 
La
dd
er
 
Un
-tr
ea
te
d 
Tg
 
PF
-4
29
24
2/
 
Tg
 
Ne
lfin
av
ir/
 
Tg
 
ATF6 
p36 
25
15
10
75- 
50- 
37- 
Β-ACTIN 
C 
La
dd
er
 
Co
nt
ro
l 
Un
-tr
ea
te
d 
Tg
 PF
-4
29
24
2 
Tg
 
Ne
lfin
av
ir 
Tg
 
CREB3L2 FL  
CREB3L2 CF 
250
- 
150
- 
100
- 75- 
50- 
37- 
Β-ACTIN 
A 
Figure 5.7:The impact of PF-429242 and Nelfinavir on UPR components in the 
H929 myeloma cell line. A. CREB3L2, B. XBP1s and C. ATF6. The cells were pre-
treated with 10µM PF-429242 or 10µM Nelfinavir for 24hr and then stressed using 1 
µM TG for 4hr. Protein samples were collected and analysed by Western blotting. 1-
375 aa of CREB3L2 was overexpressed in Hela cells and used as a control for the 
cleaved form. FL, Full Length. CF, Cleaved Form. β-ACTIN was used as loading 
control.  
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5.5 The impact of both S1P and S2P inhibitors in H929 
The results obtained have demonstrated that each inhibitor had different 
inhibitory impact, particularly on CREB3L2.  Since the two proteases act 
sequentially at different sites to generate fully active cleaved proteins, it is 
conceivable that simultaneous application of the two inhibitors may have a 
more pronounced effect. Therefore, the H929 cell line was treated with 
different combinations of PF-429242 and Nelfinavir and the resulting levels of 
CREB3L2 were assessed (Figure-5.8). In this experiment, the cells were not 
treated with TG to allow an evaluation of the constitutive processing events. 
The results showed that using PF-429242 alone inhibited the formation of 
CREB3L2 cleaved form. However using Nelfinavir alone promoted the 
accumulation of the cleaved form of CREB3L2.  The pattern of expression 
after combinatorial treatment suggests that the effect of PF-429242 is 
predominant, with a reduction in the observed cleavage. 
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Figure 5.8: The impact of combined PF-429242 and Nelfinavir on CREB3L2 in 
the H929 cell line. The cells were treated with a combination of different 
concentrations of inhibitors as indicated for 24hr. Protein samples were collected 
and analysed by Western blotting. 1-375 aa of CREB3L2 was overexpressed in to 
Hela cells and used as a control for the cleaved form. β-ACTIN was used as loading 
control.  
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Densitometry was used to quantify the bands obtained in chapter-5 to 
summarize the impact of PF-429242, AEBSF and Nelfinavir on CREB3L2, 
XBP-1s and ATF6 (Figure-5.9). 
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5.6 Discussion  
 
The UPR is an important pathway protecting the cells from ER-stress by 
activating multiple signalling arms (IRE1, ATF6 and PERK) that work by 
slowing down normal protein production and up-regulating certain proteins 
such as chaperones to allow adaptation. Activation of ATF6 is regulated by 
the intramembrane proteolysis via S1P/S2P cleavage (104). However, ATF6 
is not the only protein to be regulated in this fashion. Other transcription 
factors, including CREB3L2 are also similarly processed and are likely to 
make important contributions to the integrated stress response. Therefore, 
inhibiting the regulated intramembrane proteolysis by targeting S1P/S2P may 
prevent adaptation to stress and lead to cell death. Thus, the impact of S1P 
and S2P inhibitors on UPR signalling elements in myeloma cell lines were 
examined in a dose response analysis and kinetic analysis. 
 
A series of papers had originally established that after sterol depletion, 
SREBPs are cleaved by intramembrane proteolysis to generate active 
transcription factors (109-111). The structurally related ATF6 was 
subsequently shown to undergo the same sort of processing (112). Two 
studies aimed at examining the impact of preventing this process employed 
the generic serine protease inhibitor (96, 113). In both instances the authors 
followed the effect of AEBSF on thapsigargin induced ER-stress. 
 
Okada et al. showed that the induced cleavage of ATF6 in the Golgi following 
ER stress could be inhibited by AEBSF. However, the translocation of ATF6 to 
the Golgi remained intact, suggesting a specific effect on the proteolysis (96). 
In addition, Colgan et al., 2007 showed a similar effect on the generation of 
the active form of SREBP2 (113).  In both experimental systems, downstream 
target genes of ATF6 and SREBP2 were altered after treatment with AEBSF. 
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Given these results, initially AEBSF was evaluated in ABC-DLBL cell lines 
(OCI-Ly3 and OCI-Ly10). If S1P is inhibited, it is predicted that the 
unprocessed form might accumulate in the ER. The results showed that 
AEBSF led to a loss of all forms of CREB3L2. In the study by Okada et al., 
2003 application of AEBSF reduced the amount of processed protein, but had 
little effect on the level of unprocessed form. In contrast, the experiments by 
Colgan et al. showed similar results to those obtained in Figure 5.1, with an 
overall loss of SREBP2. Given that AEBSF can inhibit a wide range of serine 
proteases, including chymotrypsin, kallikrein, plasmin, thrombin and trypsin, it 
is likely to be having a broader impact than just targeting S1P (96). Thus, 
despite the published data showing that AEBSF can limit production of active 
ATF6 and SREBP2, the potential for non-specific effects makes AEBSF a less 
valuable tool for studying CREB3L2 and was not included in additional 
experiments. 
 
Instead, compounds with higher selectivity were investigated. Another site-1 
protease inhibitor (PF-429242) and a site-2 protease inhibitor (Nelfinavir) were 
first examined in myeloma cell lines. As mentioned above, it was predicted 
that using either an S1P or S2P inhibitor would inhibit the formation of the 
active form, which in turn will result in the accumulation of the full-length 
protein. In agreement with this prediction, treatment with PF-429242 led to the 
loss of the cleaved form accompanied by an increase in the amount of full 
length. However, similar to the results with AEBSF both forms of CREB3L2 
were inhibited using Nelfinavir, which was not expected. In a previous report 
by Guan et al., treatment of the liposarcoma cell line SW872 with Nelfinavir 
resulted in both an increase in unprocessed ATF6 and SREBP1 and a 
reduction in the processed forms (98). This was accompanied by an increase 
in apoptosis, which the authors attributed to the accumulation of unprocessed 
ATF6 and SREBP1 triggering a UPR.  Thus, treatment with PF-429242 or 
10µM Nelfinavir may affect the cell’s capability to respond to the ER-stress, 
but through different mechanisms. 
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Based on evidence from the papers cited above, ATF6 represents the 
prototypical target of S1P/S2P cleavage during an ER-stress response.  
Therefore, the impact of S1P  (PF-429242) and S2P (Nelfinavir) inhibitors on 
ATF6 in myeloma cell lines were studied. The results showed that ATF6 did 
not respond to PF-429242 (S1P inhibitor) however, expression of both forms 
were inhibited using Nelfinavir (S2P inhibitor). While these results are 
unanticipated, we cannot rule out the possibility that (1) ATF6 might not 
localise effectively to the Golgi in these cells and (2) the effect may be 
attributable to off-target effects of Nelfinavir. Additionally, Aragon et al., found 
that ATF6α deficiency had no impact on the formation of antibody secretory 
cells and antibody secretion (52). The lack of requirement for ATF6 in plasma 
cells may be consistent with an alternative mode of activity in the B-cell 
lineage. In support of this, ATF6 has been shown to use a different 
mechanism of intracellular trafficking and stress signalling compared to 
CREB-H, which is structurally more similar to CREB3L2 (114).  
 
Perhaps the most surprising result is the observed effect of S1P (PF-429242) 
and S2P (Nelfinavir) inhibitors on XBP1 in myeloma cell lines. mRNA 
encoding the XBP1 transcription factor is spliced in response to IRE1 
activation by ER stress. This occurs at the same time, but independently of 
S1P/S2P activity on ATF6 or CREB3L2. However, a recent report provides a 
possible link between S1P/S2P and the expression of XBP1. Guo et al., found 
that ATF6 can bind to the promoter region of XBP1 and increase expression 
in chondrocytes (115). Although the effect of PF-429242 and Nelfinavir was 
not particularly pronounced, since CRE motifs allow binding of both CREB 
and ATF family members the XBP1 promoter might potentially also be 
regulated by CREB3L2.  
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In conclusion, PF-429242 and Nelfinavir were validated as effective inhibitors 
of CREB3L2 processing, but are likely to have a wider effect on additional 
pathways important in cells undergoing the transition to antibody secretory 
cells or tumours originating during this process.   
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6. Effect of site-1 protease (S1P) and site-2 protease (S2P) 
inhibitors on human differentiating B-cells 
 
6.1 Impact of S1P inhibitor (10 µM PF-429242) on human antibody 
secreting cells 
 
The regulated expression of CREB3L2 was first established in myeloma and 
ABC-DLBCL cell lines. Then, using the in vitro model to generate mature 
plasma cells, CREB3L2 expression was analysed by Western blotting. As 
shown in Chapter-4, CREB3L2 is expressed in human differentiated B-cells, 
plasmablasts and plasma cells (slightly weak expression on Day-3, stronger 
expression from Day-6/7 to Day-13). In both primary differentiating B-cells and 
B-cell lines, inhibition of S1P/S1P profoundly reduced the generation of 
cleaved CREB3L2, as well as other transcription factors processed in the 
same fashion. It is predicted that the loss of the active forms would lead to a 
change in the differentiation capacity or functional activity of B-cells.  
Therefore, the impact of S1P inhibitor (10 µM PF-429242) on ASCs was 
initially studied. The cells were treated with 10 µM PF-429242 and or dH2O 
(S1P inhibitor vehicle that acts as a control) on Day-6, Day-8 or Day-10 and 
analysed on Day-8, Day-10 and Day-13, respectively, for cell number, 
phenotype, expression of UPR-related factors and immunoglobulin 
production.  
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6.1.1 Cell number 
The first assessment for the impact of 10 µM PF-429242 on the ASCs was the 
absolute cell number. After the incubation, the cells were accurately counted 
using CountBright TM beads on Day-8, Day-10 and Day-13 to examine the 
possible impact of the inhibitor. The results revealed no changes in the cell 
count between the cells treated with 10 µM PF-429242 or dH2O (Figure 6.1).  
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Figure 6.1: Effect of S1P inhibitor (10 µM PF-429242) on cell number. ASCs  
(Day-6, Day-8 and Day-10) were treated with 10 µM PF-429242 and or dH2O and 
the cells were counted at the indicated time points using CountBright TM absolute 
counting. Blue bars represent the count for dH2O treated cells whereas the red bars 
represent the count for 10 µM PF-429242 treated cells. 
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6.1.2 Cell phenotype 
The surface phenotype is a key indicator of progression through the 
differentiation stages. To determine whether inhibition of S1P at the 
plasmablast stage was sufficient to block the acquisition of full plasma cell 
phenotype, ASCs were treated with 10 µM PF-429242 or dH2O. At each 
stage, the cells were stained for CD19, CD20, CD138 and CD38 and 
analysed by flow cytometry. The results revealed no discernable changes in 
expression of the evaluated markers after 10 µM PF-429242 treatment 
compared to its vehicle (dH2O, control) (Figure 6.2).  
 
 
 
Figure 6.2: The impact of S1P inhibitor (10 µM PF-429242) on cell surface 
phenotype. ASCs  (Day-6, Day-8 and Day-10) were treated with 10 µM PF-429242 
or dH2O and then stained using B-cell (CD19 and CD20) and ASC markers, (CD38, 
and CD138) and analysed by flow cytometry at the indicated time points.   
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6.1.3 CREB3L2 expression 
The expression of CREB3L2 is characterised by the presence of two forms: 
full-length and cleaved form in different proportions depending on the state of 
the cell and the stimuli (e.g ER stress stimulus; thapsigargin or the production 
of antibodies as the B-cells differentiate). Upon ER stress, CREB3L2 is 
cleaved via S1P/S2P generating the cleaved form that migrates to the nucleus 
to activate its target genes (67). However, using S1P/S2P inhibitors prevents 
the cleavage of CREB3L2, which leads to the accumulation of the full-length 
protein in the ER potentially triggering apoptosis. The results obtained in the 
previous two figures suggest that blocking conversion of CREB3L2 to the 
active form does not have this effect at late time points during differentiation. 
To confirm that inhibition of S1P was affecting protein processing, Western 
analysis of protein lysates was performed. The results show that the cleavage 
of CREB3L2 in the antibody secretory cells was strongly reduced upon the 
treatment with 10 µM PF-429242 compared to its vehicle (dH2O) at the protein 
level (Figure 6.3). 
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Figure 6.3: The impact of S1P inhibitor (10 µM PF-429242) on CREB3L2 
protein expression. ASCs (Day-6, Day-8 and Day-10) were treated with 10 µM 
PF-429242 or dH2O for the indicated times and the cells were collected for protein 
preparation and analysis using 10% SDS-PAGE and Western blot. The lane 
labelled “Control” is loaded with lysate containing the N-terminus of CREB3L2 that 
has been overexpressed in Hela cells. β-ACTIN was used as a loading control.  
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6.1.4 XBP1 expression 
To date, only one UPR regulator has been implicated in plasma cell 
differentiation, XBP1. Therefore, RNA samples collected from Day-8, Day-10 
and Day-13 with and with out S1P inhibitor (10 µM PF-429242) treatment 
were initially tested for XBP1 splicing by PCR. In addition, RNA sample from 
U266 cells that had been treated with 1μM thapsigargin for 2, 4 and 6 hours 
were included in the gel as a control for splicing. The results showed a slight 
inhibition of XBP1 splicing upon 10 µM PF-429242 treatment compared with 
its vehicle (Figure 6.4) confirming the impact of S1P inhibitor  (10 µM PF-
429242) treatment on XBP1 splicing. It is also worth noting that contrary to 
what might be expected, XBP1 shows very little splicing in the in vitro 
generated antibody secreting cells, particularly at the later time points. 
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Figure 6.4: The impact of S1P inhibitor (10 µM PF-429242) on XBP1 splicing. 
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6.1.5 Immunoglobulin secretion (IgM and IgG)  
The S1P inhibitor (10 µM PF-429242) had little discernable effect on cell 
number or the phenotypic characteristics of ASCs (Day-8, Day-10 and Day-
13); however, it is crucial to quantify the immunoglobulin (IgM and IgG) levels 
to determine whether this was matched by preservation of function. Thus, the 
supernatant were collected from the treated /untreated cells and analysed 
using ELISA. The results showed that there is no difference in the 
immunoglobulin (IgM and IgG) levels between the treated and the untreated 
samples suggesting that 10 µM PF-429242 does not affect secretion (Figure 
6.5). 
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Figure 6.5: The impact of S1P inhibitor on immunoglobulin production. 
ASCs  (Day-6, Day-8 and Day-10) were treated with 10 µM PF-429242 or 
dH2O and the supernatants were collected at the indicated time points for 
IgM and IgG quantifications using ELISA. Blue bars represent the amount 
for dH2O treated cells whereas the red bars represent 10 µM PF-429242 
treated cells. 
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Thus, based on cell counts, cell phenotypes and immunoglobulin levels (IgM 
and IgG), S1P inhibitor (10 µM PF-429242) did not affect the viability or 
function of the human differentiated antibody secretory cells when treated on 
Day-6 or Day-8 or Day-10 despite having an impact on the protein level of 
CREB3L2 cleaved form, suggesting that CREB3L2 or other S1P-regulated 
transcription factors are not required for terminal differentiation.  
 
On the other hand, meta-profile analysis of DLBCL gene expression 
signatures has shown that CREB3L2 is characteristic of the activated B-cell 
(ABC) subset (Figure 6.6) (87). In addition, CREB3L2 protein is detectable in 
the human differentiated B-cells using the in vitro model (Chapter-4) at the 
activated B-cell stage, corresponding to Day-3. This would imply that 
CREB3L2 is consistently expressed and likely to function in B-cells initiating 
the process of plasma cell differentiation. Therefore, to determine whether 
CREB3L2 might play a role in starting the transition to becoming an ASC, it 
necessary to treat the cells with S1P inhibitor at the earlier activated B-cell 
stage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: ABC-DLBCL meta-profile depicted as a Wordle where font size 
indicates degree and consistency of expression. Figure from Matt Care. 
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6.2 Impact of S1P inhibitor and S2P inhibitor on the transition from 
activated B-cell to ASC  
 
 Based on the results obtained by Western blotting of the endogenous 
expression of CREB3L2 in human differentiated B-cells (Chapter-4), the full 
length and cleaved form of CREB3L2 were expressed from the B-cell stage 
(Day-3) onwards. Since blocking S1P at the later stages of differentiation had 
no real impact, it was hypothesised that instead CREB3L2 and related factors 
may in fact be primarily operating during the initial phases. To test this, Day-3, 
Day-4 and Day-5 human differentiated B-cells were treated with 10 µM PF-
429242/dH2O (vehicle control) or 10 µM Nelfinavir/ethanol (vehicle control) for 
24 hours and analysed for the same parameters as described in the above 
experiments.  
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Figure 6.7: Diagrammatic representation of experimental design to test the 
impact of S1P and S2P inhibitors PF-429242 and Nelfinavir on human B-cell 
differentiation. The cells were treated on Day-3, Day-4 and Day-5 and analysed 
24 hours post treatment for protein and RNA expression, cell count, surface 
phenotype and immunoglobulin secretion. 
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6.2.1 Expression of UPR-related transcription factors 
The data in Chapter 5 demonstrated that S1P and S2P inhibitors not only 
affected CREB3L2, but also impacted on other UPR-related transcription 
factors in myeloma and ABC-DLBCL cell lines. To determine whether the 
same was true in primary cells, human differentiated B-cells and ASCs (Day-
3, Day-4 and Day-5) were treated with 10 µM PF-429242/dH2O or 10 µM 
Nelfinavir/Ethanol for 24 hours and analysed on Day-4, Day-5 and Day-6 
respectively. At each time point, cells were collected for lysate preparation 
and analysed by Western blotting. The results in Figure 6.8 show the impact 
of the inhibitors, revealing a profound inhibition by 10 µM PF-429242 on the 
cleavage of CREB3L2 at each of the time points assessed. In contrast, 10 µM 
Nelfinavir had less of an impact CREB3L2 processing, but did diminish the 
full-length form likely due to its multiple bioactivities (108). These results 
indicate that both drugs are likely to be functioning as effective inhibitors at the 
concentrations and times tested, but that PF-429242 might have a greater 
impact on CREB3L2 regulated targets. 
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Figure 6.8: The impact of S1P inhibitor (PF-429242) or S2P inhibitor 
(Nelfinavir) on CREB3L2 expression in differentiating B-cells. Cells  (Day-3, 
Day-4 and Day-5) were treated with 10 µM PF-429242/dH2O or 10 µM 
Nelfinavir/Ethanol for 24 hours and cell lysates analysed by immunoblotting. Control 
was the N-terminus of CREB3L2 that has been overexpressed in Hela cells. β-
ACTIN was used as a loading control.  
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Considered to be one of the three conventional arms of the UPR, ATF6 is 
processed by the same step-wise proteolytic mechanisms as CREB3L2. To 
determine whether inhibition of S1P and S2P had a similar effect on ATF6 
expression, the lysates were assessed by immunoblotting with antibody that 
recognised the cleaved form (Figure 6.9). Although far less pronounced than 
the effect on CREB3L2, treatment with PF-429242 did modestly reduce the 
amount of detectable ATF6 and this was similar to the reduction of ATF6 
achieved with Nelfinavir. 
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Figure 6.9: The impact of S1P inhibitor (PF-429242) or S2P inhibitor 
(Nelfinavir) on ATF6 expression. Cells  (Day-3, Day-4 and Day-5) were treated 
with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 24 hours and lysates 
analysed by Western blot using anti-ATF6. Β-ACTIN was used as a loading control.  
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XBP1 is an important transcription factor that has been implicated in the UPR, 
particularly in plasma cells. In addition, XBP1 has been postulated as 
potential therapeutic target for multiple myeloma (116). Given that S1P/S2P 
play a role in regulating multiple components of the UPR and the results 
obtained in Chapter-5, it was of interest to determine whether XBP1 might be 
affected as an indirect consequence.  
 
Therefore Day-3, Day-4 and Day-5 cells were treated with S1P inhibitor (10 
µM PF-429242) or S2P inhibitor (10 µM Nelfinavir) for 24 hours and analysed 
for XBP1s using Western blotting. Consistent with its role in the UPR and 
generation of ASC, XBP1 is not readily detected until Day-5 of the culture, 
when cells are phenotypically changing and beginning to secrete 
immunoglobulin (Figure 6.10).  Interestingly, expression of XBP1s is inhibited 
by 10 µM PF-429242 in cells treated on Day-5; whereas its expression is 
inhibited by 10 µM Nelfinavir in cells treated a day earlier (Figure 6.10). 
Hence, although the inhibitors do not directly target it, XBP1s is also sensitive 
to the treatment and its loss may enhance any observed effects. 
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Figure 6.10: The impact of S1P inhibitor 
(PF-429242) and or S2P inhibitor (Nelfinavir) 
on XBP1s expression. Cells  (Day-3, Day-4 
and Day-5) were treated with 10 µM PF-
429242/dH2O or 10 µM Nelfinavie/Ethanol for 
24 hours and cell lysates analysed using 10% 
SDS-PAGE followed by Western blotting using 
an antibody to XBP1. Β-ACTIN was used as a 
loading control. NS, non-specific band. 
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To determine whether the loss of detected XBP1s after treatment with 
S1P/S2P inhibitors was a reflection of an alteration in its splicing, RNA 
samples were initially tested using a PCR assay that detects both forms. In 
addition, RNA sample from U266 cells that have been treated with 1μM 
thapsigargin for 4 hours were included in the gel as a control for splicing. The 
results provided no clear conclusive impact of the inhibitors; however, splicing 
was detected from Day-5 onward, which agreed with protein expression 
pattern (Figure 6.11).  
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Figure 6.11: The impact of S1P inhibitor (PF-429242) or S2P inhibitor 
(Nelfinavir) XBP1 splicing. Cells  (Day-3, Day-4 and Day-5) were treated with 10 
µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 24 hours and splicing 
evaluated by RT-PCR. Control is an RNA sample from U266 cells that have been 
treated with 1µM Tg for 4 hours.  Tg, Thapsigargin. 
Chapter-6 126	  
6.2.2 Cell count 
At the activated B-cell stage, the cells are undergoing rapid proliferation, with 
as many as 3 divisions within the space of 24 hours (117). From Day-3 to 
Day-6 the cells continue to divide prior to completing terminal differentiation, 
which is accompanied by exit from cell cycle.  To determine whether S1P/S2P 
regulated proteins would affect the expansion of activated B-cells, cells were 
treated with 10 µM PF-429242 or 10 µM Nelfinavir for 24 hours. After the 
incubation, the cells were enumerated on Day-4, Day-5 and Day-6. The 
results revealed minimal changes in the cell counts between the cells treated 
with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol (Figure 6.12) 
suggesting that within the time-frame of the experiment neither proliferation or 
cell viability are dependent on S1P/S2P-regulated pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on B-cell expansion. Activated B-cells (Day-3, Day-4 and Day-5) 
were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 24 
hours and the cells were counted using CountBright TM absolute counting. Blue 
bars represent the count for dH2O treated cells, red bars represent cell count for 
10 µM PF-429242 treated cells, green bars represent the count for ethanol treated 
cells, purple bars represent cell count for 10 µM Nelfinavir treated cells. 
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6.2.3 Cell phenotype 
The results above suggest that S1P/S2P inhibitors do not profoundly alter cell 
cycle regulation of differentiating activated B-cells. As the decision to become 
an ASC has been linked to proliferative capacity (118), it was important to 
determine whether there were any differences in the accompanying changes 
in surface phenotype. Cells were examined on Day-3 (untreated), Day-4, Day-
5 and Day-6 treated for expression of CD19, CD20, CD138 and CD38. The 
results revealed no changes on cell phenotype between treated (either with 10 
µM PF-429242 nor 10 µM Nefinavir) and untreated (control; treated with 
dH2O or ethanol) cells (Figure 6.13), consistent with the cell number data.  
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Figure 6.13: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on cell phenotype. In vitro differentiated cells  (Day-3, Day-4 and 
Day-5) were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
24 hours and subsequently stained using B-cell markers (CD19 and CD20) and 
ASC markers (CD38 and CD138) and analysed using flow cytometry. 
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6.2.4 Immunoglobulin levels 
Although, phenotypically the cells appeared to be differentiating normally, it 
was still possible that inhibition of S1P/S2P could affect the function of ASCs. 
Therefore, the cell culture supernatants were collected from the treated 
/untreated cells and analysed using ELISA. In the single donor that was 
evaluated in this experiment, it appeared that both inhibitors caused a slight 
reduction in secretion of IgG, with a more pronounced effect on IgM after 
treatment with Nelfinavir (Figure 6.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on immunoglobulin production. Cells  (Day-3, Day-4 and Day-5) 
were treated with 10 µM PF-429242/dH2O and or 10 µM Nelfinavir/Ethanol for 24 
hours and the supernatants were collected for IgM and IgG quantifications using 
ELISA. Blue bars represent dH2O treated cells, red bars represent 10 µM PF-
429242 treated cells, green bars represent ethanol treated cells and purple bars 
represent 10 µM Nelfinavir treated cells. 
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6.3 Day-3 to Day-6 
While the impact of 10μM PF-429242 or 10μM Nelfinavir on cells during the 
activated B-cell to plasmablast transition was minimal in terms of cell number 
and phenotype, the results of Figure 6.14 suggested that the inhibitors could 
alter the functionality of ASC. The experiments conducted thus far only 
examined the cells after 24 hours of treatment. It was plausible that a greater 
effect might be observed after prolonged exposure to the drugs. Therefore, 
the cells were treated with the inhibitors for longer time:  either with one dose 
on Day-3 and analysed on Day-6 (72 hours) or by re-treating the cells every 
24 hours until Day-6 (Figure 6.15).  
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Figure 6.15: Diagrammatic representation of experiments to detect the 
impact of S1P and S2P inhibitors. The cells were treated on Day-3 for 72 hours 
and analysed on Day-6 for cell number, cell phenotype, protein expression, RNA 
expression and immunoglobulin levels. 
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6.3.1 Day-3 to Day-6 (One dose) 
6.3.1.1 Cell count 
To determine whether extended exposure to S1P/S2P inhibitors might result 
in a reduction of proliferation or enhanced cell death, activated Day-3 cells 
were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 
hours. On Day-6, the cells were accurately counted using CountBrightTM 
absolute counting to examine the possible impact of the inhibitors. The results 
revealed an 80% reduction in the number of treated B-cells compared to their 
controls, confirming that inhibiting S1P/S2P regulated pathways had an 
impact on cell viability (Figure-6.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on cell number. Day-3 B-cells were treated with 10 µM PF-
429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 hours and analysed on Day-6 
using CountBright TM absolute counting. 
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6.3.1.2 Cell phenotype 
The ability of cells to down-modulate B-cell associated markers while 
acquiring a PC phenotype is an essential component of the differentiation 
process. To investigate whether inhibiting S1P/S2P could interrupt this 
change, Day-3 cells were treated with 10 µM PF-429242/dH2O or 10 µM PF-
429242 10 Nelfinavir/Ethanol and the surface expression patterns were 
examined on Day-6 by flow cytometry.  
The results showed a slight change in cell phenotype upon inhibitor treatment, 
by decreasing the plasmablast formation (CD38) and retaining B cell markers 
(CD20) compared to the control (dH20 and Ethanol) (Figure 6.17). 
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Figure 6.17: The impact of S1P inhibitor 
(PF-429242) and S2P inhibitor 
(Nelfinavir) on cell phenotype during 
differentiation. Human B-cells (Day-3) 
were treated with 10 µM PF-429242/dH2O 
or 10 µM Nelfinavir/Ethanol for 72 hours. 
On Day-6, the cells were stained using B-
cell (CD19 and CD20) and ASC markers 
(CD38 and CD138) and analysed by flow 
cytometry. 
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6.3.1.3 Expression of UPR-related transcription factors 
 
The previous experiments suggested that the inhibitor treatment lead to a 
marked reduction of CREB3L2 and loss of ATF6 and XBP1s. To confirm that 
that the loss of protein was maintained over the extended period of incubation, 
Day-3 cells were treated with 10 µM PF-429242/dH2O or 10 µM 
Nelfinavir/Ethanol for 72 hours and protein expression examined. As before, 
there was a profound inhibition of S1P-mediated cleavage using 10 µM PF-
429242 on CREB3L2 and XBP1, but less of an effect on ATF6 (Figure 6.18). 
However, 10 µM Nelfinavir had an impact on CREB3L2 (both forms), XBP1s 
and ATF6.  
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Figure 6.18: The impact of S1P inhibitor (PF-429242) or S2P inhibitor 
(Nelfinavir) on CREB3L2, XBP1s and ATF6 after 72 hr treatment. Day-3 B-cells 
were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 hours 
and cell lysates analysed by Western blot. Migrations of TFs are indicated by 
arrows. Control was the N-terminus of CREB3L2 that has been overexpressed in 
Hela cells. Β-ACTIN was used as a loading control.  
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6.3.1.4 Immunoglobulin levels 
The results in Figure 6.14 suggested that inhibiting S1P/S2P might prevent 
the secretion of antibody. To ascertain whether the effect was more 
pronounced with an extended incubation, the supernatants were collected 
from the treated /untreated cells and analysed using ELISA. The results show 
almost a complete elimination of IgM in the treated samples compared with 
the control (Figure 6.19). On the other hand, IgG levels were reduced by 75-
90%. These results suggest that prolonged exposure to 10 µM PF-429242 
and 10 µM Nelfinavir severely cripples immunoglobulin production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on immunoglobulin production after 72 hrs of treatment. Day-3 
B-cells were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
72 hours and the supernatant were collected for IgM and IgG quantifications using 
ELISA. Blue bars represent IgM levels whereas the red bars represent IgG levels.   
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6.3.1.5 Cell morphology  
 
The data in Figure-6.16 clearly shows a dramatic drop in cell number after 
treatment with 10 µM PF-429242 or 10 µM Nelfinavir, whereas the surviving 
cells were able to show phenotypic maturation. Interestingly, Nelfinavir also 
generated a population of cells that had increased FSC/SSC compared to 
other cells at Day-6 (Figure-6.17). To further investigate the impact of S1P or 
S2P treatment on plasmablasts, cytospin samples were assessed for 
morphological differences (Figure-6.20). Unexpectedly, cells treated with 
Nelfinavir exhibited polyploidy. In control cells, 94% had 1 nuclear lobe, 4.6% 
had 2 nuclear lobes and 1.4% had >2. In contrast, after 72 hours of Nelfinavir 
exposure 69% of cells had a single nuclear lobe, 22% had 2 lobes and 9% 
featured more than 2 nuclear lobes in a single cell. Treatment with PF-429242 
generated vacuolated cells, consistent with increased cell death. 
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Figure 6.20: The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on the morphology of human differentiated B-cells. Day-3 B-cells 
were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 
hours. After incubation, the cells were stained using Geimsa stain.  
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6.3.2 Day-3 to Day-6 (Multiple doses) 
 
The impact of S1P and S2P inhibitors was further investigated by repeating 
the treatment with the inhibitors. Thus, Day-3 B-cells were treated with 10μM 
PF-429242/dH2O or 10μM Nelfinavir/Ethanol, the cells were re-seeded and 
re-treated with the inhibitors on Day-4 and Day-5 and analysed on Day-6 
(Figure- 6.21) for protein and RNA expression, cell count, cell phenotype and 
immunoglobulin production. 
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Figure 6.21: Diagrammatic representation of experimental design to test the 
impact of S1P and S2P inhibitors administered in multiple doses. The cells were 
treated on Day-3, and re-treated on Day-4 and Day-5. Then the cells were analysed 
on Day-6 for cell number, cell phenotype, protein and RNA expression and 
immunoglobulin levels. 
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6.3.2.1 Expression of UPR-related transcription factors 
The single dose of S1P or S2P inhibitor applied at Day-3 was able to abolish 
CREB3L2 and XBP1 expression at Day-6 and dampen expression of ATF6. 
To determined whether multiple doses might further reduce protein 
expression, patterns of the three UPR elements; CREB3L2, XBP1s and ATF6 
were checked after the triple dose of inhibitors. As before, both forms of 
CREB3L2 were lost as was XBP1s (Figure 6.22). Furthermore, multiple doses 
more effectively reduced the levels of ATF6. 
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Figure 6.22: The impact of multiple doses of S1P inhibitor (PF-429242) and or 
S2P inhibitor (Nelfinavir) on CREB3L2, XBP1s and ATF-6 expression. B-cells 
were treated repeatedly with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol 
on Day-3, Day-4 and Day-5 and the cells were collected for protein analysis by 
Western blotting on Day-6. Migrations of TFs are indicated by arrows. Control was 
the N-terminus of CREB3L2 that has been overexpressed in Hela cells. β-ACTIN 
was used as a loading control. NS, non-specific band. 
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6.3.2.2 Cell count 
On Day-6, the cells were accurately counted using CountBright TM absolute 
counting to examine the effect of treating the cells repeatedly with S1P and 
S2P inhibitors during the activated B-cell to plasmablast transition. The results 
demonstrated more than 90% reduction in the number of treated B-cells 
compared to their controls, confirming that S1P inhibitor (10 µM PF-429242) 
and S2P inhibitor (10 µM Nelfinavir) had a profound impact on cell viability 
during the early stages of becoming an ASC (Figure-6.23). 
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Figure 6.23: The impact of repeated doses of S1P inhibitor (PF-429242) 
and S2P inhibitor (Nelfinavir) on cell number. Day-3 B-cells were treated 
with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 24 hours and then 
re-treated with the same inhibitors on Day-4 and Day-5 and analysed on Day-6 
using CountBright TM absolute counting. 
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6.3.2.3 Cell phenotype 
The impact of multiple treatments on both the expression of CREB3L2, XBP1 
and ATF6 and cell survival was compelling. To determine whether this 
extended to preventing phenotypic alterations, the cells were repeatedly 
treated on Day-3, Day-4 and Day-5 with 10 µM PF-429242/dH2O or 10 µM 
PF-429242 10 Nelfinavir/Ethanol and analysed on Day-6. The cells were 
stained with CD19, CD20, CD138 and CD38 and evaluated using flow 
cytometry. The results showed that there is an increase in CD38 high 
population from PF-429242 treated samples compared to the control. 
However, CD20 is retained in PF-429242 treated samples compared to the 
control (dH20 and Ethanol) (Figure 6.24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D1911 
Day-3 
dH2O 
PF-429242 
Ethanol 
Nelfinavir 
CD
20
 
CD19 C
D3
8 
CD138 S
SC
 
FSC 
Day-6 
	  
Figure 6.24: The impact of repeated 
doses of S1P inhibitor (PF-429242) and 
S2P inhibitor (Nelfinavir) on cell 
phenotype during the transition from 
activated B-cell to plasmablast. B-cells 
(Day-3) were treated with 10 µM PF-
429242/dH2O or 10 µM Nelfinavir/Ethanol 
for 24 hours and then the cells were re-
treated with the same inhibitors on Day-4 
and Day-5 and analysed on Day-6. On 
Day-6, the cells were stained using B-cell 
markers (CD19 and CD20) and ASC 
markers (CD38 and CD138) and 
analysed using flow cytometry. 
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6.3.2.4 Immunoglobulin levels 
The previous results using a single dose showed that the cells were unable to 
produce much immunoglobulin, despite evidence for phenotypic changes 
associated with the plasmablast stage. To further investigate the impact of 
multiple doses of S1P and S2P inhibitors on immunoglobulin (IgM and IgG) 
production, the supernatants were collected from the treated /untreated cells 
and analysed using ELISA. In this experiment both IgM and IgG were reduced 
by greater than 90% after repeated exposure to the inhibitors (Figure 6.25). 
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Figure 6.25: The impact of multiple doses of S1P inhibitor (PF-429242) and 
S2P inhibitor (Nelfinavir) on IgM and IgG levels. Day-3 B-cells were treated 
with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 24 hours and then 
re-treated with the same inhibitors on Day-4 and Day-5 and analysed on Day-6. 
The supernatants were collected and the immunoglobulins (IgM and IgG) were 
quantified using ELISA.  
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    6.4 Validation of S1P/S2P Inhibitor Single Application on Day3 with 
Evaluation on Day6  
 
The preliminary set of experiments described above suggested that the 
optimum condition for evaluating the impact of S1P and S2P inhibitors on 
the UPR elements (CREB3L2, XBP1s and ATF6) in differentiating human 
B-cells was using a single dose of inhibitor on Day-3 activated cells 
followed by evaluation 3 days later when the cells had progressed to the 
plasmablast stage. A total of 7 donors were assessed for protein 
expression (Figure 6.26), cell count (Figure 6.27), cell phenotype (Figure 
6.28), and IgM and IgG levels (Figure 6.29) following treatment with 10 µM 
PF-429242 or 10 µM Nelfinavir.  
 
Initially, protein samples were evaluated to confirm that S1P/S2P inhibitors 
were producing the appropriate effect on the expression of CREB3L2, 
XBP1s and ATF6 in each of the 7 donors. The results showed a consistent 
inhibition of both forms of CREB3L2 by PF-429492 and Nelfinavir, with a 
near complete loss of protein upon treatment with the S1P inhibitor. 
Interestingly, one donor (D704) had a prominent band detected by the anti-
CREB3L2 at approximately 50 kDa that was also affected by the inhibitor. 
This band was variably observed in different donors, but never to the 
extent as seen in this particular experiment. There are several predicted 
ESTs for CREB3L2; it is possible that the B-cells in this differentiation 
expressed a particular isoform containing the epitope recognised by the 
antibody. This sample was also relatively resistant to Nelfinavir treatment. 
Furthermore, the expression of both XBP1s and ATF6 appeared to closely 
mirror that of CREB3L2 (Figure 6.26).  
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The impact of S1P and S2P inhibitors on the accumulation of active UPR-
related transcription factors indicated that the drugs were effectively 
targeting the expected pathways. To ascertain whether this would be 
accompanied by a change in other attributes, a range of assays were 
performed. Figure 6.27 depicts the absolute counts of cells obtained after 3 
days of culture in media containing either PF-429242 or Nelfinavir. 
Consistent with the previous results, counts obtained from 7 human donors 
gave fewer cells after S2P inhibition and showed a severe reduction in 
response to S1P inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.26 Validating the impact of S1P inhibitor (PF-429242) or S2P 
inhibitor (Nelfinavir) on the endogenous protein expression of CREB3L2, 
XBP1s and ATF6. Day-3 B-cells from 7 human donors were treated with 10 µM 
PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 hours. Cell were collected 
for protein preparation and analysis using 10% SDS-PAGE followed by Western 
blot for (A) CREB3L2, (B) XBP1 and (C) ATF6. Control was the N-terminus of 
CREB3L2 that has been overexpressed in Hela cells. β-ACTIN was used as a 
loading control. Individual donors are indicated at the top of each blot. 
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Figure 6.27 Validating the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on cell viability. Day-3 B-cells were treated with 10 µM 
PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 hours and analysed on 
Day-6 for cell number using CountBright TM absolute counting. Counts for 
individual donors are depicted in each graph. 
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The impact of S1P and S2P inhibitors on the transition from B-cells to more 
mature antibody secretory cells based on cell phenotype was validated as 
well using flow cytometry (Figure 6.28). The results from 7 donors showed 
that PF-429242 and Nelfinavir appeared to cause retention of CD20 (B-
cells) while delaying the acquisition of CD38 (plasmablast) compared with 
the control (dH2O and Ethanol), which are the same results obtained 
earlier.  
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Figure 6.28 Validating the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on cell surface phenotype. Human activated B-cells 
(Day-3) were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol 
for 72 hours. On Day-6, the cells were stained for CD19, CD20, CD38 and 
CD138 and analysed using flow cytometry. Donor numbers are shown at top. 
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Moreover, using the supernatant samples from the 7 donors, IgM and IgG 
levels were quantified by ELISA. The results provide evidence for 
substantial reduction in the IgM and IgG levels in the treated samples 
compared to the control suggesting that the protease inhibitors not only 
affect the cell viability but also the immunoglobulin secretion (Figure 6.29).  
Of interest, the donor (D704) who was characterised by the presence of a 
potentially new form of CREB3L2 showed relative resistance in the ability 
to secrete IgG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.29 Validating the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on immunoglobulin secretion. Day-3 B-cells from 7 
human donors were treated with 10 µM PF-429242/dH2O or 10 µM 
Nelfinavir/Ethanol for 72 hours and analysed on Day-6. The supernatants were 
collected and the immunoglobulins (IgM and IgG) were quantified using ELISA.  
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6.5 Gene expression profile 
 
The changes in the various characteristics described above suggest that 
inhibition of S1P or S2P might have a profound impact on the gene 
expression programs governing plasma cell differentiation or survival. 
While many of the pathways have been described, the full extent of the 
requirements for generating ASC populations is unknown. To determine 
the potential role that S1P/S2P-regulated pathways might play in this 
process, RNA samples were prepared from cells that had been treated 
from Day-3 for 72 hours with PF-429242, Nelfinavir or vehicle and 
processed for evaluation of global gene expression by microarray. Figure-
6.30 depicts select genes that show greater than 1.4-fold difference in the 
conditions tested. Amongst these, genes such as ALDOC and ABCA1 
were downregulated by both inhibitors, but there were clear differences in 
the patterns of expression following the two types of treatment.  
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A 
B 
Figure-6.30: Impact of S1P/S2P inhibition on plasmablast gene expression. 
Day-3 B-cells from 3 donors were treated with (A) 10 µM PF-429242 or (B) 
Nelfinavir and analysed on Day-6 using Illumina bead arrays. Selected genes 
showing greater than 1.4-fold change in expression are depicted. The red diamonds 
indicate genes contributing to gene ontology terms in Figure-6.31. 
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To better understand the how the groups of genes might be impacting of ASC 
behaviour, gene signature and ontology analysis was performed using over 
28,000 signatures (Figure-6.31). Remarkably, the signatures most significantly 
associated with the downregulated genes after PF-429242 treatment were 
related to SREBP and lipid metabolism, suggesting that a substantial 
proportion of the change in gene expression might be attributable to the loss 
of processed SREBP. The most prominent signature associated with 
downregulated genes in the Nelfinavir treated cells was hypoxia/HIF related 
and this was additionally observed in the PF-429242 samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure-6.31: Impact of S1P/S2P inhibition on plasmablast gene expression 
signatures. Day 3 B-cells from 3 donors were treated with (A) 10 µM PF-429242 or 
(B) Nelfinavir and analysed on day 6 using Illumina bead arrays. Gene 
ontology/signature enrichment was evaluated using 28,000+ signatures and 
ontology terms. The terms highlighted in red are linked to the genes marked by red 
diamonds in Figure-6.30. Signature analysis conducted by Matthew Care. 
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An integrated signature enrichment analysis revealed several additional 
ontology terms of interest (Figure-6.32). Inhibition of S1P in differentiating B-
cells also affected serine/AA synthesis, fatty acid metabolism, mTOR 
signalling and targets associated with regulation by IRF4. Collectively, these 
results suggest that inhibition of S1P/S2P results in a substantial change in 
genes associated with metabolic process that are likely to explain the loss of 
cell function and viability. 
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Figure-6.32: Hierarchical clustering of gene signature and ontology terms 
enriched amongst genes downregulated in PF-429242 treated plasmablasts. 
Enrichment of gene signatures was determined using a hypergeometric test against 
a curated set of 28,000+ signatures and ontology term associations. Enriched 
signatures and ontologies were clustered according to genes contributing to 
enrichment, and summary labels are shown on the right.  Analysis conducted by 
Matthew Care. 
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6.5.1 SREBP-1 (Sterol Regulatory Element Binding Protein-1) 
Based on the gene expression profile results, SREBP-1 was one of the most 
highly differentially expressed and affected by PF-429242. Therefore, it was 
further investigated. Two antibodies (a rabbit polyclonal and mouse 
monoclonal) were tested revealing that the monoclonal recognised specific 
bands of the appropriate molecular weight for both the full length and the 
processed form of SREBP-1 whereas, the rabbit SREBP-1 antibody had many 
non-specific interactions (Figure 6.33).  
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Figure 6.33 Evaluation of SREBP-1 antibodies. Two commercially available 
antibodies against SREBP-1 were tested on lysates from human differentiated 
B-cells and ASCs Day-3, -7, -9, -11 and -13 using Western blotting.  
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Thus, the mouse monoclonal SREBP-1 antibody was used to study protein 
expression in cells treated with PF-429242 and Nelfinavir for 12 hours from 
Day-3 to Day-6 (total of 72 hours) (Figure 6.34). The results showed that 
SREBP-1 inhibition started 36 hours post treatment with PF-429242 and 
Nelfinavir and continued until 72 hours. The degree of inhibition of SREBP-1 
by PF-429242 is much greater than Nelfinavir.   
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Figure 6.34 The impact of S1P and S2P inhibitors on SREBP-1 protein 
expression. The cells were treated with 10 µM PF-429242/dH2O or 10 µM 
Nelfinavir/Ethanol from Day-3 and collected every 12 hours to examine the 
impact of the inhibitors on SREBP-1 protein expression.  
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6.5.2 CD40L Expression 
The gene expression profile results showed that CD40L is expressed upon 
PF-429242 treatment (data not shown). Therefore, surface CD40L expression 
was examined on differentiating human B-cells from 3 donors after treating 
Day-3 cells with PF-429242/dH2O or Nelfinavir/Ethanol for 12 hours until Day-
6. At each time point, cells were collected and stained for CD154 (CD40L) and 
CD20 and the phenotype was checked using flow cytometry (Figure 6.35). 
The flow cytometry plots show that CD40L expression is enhanced upon PF-
429242 treatment on Day3+60 hours and Day3+72 hours compared to the 
control (dH2O), suggesting that CREB3L2 has an inhibitory impact on CD40L 
expression.  
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Figure 6.35 The impact of PF-429242 and Nelfinavir on CD40L 
expression on differentiating human B-cells. Human activated B-cells 
(Day-3) cells from 3 donors were treated with 10 µM PF-429242/dH2O or 10 
µM Nelfinavir/Ethanol for 12-hour intervals up to Day-6. At each time point, the 
cells were collected and stained for CD154 (CD40L) and CD20 (B-cells).   
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6.6 A The impact of S1P and S2P inhibitors on human plasma cells 
(Day-13) 
 
The impact of S1P and S2P inhibitors on the initial stages of plasma cell 
differentiation encompassing the activated B-cell stage (Day-3) to 
plasmablast stage (Day-6) have been evaluated and validated in (6.1-6.4). 
Initial experiments also examined the effect of the inhibitors during the 
transition from plasmablast  (Day-6) to plasma cell (Day-13). Neither PF-
429242 nor Nelfinavir affected the cell viability of ASCs when treated after 
Day-5, but multiple aspects of cell biology are affected when the cells 
treatment start from Day-3 where the expression of CREB3L2 begins.  
 
Since CREB3L2 is highly expressed in human plasma cells (Day-13) as 
shown in Chapter-4 it was of interest to determine the longer-term effects 
of reducing CREB3L2 along with other affected transcription factors. Thus, 
the impact of S1P and S2P inhibitors on human plasma cells was 
evaluated by treating the cells starting from Day-3, re-treating the cells on 
Day-6 and then evaluating on Day-13 (which is plasma cell stage) for cell 
count (Figure 6.36), cell phenotype (Figure 6.37) and IgM and IgG levels 
(Figure 6.38). 
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The total cell number on Day-13 from the 7 donors generated from Day-3 and 
Day-6 treatment, showed around 90% reduction in cell number of PF-429242 
treated samples whereas, the impact of Nelfinavir varied from donor to donor.  
 
In addition, the cell phenotype of Day-13 cells was examined revealing 
minimal change in phenotype compared with the control (dH2O and Ethanol), 
in the Nelfinavir treated cells (Figure 6.35). Although treatment with PF-
429242 severely diminished cell viability, some cells with a phenotype 
consistent with plasma cells (CD38hi CD138+) did emerge. In addition, 
according to the MFI values, it appears that PF-429242 treatment can 
promote plasma cell differentiation (Figure-6.52).  
 
Figure 6.36 The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on plasma cell number. Human activated B-cells (Day-3) from 7 
donors were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
72 hours. On Day-6, the cells were re-treated with the inhibitors and incubated up 
to Day-13.  After the culture period the cells were enumerated using CountBright 
TM absolute counting. 
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Figure 6.37 The impact of S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on plasma cell phenotype. Human activated B-cells from 8 donors 
(Day-3) were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
72 hours. On Day-6, the cells were re-treated with the inhibitors and incubated up 
to Day-13.  After culture, the cells were stained for CD19, CD20, CD38 and 
CD138 and analysed by flow cytometry. 
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To provide further evidence that inhibition of S1P/S2P might have a lasting 
effect on plasma cell function, tissue culture supernatants were harvested to 
evaluate the levels of secreted immunoglobulin. As expected, treatment with 
PF-429242 almost completely abrogated the production of antibody (Figure 
6.38). In contrast to the relatively modest effect on cell number and 
phenotype, Nelfinavir had a more pronounced effect on Ig secretion, 
particularly IgG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.38 The impact of S1P inhibitor (10 µM PF-429242) and S2P inhibitor 
(10 µM Nelfinavir) on plasma cell secretion. Human activated B-cells (Day-3) 
(7 donors) were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol 
for 72 hours. On Day-6, the cells were re-treated with the inhibitors and incubated 
up to Day-13.  After culture, the supernatants were collected and IgM and IgG 
were quantified using ELISA.  
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6.6 B The impact of transient application of S1P and S2P inhibitors on 
human ASCs  
 
PF-429242 and Nelfinavir had an inhibitory affect on the cleavage and 
processing of the UPR elements CREB3L2, XBP1s and ATF6, which was 
accompanied by a change in the biological characteristics of the differentiating 
populations. Since both drugs act as reversible, competitive inhibitors, it may 
be that cells cultured after transient exposure may re-express the relevant 
factors and regain some functionality. Therefore, to examine whether the 
inhibitory affect can be rescued cells were treated on Day-3 with PF-429242 
or Nelfinavir for 72 hours. After the incubation, the cells were re-seeded with 
the Day-6 standard condition (IMDM/10%FCS, amino acids, Il-6, Il-21, TX-
HYB, lipids) and analysed on Day-13 for cell count (Figure 6.39) and cell 
phenotype (Figure 6.40). The results validated the inhibitor effect of PF-
429242 and Nelfinavir on Day-6 antibody secretory cells. In addition, the 
results show that the inhibitory effect of PF-429242 is not fully rescued even if 
the cells are provided with the necessary mix of cytokines required to support 
differentiation (without the PF-429242). However, the inhibitor effect of 
Nelfinavir can be rescued, generating cells that had grown normally in count 
and phenotype compared to the control (Ethanol) (Figure 6.36 and 6.37). 
These results enhance the importance of PF-429242 as a potential 
therapeutic drug for B-cell and ASC disorders. 
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In the previous experiment (Figure 6.37) PF-429242 had affected plasma cell 
phenotype by increasing CD138 expression compared to the control (dH2O) 
and this was also observed after attempted rescue (Figure 6.40). However, 
Nelfinavir had less of an impact on plasma cell phenotype consistent with the 
restoration of cell count in the presence of appropriate nutrients.   
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Figure 6.39 The impact of transient S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on ASC number. Human activated B-cells (Day-3) from 2 
donors were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
72 hours. On Day-6, the cells were re-seeded with the Day-6 standard condition 
(without the inhibitors) and incubated up to Day-13 to examine the possible 
rescue levels. On Day-13, the cells were collected and counted using CountBright 
TM beads. 
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Figure 6.40 The impact of transient S1P inhibitor (PF-429242) and S2P inhibitor 
(Nelfinavir) on plasma cell phenotype. Human activated B-cells from 2 donors 
(Day-3) were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 72 
hours. On Day-6, the cells were re-seeded with Day-6 standard conditions (without 
the inhibitors) and incubated up to Day-13.  After incubation, the cells were stained for 
CD19, CD20, CD38, CD138 and CD27 and evaluated by flow cytometry. 
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6.7  Testing the impact of S1P and S2P inhibitors on B cell proliferation 
(Day-3 to Day-6) 
The experiments detailed above have indicated that treatment with S1P/S2P 
inhibitors has a marked impact on cell number. A body of evidence suggests 
that the ability to differentiate to an ASC is increased as the cells divide (16). 
CFSE (CarboxyFluorescein Succinimidyl Ester) is a dye used to track cell 
proliferation and the formation of the multiple generations by flow cytometry. 
To determine whether the inhibitors altered the proliferative capacity of 
differentiating B-cells, 24 hours post isolation the cells from three donors were 
labelled with 5mM CFSE. 24hours later, the staining was assessed compared 
to a negative control (Day-0). On Day-3, the cell proliferation was checked 
and then cultures treated with 10 μM PF-429242/dH2O or 10 μM 
Nelfinavir/Ethanol and incubated for 72 hours. After the incubation, the cells 
were collected and analysed for the CFSE using flow cytometry (Figure 6.41). 
The results revealed that PF-429242 and Nelfinavir treatment delayed the 
proliferation compared to the controls (dH2O and Ethanol, respectively). 
Despite that, the formation of the multiple generations was not clear due to the 
rapid division. Therefore, to improve the resolution of generations, CFSE has 
to be evaluated in a shorter time point between Day-3 and Day-6. 
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Day-0 Figure 6.41 The impact 
of PF-429242 and 
Nelfinavir on cell 
proliferation.  Human 
B-cells were isolated 
using the memory B-cell 
isolation kit and labelled 
with 5mM CFSE 24 
hours post isolation. 
Day-3 B-cells were 
treated with 10 μM PF-
429242 and 10 μM 
Nelfinavir and analysed 
on Day-6 using flow 
cytometry. CFSE 
intensity appears on the 
X-axis of each plot. 
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6.8 Evaluation of the role of autophagy in response to PF-429242 and 
Nelfinavir 
 
Autophagy is a lysosomal degradation process initiated by forming an 
autophagosome that fuses with endolysosmal vesicles leading to degradation 
of the contents.  It occurs in response to nutrient starvation and accumulation 
of unfolded protein in the ER. In addition, it may occur during differentiation, 
development, infections and cancer.  There are three known autophagy 
processes; chaperone mediated autophagy (CMA), macro- and 
microautophagy (1). CMA has only been described in mammals whereas 
micro and macroautophagy have been detected in plant, fungi and mammals.  
Autophagy is controlled by number of autophagy-related genes (Atg proteins) 
(Figure 6.42). The process starts with the membrane nucleation, which 
requires Atg6 and PI3K followed by an elongation step. The membrane 
elongation requires two ubiquitin-like conjugation systems; Atg8-PE (LC3-II) 
and Atg5-Atg12 thus, forming the autophagosome that fuse with the lysosome 
to form the autophagolysosome hence its degradation. The membrane 
elongation causes the conversion of LC3 (Light Chain 3 known as Atg8 in 
fungi) from LC3I to LC3II, which is used as a marker for autophagy (1). 
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  Figure 6.42 Autophagy pathway. The process starts with membrane nucleation, which requires Atg6 and PI3K 
followed by an elongation step. The membrane elongation 
requires two ubiquitin-like conjugation systems, Atg8-PE 
(LC3-II) and Atg5-Atg12, which form the autophagosome 
that fuses with the endosome and lysosome to generate 
an autolysosome that is subsequently degraded (1). 
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The accumulation of mis-folded proteins in the ER increases the ER load and 
folding capacity leading to ER-stress. The UPR is a mechanism by which 
prokaryotic and eukaryotic cells attempt to resolve ER-stress. A component of 
the UPR includes proteasome-mediated degradation of mis-folded proteins. If 
the level of mis-folded proteins exceeds the proteasome capacity, autophagy 
will be trigged. In addition, it has been shown by Ogata et al. that autophagy 
inhibits cell death mediated by ER-stressors (tunicomycin or thapsigargin) 
(119). Thus, autophagy can be considered a mechanism that promotes cell 
survival by removing the aggregates that form due to ER-stress (120). 
 
Although autophagy has been proposed to act in a positive fashion to 
preserve optimal secretory activity in plasma cells, failure to restrict the level 
of autophagy may lead to cell death. To determine whether the failure to 
increase cell numbers in human differentiating B-cells treated with S1P and 
S2P inhibitors was related to autophagy, protein samples were examined for 
LC3I/LC3II by Western blotting. LC3 is the mammalian homologue to Atg and 
is considered to be the most reliable marker for autophagosome detection and 
monitoring autophagy (1). The results show that PF-429242 treatment was 
associated with enhanced autophagy due to the conversion of LC3I to LC3II 
compared to the control (dH2O), whereas, the other autophagy markers did 
not show any conclusive results. On the other hand, Nelfinavir did not show 
any changes (Figure 6.43). 
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Figure 6.43 Investigation of the 
impact of PF-429242 and 
Nelfinavir on autophagy. Day-3 
human activated B-cells were 
treated with 10 μM PF-429242 or 
10 μM Nelfinavir and incubated 
for 72 hours then analysed on 
Day-6 for autophagy using 
markers ATG7, ATG3  (not 
shown) and LC-III. 
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6.9 Detailed kinetic analysis of the effect of S1P and S2P inhibition 
during the transition between activated B-cell and plasmablast stage 
 
Human differentiated B-cells (Day-3) treated with PF-429242/dH2O and 
Nelfinavir/Ethanol for 72 hours have been assessed by multiple parameters, 
including evaluation by microarray to check their impact on gene expression. 
While this assessment provided an insight into the changes that occurred at 
the time when the cells had reached a relatively homogeneous stage in 
differentiation, it was of interest to determine how inhibition of S1P/S2P was 
affecting the cells as they progressed through this phase. Thus, Day-3 B-cells 
were treated with PF-429242/dH2O and Nelfinavir/Ethanol for a series of 
shorter time points. Samples were collected every 12 hours from Day-3 until 
Day-6 for protein expression by Western blotting, RNA samples for expression 
profiling, cell count using CountBright TM absolute counting (C36950, Life 
technology), cell phenotype for CD19, CD20, CD38 and CD138 and 
supernatant for IgM and IgG quantification (Figure 6.44).  
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Figure 6.44 Diagrammatic representation of the experimental design to test the 
temporal effect of S1P and S2P inhibitors. Activated B-cells were treated with the 
indicated drug and harvested every 12 hours starting from Day-3 until Day-6. At each 
time point, samples were collected for cell count, surface phenotype, protein 
expression, RNA expression and immunoglobulin (IgM and IgG levels) quantification. 
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6.9.1 Expression and processing of CREB3L2 
 
Careful monitoring of protein expression is important to verify that the 
S1P/S2P inhibitors are targeting the transcription factors likely to be acting on 
the underlying molecular changes accompanying plasma cell differentiation. 
During the kinetic evaluation, inhibition of CREB3L2 cleavage by PF-429242 
accompanied by an increase in full-length protein was first detected 24 hours 
post-treatment (Figure 6.45). Nelfinavir also showed potency at 24 hours, but 
predominantly led to a loss of full-length protein. By 72 hours, PF-429242 had 
abrogated expression of CREB3L2, but in this experiment the effect of 
Nelfinavir was transient with the re-emergence of CREB3L2. 
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Figure 6.45 Kinetic analyisis of the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on CREB3L2 expression. Day-3 B-cells were pre-treated with 10 
µM PF-429242/dH2O and or 10 µM Nelfinavir/Ethanol for 12-hour intervals until Day-6. At 
each time point, lysates were evaluated by Western blotting. 
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6.9.2 Cell count 
 
The detailed kinetic analysis have confirmed the importance of studying the 
impact of PF-429242 and Nelfinavir on differentiating B-cells between Day-3 
and Day-6 and revealed when the drugs first show an effect on cell number 
and when the difference is at its peak. From the cell count (Figure 6.46), the 
PF-429242 and Nelfinavir appear to start impacting on the B-cells 36 hours 
from the treatment with increasing activity up to 72 hours (Day-6).  
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Figure 6.46 Kinetic analysis of the impact of S1P inhibitor (PF-429242) and 
S2P inhibitor (Nelfinavir) on differentiating B-cell number. Day-3 B-cells were 
treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 12-hour 
intervals until Day-6. At each time point, the cells were collected for counting 
using CountBright TM beads. 
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6.9.3 Cell phenotype 
The detailed examination of the impact of S1P/S2P inhibitors provides 
comprehensive information on the critical window where the affected 
transcription factors are most likely to be exerting an influence on the 
underlying change in gene expression. To determine whether the timing of the 
reduction in cell number was accompanied by other changes, surface 
phenotype was evaluated. 
 
Consistent with the cell number observation, PF-429242 started affecting cell 
phenotype 36 hours after the treatment, revealing a reduction of CD20 
expression compared to the control (dH2O) and increase in CD38 population 
in PF-429242 treated sample clearly at D3+72h (Figure 6.47). These changes 
in cell phenotype increased over time until 72 hours post treatment where 
culture with PF-429242 generated two populations (CD38high and CD38low) 
whereas the control had only one cell population (CD38high). 
 
On the other hand, the impact of Nelfinavir on cell phenotype was different. 
Although Nelfinavir also affected cell count as early as 36 hours post 
treatment, its effect on cell phenotype was delayed. 48 hours post-Nelfinavir 
treatment CD20 expression was increased compared to its control (Ethanol), 
with no changes observed in CD38/CD138 expression (Figure 6.47).  
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Figure 6.47 Kinetic analysis of the impact of S1P inhibitor (PF-429242) and 
S2P inhibitor (Nelfinavir) on cell phenotype. Day-3 B-cells were treated with 10 
µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 12-hour intervals until Day-
6. At each time point, the cells were stained for CD19, CD20, CD38 and CD138 
and analysed by flow cytometry. 
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6.9.4 Immunoglobulin levels 
The ability to secrete immunoglobulin should accompany the phenotypic 
changes associated with becoming an ASC. To determine whether the impact 
of S1P inhibitor and S2P inhibitor on phenotype was matched by secretory 
output, it was important to quantify the immunoglobulin (IgM and IgG) levels. 
Thus, at each time point, the supernatants were collected and analysed using 
ELISA. The results revealed a profound reduction in the IgM and IgG levels 
(more than 90%), which was first detectable 36 hours post treatment in the 
treated samples compared with the control (Figure 6.48). The exception was 
Nelfinavir at 72 hours where the inhibition was less (same results in the 
protein expression, Figure 6.45) that needs to be repeated for validation. 
Thus, 10 µM PF-429242 and 10 µM Nelfinavir had an inhibitory affect on the 
secreted IgM and IgG levels from ASCs that were in agreement with the 
previous observations using these samples. 
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Figure 6.48 Kinetic 
analysis of the impact 
of S1P inhibitor (PF-
429242) and S2P 
inhibitor (Nelfinavir) on 
IgM and IgG levels. 
Day-3 B-cells were 
treated with 10 µM PF-
429242/dH2O or 10 µM 
Nelfinavir/Ethanol for 12-
hour intervals until Day-
6. At each time point, the 
supernatants were 
collected and the 
immunoglobulins (IgM 
and IgG) were quantified 
using ELISA.  
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6.10 Validation of kinetic analysis of PF-429242 and Nelfinavir 
treatment on differentiating B-cells 
 
6.10.1 Protein expression 
The detailed investigation on the impact of PF-429242 and Nelfinavir on the 
human differentiated B-cells and antibody secretory cells has the potential to 
provide us with a better understanding of the pathways regulated by these 
inhibitors. To ascertain whether CREB3L2 processing was uniformly affected, 
the impact on CREB3L2 protein expression was validated using three 
additional donors. The results showed that the inhibitory affect of PF-429242 
and Nelfinavir started as early as 12-24 hours until 72 hours post-treatment 
(Figure 6.49), which matches the results obtained before.  
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Figure 6.49 Validation of the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on CREB3L2 protein expression during the activated B-
cell to plasmablast transition. Day-3 B-cells from two donors, (A) D806 and (B) 
D704, were treated with 10 µM PF-429242/dH2O or 10 µM Nelfinavir/Ethanol for 
12 hour-intervals until 72 hours (Day-6). At each time point, the cells were 
collected and prepared for protein examination by Western blotting. 
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6.10.2 Cell count 
The impact of PF-429242 and Nelfinavir on differentiating B-cells was 
validated using three donors. The results depicted in Figure 6.48 show a 
profound inhibitory affect of PF-429242 on cell count that started 36 hours 
post treatment and continued increasing until 72 hours (Day-6). On the other 
hand, the impact of Nelfinavir on the cell count was variable between the three 
donors. Its inhibitory effect started 24 hours post treatment in one donor with 
slight decrease in the other two donors, which escalated until 72 hours (Day-
6) (Figure 6.50). Thus, the inhibitory impact of PF-429242 and Nelfinavir on 
cell number during the transition period between activated B-cell and 
plasmablast has been confirmed. 
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Figure 6.50 Validating the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on cell count during activated B-cell to plasmablast 
transition. Day-3 B-cells (from three donors) were treated with 10 µM PF-
429242/dH2O or 10 µM Nelfinavir/Ethanol for 12-hour intervals until Day-6. At 
each time point, the cells were counted using CountBright TM technology. 
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6.10.3 Cell phenotype 
The impact of PF-429242 and Nelfinavir surface phenotype was validated 
using cells from three donors. Based on the results obtained in the previous 
experiment, PF-429242 treatment lead to the formation of two cell populations 
based on CD38 (CD38high and CD38low). Previous studies have identified 
CD38-/low cells capable of secreting immunoglobulin that can be identified by 
the expression of CD27 (121). Moreover, the acquisition of CD27 prior to 
CD38 has been postulated to identify the “pre-plasmablast” stage (122). 
Therefore CD27 staining was included in the study to investigate whether PF-
429242 altered formation of pre-plasmablasts. The results showed that PF-
429242 treatment lead to the delayed the acquisition of CD27 beginning at 36 
hours, suggesting a possible effect on the commitment to becoming an ASC. 
In addition, in respect to the impact of PF-429242 on CD38 and CD20, similar 
results were obtained as in the previous experiment confirming its effect on 
the plasmablast population. 
 
Furthermore, the impact of Nelfinavir on cell phenotype was similar among the 
three donors. Its impact started at 36 hours post treatment with a slight 
retention of CD20 expression, but no changes in CD27 expression in the 
treated cells compared to its control (Ethanol) (Figure 6.51). 
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In summary, the impact of PF-429242/dH2O and Nelfinavir/ETOH on B-cells 
(Day-6) were evaluated by calculating the significance of difference between 
the groups in CD38-, CD38+ and CD138+ fractions (Figure-6.52). It revealed 
that, PF-429242 treatment generated significant difference in the level of 
CD38 expression and appeared promote plasma cell differentiation compared 
to the control. The increase in autophagy after PF-429242 treatment may 
have allowed a small number of cells to successfully adapt and become more 
mature.  
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Figure 6.51 Validating the impact of S1P inhibitor (PF-429242) and S2P 
inhibitor (Nelfinavir) on phenotypic changes prior to the plasmablast stage. 
Day-3 B-cells (from three donors) were treated with 10 µM PF-429242/dH2O or 
10 µM Nelfinavir/Ethanol for 12-hour intervals until Day-6. At each time point, the 
cells were collected and stained for CD27, CD20, CD38 and CD138 and analysed 
by flow cytometry. 
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Figure-6.52: Summary on the impact of PF-429242/dH2O and Nelfinavir/ETOH on B-
cells (Day-6) based on A. CD38-. B. CD38+ and C. CD138+. The significance 
difference between the tested groups (dH2O/PF-429242 and ETOH/Nelfinavir) was 
tested using t-test and P values were calculated (P<0.05 is significant, P>0.05 is not 
significant).  
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6.11 Determination of ASC formation by ELISpot (Enzyme-Linked 
Immunospot) 
The results shown in Figure 6.49 indicated that treatment of activated B-cells 
with the S1P inhibitor PF-429242 resulted in a delay in the acquisition of 
CD27 and the generation of distinct CD38high and CD38low populations at Day-
6. These findings suggested that blocking S1P-regulated pathways might 
impede commitment to ASC formation or differentially affect naïve vs memory 
precursor populations. Since the defining feature of ASCs is the ability to 
secrete antibodies, a sensitive ELISpot assay was employed to measure 
active Ig production from purified cells. B-cells were extracted from three 
donors and treated with PF-429242 on Day-3 (Figure 6.53) for 72 hours.	  
 
 
 
 
 
 
 
On Day-6, 1X106 cells were sorted based on CD38 expression levels 
(CD38high and CD38low) following treatment with PF-429242 or the control with 
dH2O (Figure 6.54).  	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Figure 6.53 Phenotypic characterisation of activated B-cells. B-cells were 
extracted from three healthy donor blood samples. The cell phenotypes were 
checked before PF-429242 treatment. 
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Figure 6.54 Sorting 
strategies for ELIspot 
examination. Human 
differentiated B-cells 
(from three donors) were 
treated with 10 μM PF-
429242 for 72 hours. 
After the incubation, the 
cells were sorted based 
on CD38 (high and low) 
for treated cells and the 
control (dH2O). 
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An equal amount (2,000 cells or 5,000 cells) of the sorted cells (CD38high, 
CD38low from either PF-429242 treatment or dH20 control) were seeded into 
each well of a 96-well plate and the IgM and IgG secretory cells were 
enumerated using ELIspot technique (Figure 6.55).  	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Figure 6.55 Quantification of IgM and IgG secretory cells by ELIspot. 
Human differentiated B-cells (from three donors) were treated with 10 M PF-
429242 or dH2O for 72 hours. After the incubation, the cells were sorted based 
on CD38 expression (high and low). An equal number of the sorted cells (2,000 
cells or 5,000 cells) were used to quantify the secretory cells after culturing in 
the presence of PF-429242 or dH2O using ELIspot technique.  
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The results revealed an interesting distribution of secretory capacity. In control 
cultures an equal number of cells from both CD38high and CD38low sorts were 
capable of secreting IgM, whereas the number of IgG secreting cells was 
slightly lower in the CD38low population. In terms of PF-429242 treatment, the 
number of IgM-secreting cells in the CD38high group was comparable to that 
observed in the control. The number of IgM-secreting cells derived from 
CD38low was reduced by 2-fold or greater.  The most profound effect of PF-
429242 was on the generation of IgG-secreting cells. The number of IgG-
producing CD38high cells was lower than the control and CD38low production of 
IgG was severely reduced. Thus, the capacity to secrete immunoglobulin 
tallied well with the phenotypic characteristics of the cells and treatment with 
PF-429242 showed a preferential effect on the ability of CD38low to secrete Ig. 
Furthermore, the capacity to secrete IgG was more profoundly altered by PF-
429242, suggesting either a differential effect on naïve versus memory B-cells 
or a role for S1P in class switching. 	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6.12 Discussion 
 
When B-cells encounter antigen they undergo a process of terminal 
differentiation to become effector cells that secrete antibodies, which provide 
protective humoral immunity. This is a step-wise process, during which first 
the B-cells become activated and start proliferating. The cells then start to 
lose the B-cell phenotype and acquire changes compatible with antibody 
secretion. These changes are coordinated by TFs that prepare the cells for 
high-level secretion. As the cells produce large amounts of immunoglobulin, 
the UPR becomes activated to cope with the amount of protein transiting the 
ER. To date, the only branch of the UPR that has been shown to participate is 
IRE1-XBP1(123). However, results presented in the previous chapters have 
shown that the ER-stress activated TF CREB3L2 is expressed in myeloma 
and ABC-DLBCL cell lines. In addition, CREB3L2 is expressed as cells 
differentiate from activated B-cells to ASCs using the in vitro model. The data 
presented in Chapter-5 established that S1P/S2P inhibitors could prevent the 
expression of active CREB3L2. Moreover, these inhibitors also reduced the 
expression of ATF6 and XBP1. The loss of these proteins would be predicted 
to have an impact on the generation, maintenance or function of ASCs. 
 
Since CREB3L2 expression is highest in ASCs, initially S1P/S2P inhibitors 
were tested on cells that had reached the plasmablast or plasma cell stage. 
To confirm that inhibition of S1P/S2P was affecting protein processing, 
Western analysis of protein lysates was performed. The results show that the 
cleavage of CREB3L2 in the ASCs was strongly reduced upon the treatment 
with inhibitor compared to vehicle at the protein level. Despite this, the 
inhibitors did not affect the cell counts, cell phenotypes or immunoglobulin 
levels (IgM and IgG), indicting that inhibition of S1P/S2P did not affect the 
viability or function of the human differentiated antibody secretory cells when 
treated on Day-6 or Day-8 or Day-10, suggesting that CREB3L2 or other 
S1P/S2P-regulated transcription factors are not required for final stages of 
terminal differentiation.  
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Although CREB3L2 is most highly expressed in plasma cells, meta-profile 
analysis of DLBCL gene expression signatures has shown that CREB3L2 is 
characteristic of the activated B-cells (ABC) subset (87). Additionally, both the 
full length and cleaved form of CREB3L2 proteins were detected at low levels 
in the Day-3 activated B-cells. During the early stages of ASC commitment, 
IRF4 is the predominant TF that initiates the process, driving transcription of 
BLIMP1 and ZBTB20 that together control the ASC gene network(124, 125). 
XBP1 is activated later and recent evidence suggests that it is not required to 
generate ASCs, but does contribute to the production of immunoglobulin(5, 6, 
39). Combined, these data indicated that CREB3L2 might actually be 
operating in the early phases of ASC development, prior to the requirement 
for XBP1. 
 
The first experiment designed to test this applied PF-429242 or Nelfinavir on 
Days-3, 4 or 5 during which time the cells are rapidly proliferating. 
Assessment was made 24 hours post treatment of the drug. Using these 
conditions there was a marked decrease in the protein levels of CREB3L2, 
ATF6 and XBP1, but the reduction in XBP1 splicing observed earlier was not 
reproduced. There was little change in cell count or phenotype, but some 
reduction in immunoglobulin production. This was interpreted to mean that the 
drugs were likely to be having an effect, but the time point was too soon to 
see much of an impact. Consequently, the test conditions were altered such 
that cells treated on Day-3 were analysed 72 hours later on Day-6, when the 
B-cells should have adopted a plasmablast phenotype. In contrast to the 
earlier results, allowing the cells to undergo several rounds of cell division in 
the presence of the S1P/S2P inhibitors had a dramatic effect on cell number 
with an accompanying drop in the level of immunoglobulin production. There 
was also a change in the phenotype with retention of CD20 and a delay in the 
upregulation of CD38. These results were repeated on a total of 8 donors. 
 
Work by Hodgkin and colleagues have demonstrated that the probability of 
becoming a plasma cell increases with cell division(126, 127). After receiving 
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the appropriate stimulus, the cells start to divide and stochastically decide to 
undergo further division, ASC differentiation or death. The data obtained with 
PF-429242 and Nelfinavir suggest that S1P/S2P regulated pathways can alter 
the output during this phase of expansion. To better understand how this 
might be happening, gene expression analysis was undertaken. 
 
Strikingly, the genes that were differentially regulated by the drugs contributed 
to a group of cohesive gene ontology signatures. Focussing on the signatures 
associated with treatment of PF-429242, there is a clear connection to 
metabolic regulation. The signatures include multiple aspects of metabolism, 
such as amino acid synthesis, steroid synthesis, and lipid/cholesterol 
biosynthetic processes. For example, one of genes that was downregulated 
by both PF-429242 and Nelfinavir is ABCA1 (128).It has been recognised as 
the gatekeeper for removing excess cholesterol and phospholipids from the 
tissue to the liver. In macrophages, ABCA1 is part of a complex that maintains 
cholesterol homeostasis and helps to balance the production of inflammatory 
cytokines (129). Another gene showing altered expression is INSIG1, which 
also plays a role in cholesterol regulation, as well as lipogenesis and glucose 
homeostasis (130). Interestingly, INSIG1 binds to SCAP and prevents the 
transit of SREBP to the Golgi, which is a pre-requisite for SREBP activation, 
suggesting that there may be a feedback loop for maintaining levels of active 
SREBP in plasma cells. 
 
These data are in keeping with the prediction that S1P/S2P regulated 
pathways might be altering the ability of differentiating cells to upregulate the 
necessary building blocks to expand organelles and cope with increased 
protein production. Moreover, recent evidence confirms that metabolic 
programming is essential for plasma cell survival. Upon the encountering T-
cell dependent antigen, B-lymphocytes either form short-lived plasma cells 
that can live for a few days, or enter the germinal centre and undergo somatic 
hypermutation and CSR forming long-lived plasma cells that can live for 
years. There are many metabolic pathways that are utilised during B-cell 
Chapter-6 210	  
differentiation however; it is not known which might distinguish between long-
lived and short-lived plasma cells.  A new study by Lam et al. has now 
established the metabolic properties associated with survival of long-lived 
cells. Through examining oxygen consumption rates (OCR), they found that 
long-lived plasma cells had higher respiratory capacity than the short-lived 
ones. In addition, long-lived plasma cells are able to persist due to the uptake 
of glucose and the import of pyruvate (131). It is conceivable that targets of 
CREB3L2 or other S1P/S2P regulated TFs contribute to this metabolic switch. 
 
Another signature that was identified was mTOR (mammalian Target Of 
Rapamycin), which is an important signalling mechanism for cell proliferation, 
differentiation and survival. In the context of B-cells, mTOR is activated in 
response to the stimulation of BCR or Toll like receptor. Downstream 
signalling to PI3K/Akt inhibits the negative regulator TSC, resulting in 
activation of mTOR. mTOR is required to control protein synthesis by the 
phosphorylation of 4E-BP1 and p70S6K1, which in turn increase cell growth 
and protein synthesis (123). 
 
Benhamron et al. studied the relationship between mTOR and UPR using 
XBP1-KO, TSC-KO and DKO mice. They have found that higher 
immunoglobulin levels were obtained in the DKO mice compared to the XBP1-
KO. In addition, they have identified Ly6C as an mTOR target that contributes 
to the high immunoglobulin level in DKO mice. Moreover, by studying 
morphology using electron microscopy, they found that the ER is less 
collapsed in the DKO compared to the XBP1-KO due to the constitutive 
activation of mTOR. These results suggest that cross talk between mTOR and 
UPR contribute to the maintenance of ER morphology (123). 
 
Another study has provided further confirmation for a link between the UPR 
and mTOR, with an additional contribution from BLIMP1. Tellier et al. found 
that BLIMP1 is not required for maintaining plasma cell identity once it is fully 
established, which is in fact similar to the results presented in this chapter 
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showing that S1P/S2P regulated TFs do not appear to be required by mature 
plasma cells (132). BLIMP1 had previously been shown to act upstream of 
XBP1 (58). This paper now places BLIMP1 upstream of ATF6 and other UPR 
components. Moreover, BLIMP1 helps maintain active mTOR by inducing the 
expression of amino acid supply carriers such as CD98 and preventing 
sestrin-AMPK mediated inhibition (132). The data from this chapter suggest 
that S1P/S2P regulated TFs might act in parallel with BLIMP1 to ensure that 
mTOR remains active to help regulate immunoglobulin production. 
 
The papers described above have added to our knowledge of two of the key 
transcription factors that play roles in the transition from B-cells to plasma cell 
formation. However, initiation of the process and maintenance of plasma cell 
identity are dependent on IRF4 (27, 28). In the GC, IRF4 is expressed in 
centrocytes but not centroblasts, consistent with an important role in the 
choice between memory B-cell versus plasma cell formation (27). In addition, 
it has been found that IRF4 has a dose dependent function. At low 
concentration, it induces GC formation and CSR through activating AID 
whereas, at high concentration, IRF4 activates BLIMP1 thus, promoting 
plasma cell formation (12).   
 
Moreover, IRF4 play an important role in class switch recombination (CSR). 
Klein et al., have studied the impact of deleting Irf4 in B-cells on CSR upon 
CD40 and IL-4 stimulation. They have found that Irf4-/- B-cells showed no IgG 
detected compared to the normal CSR in the wild type suggesting that IRF4 is 
required for CSR. Moreover, IRF4 induces the expression of number of CSR 
encoding genes including Aicda, Pou2af1 and Bcl6. Therefore, the deletion of 
Irf4 leads to the reduced expression of CSR encoding genes and hence 
reduced production of alternative isotypes (28, 118). 
 
Thus, the association of IRF4 targets with PF-429242 treatment has the 
potential to help explain two aspects of the changes observed with the drug: 
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the apparent block in early commitment and possible interference with class 
switching.  
 
In addition to the highlighted biological processes, treatment with PF-429242 
was also found to alter the transcript levels of CD40LG. This effect was 
verified at the protein level, with increased expression of CD154 detected on 
the surface of B-cells exposed to PF-429242. There is an extensive literature 
demonstrating that CD40 signalling blocks differentiation of plasma cells, 
promoting an intermediate memory-like state until removal of the signal allows 
terminal differentiation to proceed (133-135). Most recently, Basu et al., found 
that a high level of Blimp1 is observed in B-cells from CD40-/- mice compared 
to the wild type in part explaining the inhibitory effect of CD40 on plasma cell 
formation. In addition, they found that CD40 signalling prevents the early 
stages of the UPR by reducing the expression of IRE1α via HRD1 (ER 
resident protein), which is involved in ubiquitination and degradation of 
unfolded proteins in ER (136). Thus, CD40 acts on multiple levels to restrict 
plasma cell differentiation and the expression of CD154 on PF-429242 treated 
B-cells may reinitiate CD40 signalling coupled to abortive differentiation.  
 
The cessation of differentiation upon treatment with either drug was 
accompanied by reduced proliferation and increased cell death. The 
observation that PF-429242 treated cells had increased vacuoles  (Figure 
6.20) suggested that mechanistically the reduction in cell number might be 
linked to increased autophagy (137). The fact that autophagy markers, in 
particular LC3, were induced in PF-429242 treated samples compared to the 
control provided support to this theory. During B-cell activation, autophagy is 
induced and is required for B-cell differentiation (138). Disturbing the balance 
of ER stress and autophagy are likely promote apoptosis, as observed in the 
PF-429242 treated samples. 
 
In contrast to the PF-429242 treated samples, B-cells treated with the S2P 
inhibitor Nelfinavir generated an abnormally high number of cells with multiple 
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nuclear lobes or polyploidy. Polyploidy is characterised by the presence of 
multiple diploids in a cell and can arise through the process of endoreplication, 
such that the DNA undergo multiple rounds of replications with out cell 
division (139). Endoreplication usually results in cells with genomic instability 
and has two forms: endocycle and endomitosis. Endocycle is composed of 
only two phases; G and S phase and lack the M phase and therefore no cell 
division.  On the other hand, endomitosis is composed of G1, S and G2 but it 
is characterised by the re-entry in to the S phase from G2 without cell division. 
Endoreplication inhibits mitosis and also affects cytokinesis, which in turn may 
cause either cell death or neoplastic proliferation. A recent publication has 
linked the ER-Golgi trafficking protein RINT1 with genomic stability, ER stress 
and autophagy (140). It may be that targets affected by Nelfinavir similarly 
intersect in the regulation of these pathways.  	  
In vivo, cell division is important for generating big pools of B-cell clones in 
response to cognate antigen. It is linked to CSR, which changes the class of 
the antibody to enable specialised function. Initiation of CSR can be cytokine 
dependent, driven by transforming growth factor (TGF-β), interferon-γ (INF-γ) 
and IL-4 or cytokine independent as exemplified by LPS stimulation(118). In 
addition, the link between cell division and CSR is cytokine dependent in so 
far as more cell divisions occur before CSR at low cytokine concentrations. 
Moreover, cell division is linked with ASC differentiation, with an association 
between increased number of divisions and the increased probability of 
becoming an ASC. Cycling B-cells undergo CSR, once they become ASC, 
CSR ceases. The proliferation (CFSE) and ELispot results in this chapter are 
likely to be related to the link between B-cell fate with cell division and CSR. 
S1P/S2P inhibitors delayed proliferation compared with the controls and 
detailed investigation of the impact of PF-429242 on antibody secretion 
revealed a greater impact on the production of	  IgG.	  	  	  
Combined, the results presented in this chapter provide additional evidence 
that early commitment to ASC fate requires a coordinated process of cell 
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division, metabolic reprogramming and adaptation to demands of 
immunoglobulin production. The results additionally provide novel insight into 
the role that S1P/S2P regulated TFs play in these processes.	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7. CREB3L2 Function 
 
The data so far highlight the importance of CREB3L2 in human B-cells and 
ASCs. Given the expression pattern of CREB3L2, It is also anticipated that it 
is likely to be fulfilling a similar role in ABC-DLBCL. Therefore determining the 
exact nature CREB3L2 function in the B-cell context is essential.  
 
In this project, several studies have been conducted to study the expression 
and cleavage of CREB3L2 in myeloma cell lines, ABC-DLBL cell lines and in 
human differentiating B-cells. In addition, the impact of S1P and S2P inhibition 
in the studied cell types has been examined. The results have shown that 
CREB3L2 is highly expressed in each of the cell types and that expression is 
responsive to ER-stress. Moreover, inhibiting S1P and S2P had a profound 
inhibitory impact on CREB3L2, which in turn affected cell viability, likely 
through initiating autophagy. Furthermore, the impact of S1P and S2P 
inhibition was studied using a gene expression profile experiment. While the 
results suggest a major effect on cellular metabolism, it is difficult to attribute 
the change in gene expression to a particular component downstream of 
S1P/S2P. Therefore, to specifically determine the function of CREB3L2, a 
combination of loss-of-function using knockdown and ChIP-seq to examine 
CREB3L2 target genes that are likely to contribute to the metabolic gene 
signature described in Chapter-6 were conducted.  
 
7.1 siRNA mediated knockdown of CREB3L2 
The obtained results have shown that CREB3L2 is expressed and cleaved in 
cell lines representative of post-germinal centre B-cell neoplasms and in the 
normal B-lineage counterparts generated in vitro. In addition, the generation of 
the transcriptionally active form of CREB3L2 can be inhibited using site-1 and 
site-2 protease inhibitors (PF-429242 and Nelfinavir, respectively). However, 
the inhibitors have a more far-reaching effect than the inhibition of active 
CREB3L2 and potentially block several arms of the ER-stress response, 
including XBP1, ATF6 and SREBP. To determine the specific effect of 
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CREB3L2 on differentiating B-cells knockdown experiments were attempted 
using two different types of CREB3L2 siRNA, alone or in combination.  
  
7.1A CREB3L2 knockdown in myeloma cell lines 
Initially, the ability to use siRNA to achieve knockdown of CREB3L2 was 
tested in myeloma cell lines H929 and U266 using two different CREB3L2 
siRNA#1 and #2 (cat No 4392420 siRNA ID No s34890, s34891 respectively). 
CREB3L2 siRNA#1 targets both CREB3L2 isoforms (the long and short); 
however, CREB3L2 siRNA#2 targets only one isoform (the long one) (Figure-
7.1).  
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Figure 7.1: Targeting of CREB3L2 by siRNA. A. Diagrammatic representation 
of the location of CREB3L2 siRNA#1 on the two isoforms of CREB3L2. B. 
Diagrammatic representation of the location of CREB3L2 siRNA#2 on the two 
isoforms of CREB3L2. The diagram shows the intron/exon structure of CREB3L2 
isoforms modified from the NCBI entry. The red line shows where the siRNAs bind 
to CREB3L2.  
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H929 and U266 were transfected with 400 pmoles of CREB3L2 siRNA#1 as a 
first dose to knockdown CREB3L2 for 24hr or 48hr. At each time point, cells 
were collected and stored for protein and RNA preparation. By using 
CREB3L2 siRNA#1 that is predicted to target CREB3L2 isoform 1 and 2, the 
results revealed around 90% of CREB3L2 knockdown in both H929 and U266 
cell lines, at both 24 hours and 48 hours post transfection. To control for non-
specific effects two conditions were used: firstly, untransfected cells (H929 or 
U266: UnTr) were included to measure the effect of nucleofection on the cells 
to avoid false negative interpretation and secondly non-targeting, scrambled 
siRNA which acts as negative control for CREB3L2 was transfected in a 
separate tube. In H929 cells there appeared to be fairly substantial reduction 
in the amount of CREB3L2 in the scramble treated cells as compared to the 
cells that were not exposed to siRNA (Figure-7.2). This was more pronounced 
at 24h. At the 48h time point, both cell lines had fairly comparable amounts of 
CREB3L2 for both Untr and the scramble control, suggesting that this may be 
a better time point for evaluation. In both cell lines, additional bands between 
50-55kDa were observed, but these do not correspond to the full length or 
cleaved form of CREB3L2 and were not affected by the CREB3L2 siRNA 
(Figure-7.2).  
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Figure 7.2: Testing CREB3L2 knockdown efficacy in myeloma cell lines using 
siRNA#1. A. H929 cells were transfected using siRNA#1 for 24hr and 48hr. B. U266 cells 
were transfected using siRNA#1 for 24hrs and 48hrs. Protein lysates were assessed by 
Western blot for CREB3L2. CREB3L2 (1-375 a.a.) was overexpressed in Hela cells and 
used as control for the cleaved form. UnTr, Untransfected myeloma cells.  β-ACTIN was 
used as loading control. 
Chapter-7 218	  
Although there are potentially two isoforms of CREB3L2, the function of the 
short form remains speculative and only the longer form encodes a protein 
with the documented activity of a transcription factor. To provide additional 
evidence that changes observed after knockdown were linked to the long 
isoform, H929 and U266 were transfected with 400 pmoles of CREB3L2 
siRNA#2 (100μM stock) for 12hr (not shown), 24hr or 48hr. Moreover, it is 
recommended in knockdown experiments to use more than one siRNA to 
increase the effectiveness of testing and to minimize any off-target effects.  
At each time point, cells were collected and stored for protein and RNA 
testing. Using CREB3L2 siRNA#2, which targets CREB3L2 isoform1 only 
revealed around 70-80% of CREB3L2 knockdown in H929 cell line, at 24 and 
48 hours (Figure-7.3). As observed in the previous experiment, transfection 
with the scrambled control resulted in a loss of CREB3L2 at the 24hr time 
point, but at 48hr the levels of CREB3L2 in Untr versus scrambled were very 
similar.  
 
Although high levels of knockdown were achieved using individual siRNAs, 
since the two target distinct regions it was possible that combined introduction 
of both siRNAs might lead to a more profound CREB3L2 deficiency. To test 
this H929 cells were transfected with a pool of CREB3L2 siRNA#1and 
siRNA#2 and cultured for 24hr or 48hr. At each time point, cells were collected 
and stored for protein and RNA testing.   
 
By simultaneously using CREB3L2 siRNA#1 and CREB3L2 siRNA#2 (pool) 
that target both CREB3L2 isoforms, CREB3L2 was virtually undetectable in 
the H929 cell line (Figure-7.3). Thus, although siRNA#1 was highly efficient, a 
combination of the two siRNAs resulted in a complete loss of protein.  
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7.1 B CREB3L2 knockdown in human differentiated B-cells 
The results in Figure-4.5 have shown that CREB3L2 is expressed in activated 
human B-cells, increasing as the cells progress to the plasma cell stage (Day-
3 to Day-13). In addition, it has been shown that high expression of CREB3L2 
is a characteristic feature of ABC-DLBCL, which share a similar gene 
expression signature to the activated B-cells obtained at Day-3 during the in 
vitro differentiation process. The removal of Day-3 activated B-cells from 
CD40L-expressing cells is key to initiating differentiation and results in a rapid 
acquisition of new phenotype and underlying gene expression which 
accompany the development of antibody secretion. Therefore, Day-3 B-cells 
were deemed to be the best stage to prevent CREB3L2 function in human 
differentiated B-cells.  Thus, CREB3L2 knockdown was performed in human 
Figure 7.3: Testing CREB3L2 function in myeloma cell lines (H929) using 
siRNA#1, #2 and pool (siRNA#1 and #2). H929 cells were transfected with either 
siRNA#1 or siRNA#2 or pool for 24hrs and 48hrs and then assessed for CREB3L2 
expression levels by Western blot. CREB3L2 (1-375 a.a) was overexpressed in to 
Hela cells and used as control for the cleaved product of CREB3L2. UnTr, 
Untransfected myeloma cells. β-ACTIN was used as loading control. 
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differentiated B-cells (Day-3) using the same siRNAs that have been used in 
myeloma cell line knockdown studies. 
 
Day-3 cells were transfected with 400 pmoles of CREB3L2 siRNA#1 to 
knockdown CREB3L2 for 12hr, 24hr and 48hr. At each time point, cells were 
collected and stored for protein examination and RNA testing using gene 
expression profile analysis. Similar to the H929 experiment, the introduction of 
scrambled siRNA lead to some reduction of the processed form of CREB3L2 
at 24hr, but if anything increased full-length CREB3L2 at the 48hr time point 
(Figure-7.4).  Approximately 40-50% CREB3L2 knockdown was observed at 
all time points, which was considered to be suboptimal for evaluating the 
impact of CREB3L2 deficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Testing CREB3L2 knockdown in human differentiated B-cells 
(Day-3) using 400pmoles of siRNA#1. Day-3 B-cells were transfected with 
400pmoles of siRNA#1 and cultured for 12hr, 24hr or 48hr. Lysates were analysed 
by Western blot for CREB3L2 expression. CREB3L2 (1-375 a.a) was 
overexpressed in Hela cells and used as control for the cleaved product of 
CREB3L2. UnTr, Untransfected human B-cells. β-ACTIN was used as loading 
control. 
	  	  
$
L\lGn
I
'l
l' ;:
flI ,fi,iITilt
t
l,ltsfr
Irr;,,tIfii'i'^,,
$
L\lGn
I
'l
l' 
;:
flI ,fi,iITilt
t
l,ltsfr
Irr;,,tIfii'i'^,,
250- 
130- 
70- 
55- 
35- 
25- 
100- 
Co
nt
ro
l 
Sc
ra
m
ble
d 
 
siR
NA
 
siR
NA
 1 
Un
Tr
 
La
dd
er
 
Sc
ra
m
ble
d 
 
siR
NA
 
siR
NA
 1 
Un
Tr
 
Sc
ra
m
ble
d 
 
siR
NA
 
siR
NA
 1 
	   	  12hr 24hr 	  48hr 
β-ACTIN 
Un
Tr
 
Chapter-7 221	  
7.1.B2 600 pmoles siRNA#1 
In an attempt to achieve a higher degree of knockdown, 600 pmoles of 
siRNA#1 was used to transfect Day-3 B-cells from two donors and then 
evaluated at 24hr or 48hrs. Transfection with a higher level of control 
scrambled siRNA had no detectable effect on the full length CREB3L2, but did 
appear to result in lower amounts of the processed from, particularly at the 
earlier time point in both donors (Figure-7.5).  However, both donors showed 
approximately 80-90% of CREB3L2 knockdown. The knockdown was greater 
at the 24hr time point, but still substantial at 48hr. 
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Figure 7.5: Testing CREB3L2 knockdown in human differentiating B-cells 
(Day-3). Day-3 B-cells were transfected with 600pmoles of siRNA#1 and analysed 
at 24hr or 48hrs. . Lysates were analysed by Western blot for CREB3L2 
expression. CREB3L2 (1-375 a.a.) was overexpressed in Hela cells and used as 
control for the cleaved product of CREB3L2. Utr, Un-transfected human B-cells. β-
ACTIN was used as loading control.  
 
Chapter-7 222	  
Although 80-90% of CREB3L2 knockdown was achieved at the protein level, 
the effect on the mRNA level of CREB3L2 was modest, showing a 1.6-fold 
reduction at 24 hours and normal expression levels by 48 hours (data not 
shown). While the changes in gene expression amongst the 3 donors did not 
reach statistical significance after false discovery rate correction, there were 
some interesting trends in genes that showed differential expression after 
CREB3L2 knockdown (Figure-7.6 and -7.7). For example, it is notable that 
amongst the genes that increase expression when CREB3L2 is knocked 
down, several are associated with plasma cell development, including 
PRDM1, XBP1, CXCR4, MZB1 and JCHAIN as well as genes that are 
associated with ER-stress responses such as CERC1, SYVN1, RRBP1 and 
SDF2L1(141, 142). On the other hand, genes that were lower such as PLAC8, 
BNIP3 and PFKFB4 have been linked to autophagy (143, 144). Although the 
changes were not significant, the fact that some of the most highly 
differentially expressed genes were common to the S1P/S2P inhibition 
experiment, such as ALDOC1, PFKFB4, BNIP3 and CD83 (Figure-7.6), 
suggests that the changes might reach significance if the experiment was 
repeated. 
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Figure-7.6: Gene expression analysis was performed on triplicate knockdown 
samples and example changes in genes at 24 hours are shown. 
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7.2 Assessment of direct CREB3L2 targets by Chromatin 
Immunoprecipitation 
 
7.2.1 Chromatin Immunoprecepitation Assay (ChIP)  
ChIP is used to identify the interaction between a protein (e.g. transcripition 
factor) and some genomic DNA (e.g target genes). In Chapter-3, two 
commercial antibodies against CREB3L2 were shown to work for 
immunoprecipitation and would likely also be effective reagents to use in 
ChIP. Therefore, initial experiments were performed in myeloma cell lines 
(U266 and H929) and human differentiated plasmablasts to identify CREB3L2 
target genes.  
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Figure-7.7: Gene expression analysis was performed on triplicate knockdown 
samples and example changes in genes at 48 hours are shown. 
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ChIP was performed in U266 cells and analysed by real time-PCR (Figure-
7.8). The loci evaluated were based on previously identified CREB3L2 target 
genes (35, 84, 85) and genes featuring potential CRE regulatory motifs. Of the 
seven loci evaluated, the results highlight XBP1 and ATF4 as possible 
CREB3L2 target genes in U266.  
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Chapter-3, CREB3L2 is expressed and cleaved in myeloma cell 
lines (H929 and U266) upon treatment with one of the ER stressors 
(thapsigargin; TG) for 2 hr or 4 hrs. Therefore, U266 and H929 cells were 
treated with TG for 4 hrs and then the ChIP samples were prepared and 
analysed by real time-PCR (Figure-7.9). Additionally, the cells were pre-
treated with 10µM PF-429242 for 24 hrs prior to ChIP-qPCR (Figure-7.9).  
The results show an increase in the fold enrichment relative to isotype control 
upon 1µM TG treatment for the proposed targets ATF4, SEC23B and XBP1 
(Figure-7.9). Consistent with the result in Figure-7.6, there was no enrichment 
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Figure-7.8: Evaluation of CREB3L2 binding to predicted target genes in 
the myeloma cell line U266. Duplicate ChIPs were performed using anti-
CREB3L2 and chromatin prepared from U266 cells. The data are averages of 
the two ChIPs plotted as fold enrichment relative to a control ChIP with rabbit 
IgG. 
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of binding at the ARF4 locus. In contrast, there was a sharp decrease in the 
fold enrichment upon 10µM PF-429242 treatment, providing further evidence 
that there is an interaction between CREB3L2 and the possible target genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, H929 cells were treated with the ER stressor (TG), S1P inhibitor 
(10µM PF-429242) or S2P inhibitor (10µM Nelfinavir) and the fold enrichment 
of CREB3L2 binding to target genes was obtained (Figure-7.10). In the steady 
state, CREB3L2 binding was detected at both ATF4 and XBP1. Upon 
treatment with ER stressor (TG), the level of CREB3L2 binding increased, 
with good enrichment at ATF4 and XBP1 and weak binding to SEC32B. 
Treatment with10µM PF-429242 or 10µM Nelfinavir reduced binding to levels 
equivalent or below that seen in steady state, giving further credibility to the 
ChIP results. 
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Figure-7.9: Evaluation of CREB3L2 binding to target genes following 1µM 
thapsigargin (TG) or 10µM PF-429242 treatment in U266. Duplicate ChIPs 
were performed using anti-CREB3L2 and chromatin prepared from U266 cells. 
The data are averages of the two ChIPs plotted as fold enrichment relative to a 
control ChIP with rabbit IgG. 
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Figure-7.10: Evaluation of CREB3L2 binding to target genes following 1µM 
thapsigargin (TG), 10µM PF-429242 or 10µM Nelfinavir treatment in H929. 
Duplicate ChIPs were performed using anti-CREB3L2 and chromatin prepared 
from H929 cells. The data are averages of the two ChIPs plotted as fold 
enrichment relative to a control ChIP with rabbit IgG.  
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7.2.2 ChIP-seq 
 
The experiments presented in the previous three figures suggest that the 
CREB3L2 antibody works for ChIP and has the potential to be used to identify 
novel targets of this transcription factor. Moreover, since the binding motif of 
CREB3L2 is predicted to be similar to that of other CREB or ATF family 
members and CREB3L2 is likely to work alongside other UPR-related 
transcription factors, it was of interest to determine the extent to which 
CREB3L2 binding is detected in proximity to these other factors. To this end, 
ChIP samples were prepared from Day-6 in vitro generated plasmablasts 
using antibodies against CREB3L2, ATF6 and XBP1. The resulting material 
was subject to next generation sequencing and analysed for detection of 
peaks associated with binding.  
 
In total, 69,515 peaks were associated with CREB3L2, 30,260 with ATF6 and 
492 with XBP1. The degree of overlap of these three transcription factors was 
then calculated. The number of overlapping peaks is shown in Figure-7.11. 
Although the total number of XBP1 peaks was relatively small, there was a 
substantial amount of overlap with the other two transcription factors. ATF6 
peaks were observed in 25% of the XBP1-associated loci and CREB3L2 
binding occurred in 18% of the same loci as XBP1. Additionally, all 3 factors 
were found to co-localise in 78 peak regions, which equates to 16% of XBP1 
bound sites. 
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To provide evidence that the observed peaks were meaningful in terms of the 
function of these TFs, binding patterns were evaluated in loci identified in the 
gene expression experiments from Chapter-6 and Chapter-7. Figure-7.12 
shows the occupancy of loci that were differentially expressed after incubation 
of differentiating B-cells with the S1P or S2P inhibitors. Interestingly, the 4 
selected genes show evidence of ATF6 and CREB3L2 binding, but no 
detectable XBP1.  
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50155
Figure-7.11: Distribution of CREB3L2, ATF6 and XBP1 peaks in 
plasmablasts. ChIP-seq for ATF6, CREB3L2 and XBP1 was performed 
using day 6 plasmablasts. The overlap of binding for the indicated 
transcription factor is shown on the Venn diagram. 
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Similarly, representative loci that showed changes upon siRNA-mediated 
knockdown of CREB3L2 had evidence of direct binding by this factor (Figure-
7.13 and 7.14). While these are only a few examples, the genes that were 
down-regulated after siRNA treatment only have ATF6 and CREB3L2 binding 
whereas the genes that were more highly expressed are also bound by XBP1. 
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Figure-7.12: Occupancy of ATF6, CREB3L2 and XBP1 in loci that were 
differentially expressed after S1P/S2P inhibition. ChIP-seq was performed 
using day 6 plasmablasts with the transcription factor indicated on the left. 
Genomic input was used for normalisation. Example tracks for ALDOC, MSMO1, 
FADS1 and SCD loci are displayed with the gene structure shown at the bottom.  
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Figure-7.13: Occupancy of ATF6, CREB3L2 and XBP1 in loci that were 
more highly expressed in scramble transfected cells. ChIP-seq was 
performed using day 6 plasmablasts with the transcription factor indicated on 
the left. Genomic input was used for normalisation. Example tracks for PLAC8 
and BNIP3 loci are displayed with the gene structure shown at the bottom.  
Figure-7.14: Occupancy of ATF6, CREB3L2 and XBP1 in loci that were 
more highly expressed in CREB3L2-siRNA transfected cells. ChIP-seq was 
performed using day 6 plasmablasts with the transcription factor indicated on the 
left. Genomic input was used for normalisation. Example tracks for SYVN1 and 
XBP1 loci are displayed with the gene structure shown at the bottom.  
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Finally, as an indication of whether CREB3L2 is likely to be regulating the 
UPR in ASCs, examples of UPR-associated genes were examined for the 
presence of binding. Genes classically associated with the UPR, including 
ATF4, HSP90B1 and HERPUD1 showed occupancy by the 3 factors. The 78 
genes featuring this binding pattern are likely to make important contributions 
to the ability of ASCs to adapt to high-level immunoglobulin secretion. UFL1 is 
a gene not previously associated with plasma cell differentiation, but has been 
highlighted by the results of the ChIP-seq experiment.  
 
 
 
 
 
 
 
 
UFL1%HERPUD1%
ATF6%
XBP1%
CREB3L2%
Input%
ATF4%
ATF6%
XBP1%
CREB3L2%
Input%
ATF6%
XBP1%
CREB3L2%
Input%
ATF6%
XBP1%
CREB3L2%
Input%
HSP90B1%
Figure-7.15: Occupancy of ATF6, CREB3L2 and XBP1 in loci that are 
associated with the UPR. ChIP-seq was performed using day 6 plasmablasts with 
the transcription factor indicated on the left. Genomic input was used for 
normalisation. Example tracks for ATF4, HSP90B1, HERPUD1 and UFL1 loci are 
displayed with the gene structure shown at the bottom.  
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7.3 Discussion 
 
The previous chapters have established that active CREB3L2 is incrementally 
expressed in primary B-cells making the transition to become ASCs and is 
also observed in neoplastic cell lines representative of these stages.  
CREB3L2 is induced by ER-stress and active CREB3L2 is generated by 
proteolytic cleavage mediated by S1P/S2P. The experiments in the preceding 
chapters provided evidence that pathways downstream of S1P/S2P can 
profoundly influence the outcome of plasma cell differentiation. The goal of 
this chapter was to establish the contribution of CREB3L2 to this process. 
 
Initially, attempts were made to knockdown CREB3L2 using siRNA to 
determine the effect of reduced CREB3L2 protein levels.  CREB3L2 was 
effectively targeted in two different myeloma cell lines (U266 and H929), 
reaching a near complete loss of protein by 48 hours post transfection. 
Likewise, introduction of siRNA into Day-3 differentiating B-cells resulted in 
almost undetectable levels of CREB3L2 at a 48hr time point. However, the 
negative control siRNA also led to a reduction in the amount of CREB3L2, 
particularly at the 24hr time point. While the reason for this is not precisely 
known, siRNAs can be associated with off-target effects such as microRNA-
like recognition of other targets, activation of TLRs or overload of the RNAi 
processing machinery (145).  Since the knockdown appeared to be quite 
efficient in the primary cells, microarray analysis of the mRNA expression in 
these samples was carried out.  
 
Although the protein levels of CREB3L2 were dramatically reduced, the 
change in CREB3L2 message level was modest. This could be due to the 
siRNA exerting its effect at the level of translation, similar to a microRNA 
(146). Disappointingly, the change in gene expression when comparing 
CREB3L2 siRNA treated samples to the control siRNA was also modest and 
did not reach statistical significance.  This may be in part due to the fact that 
the control siRNA also had an impact on CREB3L2 levels. Additional 
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experiments would be required to establish a more specific knockdown, 
potentially using alternative siRNAs or an shRNA vector. Nonetheless, there 
were some genes that looked promising as targets of CREB3L2 regulation. 
For example BNIP3 has a documented role in autophagy(147, 148) and 
mitophagy in particular. BNIP3 has been shown to regulate the levels of 
mitochondria in response to increased demands on mitochondrial respiratory 
activity(149) as might also be experienced in ASC. A recent publication also 
identified a role for BNIP3 in the survival of long-lived “memory” NK cells (150) 
that are generated after an initial proliferative response to virus followed by a 
contraction phase, similar to what is observed during the plasmablast to 
plasma cell transition.  
 
It was noticeable that a number of genes associated with plasma cell 
differentiation and ER-stress were in fact up-regulated upon CREB3L2 
knockdown, contrary to what might have been predicted. Although the precise 
binding motif of CREB3L2 is yet to be established, the underlying DNA 
sequence is likely to be very similar to that recognised by other CREB or ATF 
family members. Upon knockdown of CREB3L2 these may be able to 
substitute to provide some degree of redundancy. This may also partly explain 
why a greater effect was seen with the S1P/S2P inhibitors. During knockdown 
of CREB3L2 these other factors may overcompensate and actually lead to 
increased levels of transcripts such as PRDM1, XBP1 and MZB1 in an 
attempt to restore normal production of ASCs. 
 
In keeping with this hypothesis, a high degree of overlap was observed in the 
regions bound the UPR-related TFs CREB3L2, ATF6 and XBP1. A sampling 
of the bound regions found that transcripts altered in the gene expression 
studies were indeed occupied by the affected factors. The previous example 
of BNIP3 is a case in point, with ATF6 and CREB3L2 binding to the promoter 
region and possibly intronic regulatory regions as well.  At present, the ChIP-
seq data has undergone only preliminary bioinformatics analysis; so additional 
conclusions will require more in-depth data mining. For example, it will be 
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possible to identify the types of sites bound by the TFs using de novo motif 
discovery. This will provide insight into whether the TFs are likely to bind in 
tandem or may in fact compete for the same site. The ChIP-seq tracks 
depicted above show a very close overlap of the ATF6 and CREB3L2 peaks. 
The current data cannot distinguish whether these bind simultaneously.  Using 
additional methodology such as EMSA would help to address this question.  
 
Another area of investigation would be to perform gene ontology analysis of 
the loci that are associated with particular combinations of the TFs. The 
results shown in Figure-7.14 and 7.15 are suggestive that co-occupancy of all 
three TFs is associated with regulation of UPR-responsive genes. The 
identification of loci bound by these TFs also provides scope for identifying 
new players in plasma cell differentiation.  As shown in Figure-7.15 the gene 
UFL1 has pronounced peaks for all three TFs at the promoter. UFL1 is a 
ligase for ubiquitin-fold modifier 1 (UFM1) which has recently been 
characterised as an ubiquitin-like protein. The process of conjugating UFM1 to 
target proteins has been termed ufmylation and has been linked to the ER-
stress response, fatty acid metabolism and haematopoiesis(151-154). The 
range of processes associated with UFL1-regulation makes it an attractive 
potential downstream target of CREB3L2 to study in the future. 
 
 
In conclusion, although some of the data requires further analyses and 
validation, overall the data presented in this chapter support the initial 
hypothesis that CREB3L2 directly regulates genes that are important to the 
UPR and are likely to be required for successful adaptation to the ER-stress 
encountered during PC differentiation. 
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8. Final Discussion 
 
The current consensus in the literature is that B-cell differentiation is regulated 
by the serial action of several transcription factors such as PAX5, BCL6, IRF4, 
BLIMP1 and XBP1(12, 13, 18) (Figure-8.1). PAX5 is required for initial B-cell 
lineage instruction and subsequent maintenance of the B-cell program in 
mature B-cells. Expression of PAX5 prevents ASC development in part by 
repressing XBP1 function, which is essential for plasma cell differentiation. 
Once mature B-cells receive the appropriate signal these can form(5, 6)  GC, 
the site of selection for B-cells that secrete high-affinity antibodies. BCL6 is 
the central transcriptional regulator of the GC as evidenced by the fact that 
BCL6 deletion prevents GC formation(12, 13, 22). In addition, it represses the 
exit of B-cells from the GC and exerts a repressive effect on IRF4 and 
BLIMP1, two transcription factors that are crucial for plasma cell 
differentiation(23, 24). It has been proposed that BCR, CD40 and TLR 
signalling leads to activation of NFκB which in turn promotes IRF4-mediated 
repression of BCL6. BCR signalling also leads to BCL6 phosphorylation and 
degradation, thus removing BCL6 repression on BLIMP1 and IRF4(23). 
Hence, after the correct signals are received, plasma cell differentiation 
proceeds and establishment of the full secretory phenotype is accomplished 
by expression of XBP1.  However, data suggests that early ASC can still form 
in the absence of XBP1(5, 6) therefore posing the problem of how ASCs cope 
with their metabolic requirements prior to the expression of XBP1. 
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During the transition from B-cell to plasma cell, the cells undergo dramatic 
morphological and biochemical changes related to the increased burden of 
immunogolublin production. Immunoglobulins, and proteins in general, are 
synthesised and properly folded in the ER. There are many factors that can 
affect the integrity and homeostasis of the ER, such as the toxic accumulation 
of misfolded proteins, which can impact on cell survival. However, the cells 
have adapted a physiological signalling pathway called the UPR to counteract 
these effects(69).  
 
Figure-8.1: Schematic of the regulatory network controlling plasma cell 
differentiation. Figure from Reuben Tooze. 
NF-­‐kB 
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The UPR is required during the transition from ABC to plasmablast and XBP1 
is a key component of the conserved response to ER stress(50). However, 
there are additional arms of the UPR that may be acting prior to or in 
conjunction with XBP1. For example, following ER stress, regulated 
intramembrane proteolysis (RIP) via S1P/S2P cleavage can generate active 
TFs that control target genes in the nucleus and resolve ER stress. The sterol 
regulatory element binding proteins (SREBPs), ATF6 and their structural 
homologs (CREB3L2) are regulated by RIP during a UPR (155). 
 
The gene expression profile data published by Cocco et al. showed that the 
expression of CREB3L2 is increased as B-cells transition to ASCs, prompting 
the hypothesis that CREB3L2 may be a critical participant in the ASC-
associated UPR(4). Moreover, the consistent expression of CREB3L2 in ABC-
DLBCL points to a role in the early stages of transition from activated B-cell to 
plasmablast. The high expression in ABC-DLBCL might also be linked to a 
particular role in disease pathogenesis with the prospect of targeted 
intervention. 
 
In this project, the two transcripts of CREB3L2 (isform-1 and isoform-2) were 
found to be expressed in cell lines derived from B-lineage tumours including 
the ABC-DLBCL lines OCI-Ly3 and OCI-Ly10 and myeloma lines H929 and 
U266. While the function of the short form remains speculative, it is possible 
that the additional form of CREB3L2 may function as a dominant-negative or 
plays a role in regulating CREB3L2 levels (75). To further characterise the 
expression of CREB3L2, the level of protein in the cell lines was examined 
using two ER-stressors (TG and DTT) to investigate the relationship between 
a UPR and CREB3L2 levels. The results revealed a direct relationship 
between CREB3L2 activation and UPR induction; upon ER-stress by TG or 
DTT, the FL and CF of CREB3L2 were induced and increased with time.  
 
Having established the pattern in B-cell tumour lines related to the transition 
between activated B-cell and ASC, it was of interest to determine the pattern 
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during a normal differentiation. Thus, the protein expression of CREB3L2 was 
examined in human B-cells isolated from normal donors and differentiated in 
vitro. The results revealed that the two forms of CREB3L2 (FL and CF) were 
expressed increasingly from Day-3 B-cells to Day-13 ASCs and since the 
UPR is required during B-cell differentiation, it is likely that CREB3L2 is 
participating in this response (30).  
 
Thus, based on the results obtained from B-cell lines and primary cells, 
CREB3L2 is expressed at the earliest stages of plasma cell differentiation and 
then increases, as the cells become ASCs. The generation of CREB3L2 
cleaved form coincides with immunoglobulin production and would fit with a 
response to ER stress. This pattern is similar to CREB3L2 expression in 
differentiating chondrocytes (79). In this lineage, differentiation is 
accompanied by an increase in the production of cartilage matrix proteins, 
resulting in ER stress. In this setting, CREB3L2 is required for enhanced ER 
to Golgi trafficking and is essential for the generation of mature chondrocytes. 
The similar requirements of the two cell lineages during differentiation make it 
likely that CREB3L2 will behave in a similar fashion in both instances.  
 
CREB3L2, ATF6 and SREBPs are regulated by RIP via S1P/S2P cleavage. 
Therefore, inhibiting S1P/S2P may prevent adaptation to stress and lead to 
cell death. Thus, the impact of S1P and S2P inhibitors on UPR signalling 
elements in myeloma and ABC-DLBL cell lines were initially examined using 
AEBSF (S1P inhibitor), PF-429242 (S1P inhibitor) and Nelfinavir (S2P 
inhibitor).  
 
AEBSF was first tested as an inhibitor of S1P in ABC-DLBL cell lines OCI-Ly3 
and OCI-Ly10. The results showed that AEBSF led to a loss of all forms of 
CREB3L2, which was unanticipated according to a previous publication (96). 
However, an additional study by Colgan et al. showed similar results to those 
obtained in this project, with an overall loss of SREBP-2 (113). Since AEBSF 
can inhibit a wide range of serine proteases, the utility of this drug for studying 
CREB3L2 was limited. 
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Therefore compounds that have higher selectivity, PF-429242 (S1P inhibitor) 
and Nelfinavir (S2P inhibitor), were examined. Treatment with PF-429242 led 
to the predicted loss of the cleaved form accompanied by an increase in the 
full-length protein. However, Nelfinavir treatment affected both forms of 
CREB3L2. Despite this unanticipated result, Nelfinavir has been used 
previously to assess the role of S2P-regulated TFs during the UPR (156), so it 
was included in experiments to provide additional evidence for a potential role 
of TFs made active by RIP. In addition to the observed effects on CREB3L2, 
both PF-429242 and Nelfinavir led to a loss of other UPR-related TFs. The 
reduction in ATF6 was expected, but the accompanying loss of XBP1 was 
surprising.  The detection of ATF6 and CREB3L2 binding to the XBP1 
promoter (Figure-7.14) suggested the possibility of transcriptional regulation. 
However, in contrast to the CREB3L2 knockdown experiment, the levels of 
XBP1 transcript were not affected by PF-429242 or Nelfinavir treatment (data 
not shown). Postranslational mechanisms regulating XBP1 protein stability 
have been described (157, 158) and may instead account for the observed 
difference. 
 
Accompanying the change in TF protein expression, application of either PF-
429242 or Nelfinavir had a profound effect on the biology of differentiating B-
cells (Figure-8.2). Treatment of activated B-cells with the drugs led to a 
dramatic reduction in cell number that was mirrored by an increase in 
autophagy and reduced proliferation. These effects were first observed within 
36 hours of incubation with the inhibitors and resulted in poor survival of 
ASCs. 
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Interestingly, PF-429242 treatment led to the emergence of two phenotypically 
distinct populations (CD38high and CD38low) and had a differential impact on 
the secretory capacity of surviving cells. The results revealed a failure to 
properly up-regulate CD38 compared to the control, indicative of an 
interference with ASC commitment and the potential impact of PF-429242 on 
naïve versus memory cells. In addition, the results showed a preferential 
effect of PF-429242 on IgG secreting cells compared to the control and IgM 
secreting cells suggestive of possible role of S1P-regulated events on CSR 
during B-cell differentiation.  
 
To provide a deeper understanding of the changes linked to S1P/S2P 
regulated pathways, gene expression analysis was undertaken on ASCs that 
had been exposed to inhibitors for 72 hours. The gene expression profile 
suggested a major effect on cellular metabolism, impinging on biosynthetic 
pathways involving sterols, lipids and cholesterol. The regulation of such 
pathways would be in keeping with the proposed role for S1P/S2P-cleaved 
TFs being activated by the UPR to prepare the cell for increased protein 
production. For example, SREBP-1 and SREBP-2 are known to be involved in 
Figure-8.2: The impact of PF-429242 and Nelfinavir on plasma cell 
differentiation. Day-3 activated B-cells (ABCs) were assessed at timed 
intervals following treatment with S1P/S2P inhibitors. The inhibitors exhibited 
a range of effects, including a delay in proliferation after release from CD40L, 
changes in metabolic gene expression signatures, reduction in 
immunoglobulin secretion and increased autophagy associated with reduced 
cell numbers. 
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lipid synthesis at the same time they are stimulated in response to ER 
stress(159). Moreover, reduction in UPR-associated PERK leads to a 
decrease in eIF2α phosphrylation, which in turn reduces the expression of 
C/EBP, a known regulator of the synthesis of lipids(69).  
 
However, since the S1P/S2P inhibitors affect multiple TFs it is difficult to 
attribute changes to a single RIP-activated factor. Therefore, several 
experiments were conducted to determine the contribution of CREB3L2, such 
as loss-of-function using knockdown and ChIP-seq to examine CREB3L2 
target genes. The knockdown experiments, while apparently achieving 
successful reduction in protein levels, did not generate statistically significant 
changes in gene expression. Despite the limitations, some genes looked 
promising as targets of CREB3L2 regulation such as BNIP3 that is described 
in Chapter-7. 
 
Contrary to what is predicted for the involvement of CREB3L2 in plasma cell 
development, the gene expression profile of CREB3L2 knockdown has shown 
several genes that are associated with plasma cell differentiation and ER-
stress were up-regulated. One of the possible reasons is that upon 
knockdown CREB3L2, other structurally similar proteins may substitute for 
CREB3L2 due to the similarities in the DNA binding affinity between CREB3L2 
and other CREB/ATF members. This may provide an additional explanation 
for the greater effect upon using S1P/S2P inhibitors. Furthermore, knockdown 
of CREB3L2 may lead to an increase in levels of some transcripts such as 
PRDM1, XBP1 and MZB1 in an attempt to restore normal production of ASCs.  
 
In summary, the data obtained support the initial hypothesis predicting a role 
for CREB3L2 in plasma cell differentiation through the regulation of genes 
required for adaptation to ER stress. Moreover, the results suggest that 
CREB3L2 might be acting upstream of XBP1. The protein expression pattern 
showed that CREB3L2 is induced, cleaved and can be inhibited from Day-3 in 
the differentiation protocol whereas, XBP1 is expressed later, around Day-5. 
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Although preliminary, the ChIP-seq experiment points to a combined effort by 
CREB3L2, ATF6 and XBP1 in the regulation of UPR-responsive genes. 
Based on the timing of expression and the relatively restricted number of 
XBP1 targets identified, it may be that CREB3L2, possibly in conjunction with 
ATF6 or SREBPs, provides the first wave of metabolic reprogramming, 
followed by XBP1 reinforcement. 
 
In conclusion, the results presented in this project suggest that CREB3L2 is 
involved in the early commitment to ASC fate prior to the requirement for 
XBP1 through synchronized processes such as cell division, CSR and 
metabolic reprogramming. These data highlight the importance of S1P/S2P in 
the B-cell to plasma cell transition and potentially alter the current view of the 
networks involved in this process (Figure-8.3). 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NF-­‐kB 
Figure-8.3: Schematic adding S1P/S2P function as essential for differentiation 
and development of secretory capacity at the ABC to plasmablast transition. 
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On a final note, it is worth revisiting the idea that CREB3L2 may be playing a 
unique role in ABC-DLBCL. In the OCI-Ly3 and OCI-Ly10 cell lines, CREB3L2 
was expressed at constitutively high levels for both the full length as well as 
the cleaved form. Although the levels could be further augmented by ER 
stress, this suggests that in ABC-DLBCL another pathway may be promoting 
CREB3L2 expression.  In glioma, CREB3L2 was identified as part of an 
essential pathway for proliferation and survival involving MCL1 (81). In this 
setting, the serine/threonine kinase PAK1 activates RAS-MAPK signalling 
leading to an increase in CREB3L2. CREB3L2 then transcriptionally activates 
ATF5, another transcription factor, which regulates the expression of MCL1, a 
BCL2 family regulator of apoptosis. This same pathway is also operational in 
chondrocytes (82). In B-lymphocytes PAK1 can be activated downstream of 
BCR signalling(160). One of the defining features of ABC-DLBCL is 
constitutive BCR signalling, often through the mutation of CD79A and/or 
CD79B(161). This may lead to PAK1 activation and subsequently high levels 
of CREB3L2. Interestingly, the CREB3L2 ChIP-seq revealed the presence of 
3 peaks of binding on the ATF5 locus, with no detectable ATF6 or XBP1 
(Figure-8.4 and data not shown). It is plausible that the CREB3L2-ATF5-
MCL1 axis is also functional in ABC-DLBCL and perhaps normal plasma cells 
as well, which require MCL1 for survival in the bone marrow(83). Since ATF6 
and XBP1 are not usually expressed in ABC-DLBCL it would be of interest to 
further characterise the targets that are only bound by CREB3L2 and compare 
these between normal differentiating B-cells and ABC-DLBCL. Given the 
results obtained with S1P/S2P inhibitors in primary cell cultures, it would also 
be a priority in the future to evaluate the impact of these drugs on ABC-
DLBCL. 
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Figure-8.4: Model for CREB3L2 participation in the maintenance of ABC-
DLBCL. Constitutive BCR signalling triggers the activation of PAK1 and MAPK, 
which increase the expression of CREB3L2. CREB3L2 activates the ATF5 locus 
leading to up-regulation of the anti-apoptotic protein MCL1. Other targets of 
CREB3L2 may similarly contribute to lymphomagenesis. 
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Appendix 
 
Appendix-1: The map structure of pIRES-2EGFP vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix-2: The map structure of pGEX6P-1 vector. 
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Appendix-3: The cloned part of CREB3L2 in pIRES-2EGFP and pGEX6P-1 
vectors. 
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Basic region Leucine zipper Putative transmembrane 
domain 
Luminal domain 
1 296 318 357 378 398 520 
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pGEX6P-1   
Basic region Leucine zipper Putative transmembrane 
domain 
Luminal domain 
11 
